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Gene Therapy and Stem Cell Therapy to Improve the Outcome of Human Islet
Transplantation
Abstract
Since its first introduction in 1990s, the Edmonton Protocol for human islet transplantation has helped
more than 500 patients with type 1 diabetes worldwide and met great success from bench to bedside.
The Edmonton Protocol involves isolating islets from a cadaveric donor pancreas by enzymatic digestion
and infusing into the patient's portal vein. Each recipient usually receives islets from two or three donors
for an optimal outcome and is dosed with two immunosuppressive drugs, sirolimus and tacrolimus and a
monoclonal antibody drug daclizumab to prevent the graft rejection. However, despite the administration
of immunosuppressive drugs and the recent improvement in islet isolation, preparation and
transplantation, insulin independence is rarely sustained for long term after islet transplantation. It was
reported that by a year after transplant, 50-68% of patients do not need to receive additional insulin, but by
five years after the procedure, few than 10% of total patients are free of daily insulin injection.
The wide application of human islet transplantation is hindered by two major barriers, the immune
rejection from the organ recipients and the PNF of islet grafts. Immune rejection describes a process
where transplanted islets are attached, recognized and attacked by the host immune system while the
PNF is characterized as the loss of islet viability and function caused by non-immune reasons, such as
the disruption of islet microvasculature during islet isolation and purification process, hypoxia in the core
of islet grafts and production of inflammatory cytokines at the transplantation sites.
Several strategies have been proposed to address the immune rejection and the PNF. Gene therapy, which
relies on “vectors” to deliver therapeutic genes into human islets, was successful in immunodeficient
animal models because the potent expressions of therapeutic proteins usually lead to an advantage in the
post-transplantation survival of human islets. However, gene therapy provided limited success to
overcome the immune rejection. Also gene therapy faced inherited problems such as the low transfection
efficiency of non-viral vectors and the increasing safety concerns of the viral vectors.
Cell therapy especially stem cell therapy, on the other hand, has recently met great success as a novel
regenerative medicine to support solid organ transplantation including human islet transplantation.
Among all types of stem cells, mesenchymal stem cells (MSCs) are given special interest for their selfrenewal potential, multi-lineage capacities, paracrine effects (trophic mediator) and immune modulatory
effects, making it a great candidate for improving human islet transplantation. MSCs are mostly found in
bone marrow, adipose and umbilical cord blood, are one of the most extensively studies adult stem cells
used in treating degenerative diseases as well as solid organ transplantation. Unlike embryonic stem cells
(ESCs) or induced pluripotent stem cells (iPSCs), adult stem cells show restricted proliferation and
lineage differentiation, and consequently have less risk of inducing tumor. MSC-based therapy has been
used to improve human islet transplantation from three major aspects. First, MSC was used as an
immune modulator to prevent the immune rejection of human islets. Second, MSC was used as a trophic
mediator to improve the revascularization of human islets. Third, MSC was induced in vitro to form insulin
producing cell as an alternative sources of human islets. The third aspect seems to be quite promising
theoretically, but no group has successfully generated enough “artificial” islets for human transplantation.
Our focus is mainly on the immunomodulatory effects and the trophic effects of MSCs to improve the
human islet transplantation.
We also introduce humanized mouse model into the studies of islet transplantation. Humanized mouse
model contains mature human immunity and is a good model to determine the immune rejection to
human islet after transplantation. Our study is innovative because this is the first time humanized animal
is used test the efficacy of MSC based regenerative medicine on solid organ transplantation. We plan to

answer the following questions in this study. 1) Can humanized mouse model pose an immune rejection
to human islets after transplantation? 2) What is the duration and limitation of the adoptively transferred
human immunity? 3) What is the efficacy and mechanism of stem cell therapy in improving human islet
transplantation in humanized mouse model?
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ABSTRACT
Since its first introduction in 1990s, the Edmonton Protocol for human islet
transplantation has helped more than 500 patients with type 1 diabetes worldwide and
met great success from bench to bedside. The Edmonton Protocol involves isolating islets
from a cadaveric donor pancreas by enzymatic digestion and infusing into the patient's
portal vein. Each recipient usually receives islets from two or three donors for an optimal
outcome and is dosed with two immunosuppressive drugs, sirolimus and tacrolimus and a
monoclonal antibody drug daclizumab to prevent the graft rejection. However, despite
the administration of immunosuppressive drugs and the recent improvement in islet
isolation, preparation and transplantation, insulin independence is rarely sustained for
long term after islet transplantation. It was reported that by a year after transplant,
50-68% of patients do not need to receive additional insulin, but by five years after the
procedure, few than 10% of total patients are free of daily insulin injection.
The wide application of human islet transplantation is hindered by two major
barriers, the immune rejection from the organ recipients and the PNF of islet grafts.
Immune rejection describes a process where transplanted islets are attached, recognized
and attacked by the host immune system while the PNF is characterized as the loss of
islet viability and function caused by non-immune reasons, such as the disruption of islet
microvasculature during islet isolation and purification process, hypoxia in the core of
islet grafts and production of inflammatory cytokines at the transplantation sites.
Several strategies have been proposed to address the immune rejection and the
PNF. Gene therapy, which relies on “vectors” to deliver therapeutic genes into human
islets, was successful in immunodeficient animal models because the potent expressions
of therapeutic proteins usually lead to an advantage in the post-transplantation survival of
human islets. However, gene therapy provided limited success to overcome the immune
rejection. Also gene therapy faced inherited problems such as the low transfection
efficiency of non-viral vectors and the increasing safety concerns of the viral vectors.
Cell therapy especially stem cell therapy, on the other hand, has recently met
great success as a novel regenerative medicine to support solid organ transplantation
including human islet transplantation. Among all types of stem cells, mesenchymal stem
cells (MSCs) are given special interest for their self-renewal potential, multi-lineage
capacities, paracrine effects (trophic mediator) and immune modulatory effects, making it
a great candidate for improving human islet transplantation. MSCs are mostly found in
bone marrow, adipose and umbilical cord blood, are one of the most extensively studies
adult stem cells used in treating degenerative diseases as well as solid organ
transplantation. Unlike embryonic stem cells (ESCs) or induced pluripotent stem cells
(iPSCs), adult stem cells show restricted proliferation and lineage differentiation, and
consequently have less risk of inducing tumor. MSC-based therapy has been used to
improve human islet transplantation from three major aspects. First, MSC was used as an
immune modulator to prevent the immune rejection of human islets. Second, MSC was
used as a trophic mediator to improve the revascularization of human islets. Third, MSC
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was induced in vitro to form insulin producing cell as an alternative sources of human
islets. The third aspect seems to be quite promising theoretically, but no group has
successfully generated enough “artificial” islets for human transplantation. Our focus is
mainly on the immunomodulatory effects and the trophic effects of MSCs to improve the
human islet transplantation.
We also introduce humanized mouse model into the studies of islet
transplantation. Humanized mouse model contains mature human immunity and is a good
model to determine the immune rejection to human islet after transplantation. Our study
is innovative because this is the first time humanized animal is used test the efficacy of
MSC based regenerative medicine on solid organ transplantation. We plan to answer the
following questions in this study. 1) Can humanized mouse model pose an immune
rejection to human islets after transplantation? 2) What is the duration and limitation of
the adoptively transferred human immunity? 3) What is the efficacy and mechanism of
stem cell therapy in improving human islet transplantation in humanized mouse model?
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CHAPTER 1.

INTRODUCTION

Human Islet Transplantation
Diabetes is affecting 25.8 million people in United States. Among them, 5% are
type 1 diabetes or insulin dependent diabetes. Edmonton Protocol for human islet
transplantation, first introduced by Dr. Shapiro and his group from University of Alberta
in late 1990s [1], has the potential to be a permanent treatment for patients with type 1
diabetes.
Edmonton Protocol described a manner to isolate islets using a mixture of highly
purified enzymes from the pancreas of a deceased donor (Figure 1-1) [2]. Collagenase
solution is injected into the pancreatic duct, runs through the whole pancreas and causes
distension of the pancreas. Pancreas is subsequently cut into small chunks and subjected
to further digestion until the islets are liberated and removed from the solution. Isolated
islets are then separated from the exocrine tissue and debris in a process called
purification. During the transplant, transplant surgeons are guided by ultrasound and
radiography to place a catheter through the upper abdomen and into the portal vein of the
liver. The islets are then infused through the catheter into the liver. Each recipient
receives islets from one to as many as three donors. The islets are infused into the
patient's portal vein, and are then kept from being destroyed by the recipient's immune
system through the use of two immunosuppressants, sirolimus and tacrolimus as well as a
monoclonal antibody drug used in transplant patients called daclizumab. The blood
glucose of the patient will be closely monitored and insulin may be needed until control
is achieved. If the transplantation outcome is not good, a second infusion of islets may be
needed.
Challenges of Human Islet Transplantation
In the last two decades, human islet transplantation has marched a long trip from
bench to bedside as a potential treatment for type 1 diabetes. According to the 2010
annual report conducted by Collaborative Islet Transplant Registry which is funded by
the National Institute of Diabetes and Digestive and Kidney Diseases, 571 patients with
type 1 diabetes have received human islet transplantation worldwide and nearly twothirds of recipients achieved "insulin independence", a status defined as being able to stop
insulin injections for at least 14 days, during the year following transplantation. However,



Portions modified with permission from American Chemical Society. Narang AS and
Mahato RI (2006) Biological and biomaterial approaches for improved islet
transplantation. Pharmacol Rev 58: 194-243.
Other portions modified with permission from Springer. Wu H, Ye Z and Mahato RI
(2011) Genetically Modified Mesenchymal Stem Cells for Improved Islet
Transplantation. Mol. Pharmaceutics 8: 1458-1470.
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Figure 1-1.
diabetes

The process of clinical islet transplantation for the treatment of type 1

2

insulin independence is difficult to maintain over time. At 2-year follow-up, the
proportion dropped to about one-third of recipients and at 5-year follow-up, the
proportion dropped to below 20%. This fact explained why less North American centers
performed islet transplantation and Edmonton Protocol is still an experimental treatment
for type 1 diabetes. Two of the most important limitations to the widespread of human
islet transplantation are the limited supply of islets for transplantation and the inadequate
means for preventing islet loss after transplantation [2]. Moreover, because of the
extensive posttransplantation challenges, a patient needs at least 10,000 islet equivalents
(IEs) per kilogram of body weight (extracted from two or more donor pancreases) for an
optimal transplantation outcome, making the current shortage in islet supply even worse
[3, 6]. The major reasons for islet graft failure and useful interventions are listed in Table
1-1.
To address the issue of limited supply of human islets, researchers are seeking
alternative sources of human islets by either using islets from alternative species or
generating human islets and insulin-producing cells from stem cells. Porcine islets are
widely reported as a competent alternative for xenogeneic islet transplantation with the
assistance of biological and biomaterial approaches to prevent enhanced immune
destruction of the xenografts [7, 8]. For in vitro transdifferentiation strategy, several
groups have reported successful generation of insulin-producing β-cells and islet-like
structures from both ES cells. Lumelsky, et al. demonstrated that ES cells could
differentiate in to insulin-producing cells which self-assemble into islet-like clusters.[9]
Blyszczuk et al. reported the differentiation of ES cells into insulin-producing cells
through transduction of plasmid vectors encoding paired box gene 4 (Pax-4) and
pancreatic duodenal homeobox 1 (Pdx-1).[10] However, caution should be exercised as
the differentiation from pluripotent ES cells can not 100% and the remaining
undifferentiated ES cells may still hold tumorigenicity. Several groups used MSCs as a
relatively safer source and succeed in generation islet-like cluster or insulin-producing
cells [11-13]. However, most of them relied on genetic manipulation of MSCs and the
ability of producing large numbers of functional tissues by this means was not proven.
Islet loss happens because of two major reasons, the immune rejection from the
recipients and the primary nonfunction (PNF) of islet grafts [2]. Immune rejection
describes a process where transplanted islets are attached, recognized and attacked by the
host immune system. Immunosuppressive regimens are capable of preventing immune
rejection from months to years, but the agents used in these treatments may induce
significant side effects, resulting in progressive decline in graft function. Some of the
most commonly used immunosuppressive agents such as tacrolimus (also known as FK506 or Fujimycin), mycophenolic acid (MPA), and sirolimus (also known as rapamycin)
are also deleterious to islet function and insulin secretion [4, 5]. PNF is characterized as
the loss of islet viability and function caused by non-immune reactions, such as the
disruption of islet microvasculature during islet isolation and purification process,
hypoxia in the core of islet grafts and production of inflammatory cytokines at the
transplantation sites. Once PNF happens, islets are still alive but in an apoptosis process
and ceasing to actively produce insulin in response to the fluctuation of the blood glucose
level. Failure to revascularization and subsequent apoptosis are the most frequent reasons
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Table 1-1.

Reasons for islet graft failure and useful interventions

Obstacles to islet
transplantation
Loss of viability during
isolation

Strategies

Failure to revascularize

Encapsulation with vascular growth promoting
proteins; ex vivo growth factor gene
delivery for revascularization

Inflammatory response/immune
rejection

Immunoisolation membranes; generalized
immunosuppression; immune tolerance induction;
antiapoptotic and immune modulating gene
delivery

Inadequate islet mass

Optimization of islet mass and transplantation site

Inadequate islet supply

Xenotransplantation
Stem cell-based approaches

Improved enzymatic blends for islet isolation,
culture media composition and conditions
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leading to PNF. Human islet, in its native status, is a cluster of heterogeneous cell types
with extensive intra-islet vasculature formed of fenestrated capillary endothelial lining,
which gets disrupted during islet isolation, leading to collapse of vasculature,
accumulation of endothelial fragments and compromised perfusion in the core of the
islets.[14] Therefore, unlike whole pancreas and other solid organ transplantations, islet
transplantation is ectopic and requires extensive and functional revascularization to
promote the posttransplantation survival of islet grafts.[15, 16] Less or abnormal
revascularization usually lead to hypoxia, apoptotic islet death and thus compromised
transplantation outcome.
To summarize, the long term outcome of human islet transplantation was impeded
by several obstacles, the limited supplies of donor islets, the inadequate means of
immune suppression, the loss of islets in the isolation, transportation and transplantation
process and the poor post-transplantation revascularization. All these obstacles can be
approached from two directions, to increase the resistance of islets or to reduce the
immune rejection from the recipients. Gene therapy has been proven to be an effective
strategy for achieve the formal goal while stem cell therapy can be used for the latter.
Gene Therapy
Almost all human diseases are the results of dysfunction or malproduction of
proteins. Traditional small molecule drugs usually interact with proteins such as
enzymes, hormones and transcriptional factors to exert their therapeutic potential.
However, many severe and deliberating diseases (e.g., diabetes, hemophilia, cystic
fibrosis) and several chronic diseases (e.g., hypertension, ischemic heart disease, asthma,
Parkinson’s disease, motor neuron disease, multiple sclerosis) remain inadequately
treated by the conventional pharmaceutical approaches.
Gene therapy is the use of nucleic acids as a pharmaceutical agent to treat disease.
It derives its name from the idea that DNA can be used to supplement or alter genes
within an individual's cells as a therapy to treat disease. Unlike small molecule drugs or
protein drugs which are usually formulated in capsule or tablet forms, therapeutic nucleic
acids are packaged within a specialized vector to get inside cells within the body.
Viral vectors
All viruses hold the inherited advantage to bind to their hosts and introduce their
genetic material into the host cell with high efficiency. Native viruses must be modified
to transfer genetic materials. To construct a viral vector, the genes responsible for the
viral replication and pathogenicity are first removed and replaced with a transgene
cassette. Then the recombinant viral genome is inserted into a shuttle plasmid and
transduced into a packaging cell line which contains the genes responsible for the viral
replication to generate the recombinant viral vectors. Viral vectors typically hold high
transduction efficiency and do not need additional carriers for effective gene delivery. To
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date approximately 70% of all gene therapy clinical trials employ viral vectors.
Retrovirus, lentivirus, adenovirus and adeno-associated virus (AAV) are the most
extensively studied and used viral vectors for human gene therapy. Their characteristics
have been listed and compared in Table 1-2.
Non-viral vectors
The inherited problems with recombinant viruses such as immunogenicity,
neutralizing antibodies and insertional mutagenesis have called for the design of efficient
non-viral vectors for human gene therapy. Non-viral vectors are significantly less
immunogenic and are not likely to induce insertional mutagenesis and unwanted
homologous recombination after uptake by the cells. They are also relatively easy to be
manipulated, produced and purified in large scale compared with their viral counterparts.
Non-viral gene therapy includes local administration of naked plasmid or using
specialized carriers such as cationic liposomes and polymer-based systems to deliver
plasmids to targeted area (Table 1-3). However, their clinical utility is still hampered by
the low transfection efficiency, which stems from non-specific uptake of the vector by the
epithelial barriers and extracellular matrix and poor delivery into the therapeutic target.
The intracellular gene silencing machinery also prevents the long term transgene
expression. New emerging delivery systems and vector-constructing technologies try to
address these issues.
Gene therapy usually targets one or more defected genes without affecting the
normal gene at the site of diseases. Gene therapy target can be an abnormal oncogene
whose product has the potential to cause a tumor or a defect gene whose product is
critical to maintain normal physiological functions. Compared with small molecule drugs,
gene therapy will not induce drug resistance even after repeated treatments since the
targets of gene medicine are not certain receptors but the genes encoding them.
Moreover, this technique could be a permanent treatment to give someone that is born
with a genetic disease a chance to live a normal life once and for all. However, there are
certain limitations of gene therapy as well. The major disadvantage of gene therapy is
that gene medicines are not easy to be formulated into conventional dosage forms and
delivered for a routine use. Therefore, the clinical applications of gene therapy can so far
only be conducted in hospitals with well-trained specialists. The cost of gene therapy is
so far also much higher compared with traditional medicines.
Progress in Gene Therapy
The ultimate goal of gene therapy is to improve the resistance and function of
human islets under the challenges after transplantation. Four important questions should
be asked for the success of gene therapy on human islet transplantation. Which gene
should be expressed? How to improve the gene transfer efficiency? How to improve the
gene expression potency? How to prevent the side effects of gene therapy?
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Table 1-2.

Characteristics of viral vectors for gene transfer

Characteristics
Genetic material

Retrovirus
RNA

Lentivirus
RNA

Adenovirus
dsDNA

Adeno-associated virus
ssDNA

Genome size

7-11 kb

8 kb

26-45 kb

4.7 kb

Cloning capacity

8 kb

8 kb

7-35 kb

< 5 kb

Genome forms

Integrated

Integrated

Episomal

Stable/Episomal

Diameter

100-145 nm

80-120 nm

80-100 nm

20-22 nm

Tropism

Dividing cells only

Virus protein expression No

Broad, Dividing & Non- Broad, Dividing & Non- Broad, not suitable for
dividing cells
dividing cells
hematopoietic cells
Yes/No
Yes/No
No

Transgene expression

Slow, constitutive

Slow, constitutive

Delivery method

Ex vivo

Typical yield
(viral particle/ml)
Pre-existing immunity
Immunogenicity

Ex vivo

Rapid,
Transient
Ex/In vivo

Moderate, constitutive,
transient
Ex/In vivo

< 108

< 107

< 1014

< 1013

Unlikely

Yes

Yes

Low

Perhaps,
Post-entry
Low

High

Moderate

Potential pathogenicity

Low

High

Low

None

Safety

Insertional Mutagenesis

Insertional Mutagenesis

Physical stability

Poor

Poor

Potent Inflammatory
Response
Fair

None to date but longterm not clear.
High
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Table 1-3.

Summary of non-viral methods used for gene transfer

Methods

Advantages

Disadvantages

Naked DNA

No special skills needed, easy to produce.

Microinjection

Electroporation

Up to 100% transduction efficiency (nuclear
injection)
Easy to perform, effective immunization with low
amount of DNA.
High transduction efficiency.

Low transduction efficiency, transient gene
expression.
Requires highly specialized skills for delivery,
limited to ex vivo delivery.
Poor tissue penetration.

Sonoporation

Method well tolerated for other applications.

Laser irradiation

Can achieve 100% transduction efficiency.

Transient gene expression, toxicity, tissue damage,
highly invasive.
Transient gene expression, toxicity not yet
established.
Special skills and expensive equipment necessary.

Magentofection

Safety of method established in the clinic.

Poor efficiency with naked DNA.

Liposomes

Easy to produce.

Micelles

Easy to produce and manipulate.

Protein and tissue binding, transient gene
expression.
Unstable, protein and tissue binding.

Cationic polymers

Transient gene expression, toxicity.

Dendrimers

High DNA loading, easy to produce and
manipulate.
High DNA loading, high transduction efficiency.

Solid lipid nanoparticles

Low Toxicity, controlled release and targeting.

NA

Gene gun
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Extremely toxic.

Which gene should be expressed?
Numerous genes have been introduced into human islets to prevent the loss of
function and viability of islets after transplantation. Most of these genes can be attributed
into two categories, the genes preventing the apoptosis of islets and the genes promoting
the revascularization of islets. In some rare cases, genes regulating insulin production are
also introduced into human islets.
The production of inflammatory cytokines especially interleukin-1β (IL-1β) has
been shown to inhibit islet beta cell function as well as to activate islet apoptosis in a
nitric oxide-caspase-dependent manner. Gene therapy strategies have been studied to
inhibit this pathway. For example, Giannoukakis et al. first reported that adenoviral gene
transfer of interleukin 1 receptor antagonist (IL-1Ra) prevented IL-1β-mediated nitric
oxide production from human islets in vitro as well as the suppression of insulinproducing β cell function as determined by glucose-stimulated insulin production [3]. In
our lab, Narang et al. and Panakanti et al. combined the gene expression of vascular
endothelia growth factor (VEGF) and IL-1Ra to improve the therapeutic effects of single
gene therapy while Li et al. and Cheng et al. targeted downstream pro-apoptotic factors of
IL-1β pathway and used small heparin RNA to inhibit the expression of iNOS and
caspase 3, respectively [4-7]. During the time we worked on the apoptosis of human
islets, we identified a potent anti-apoptotic factor X-linked inhibitor of apoptosis (XIAP),
which binds to and inhibits caspase 3, 7 and 9 at the same time. We hypothesized that
overexpression of XIAP can be a more effective strategy to improve the resistance of
human islets because XIAP showed ubiquitous silencing effects to almost all caspases
while previous strategies only targeted one gene at a time. The detailed results are
presented in Chapter 3.
Timely and functional revascularization is required for the survival of human
islets after transplantation. Gene transfer of angiogenesis factors such as VEGF and
hepatocyte growth factor (HGF) can be an effective strategy to fulfill this purpose and
has been widely reported by us and other groups [7-9]. VEGF is a popular angiogenic
factor, but its effect is so potent that caution should be exercised to avoid aberrant
angiogenesis [10]. Recently, HGF has been seen as a more favorable factor because it can
prevent apoptotic islet death and can promote the proliferation of pancreatic β-cells [11].
How to improve the gene transfer efficiency?
Islet is a compact cluster of about 1000 non-dividing cells. It is difficult to
transfect intact islets using non-viral approaches due to low transfection efficiency.
Cationic liposomes and polymer-based systems were employed to assist the transfection
process but are toxic at high doses [12, 13]. On the other hand, viral vectors have
demonstrated to be effective gene carriers to human islets. For example, replication
deficient adenoviral vectors, from which the viral genome E1 and E3 are deleted, are
known to efficiently transduce islets and promote transgene expression up to two weeks
[14]. In addition, adenovirus vectors can be produced in high titers and there is no risk of
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insertional mutagenesis as they do not integrate into host genome. We and others have
demonstrated adenoviral vector-based gene therapy to be effective in promoting the
revascularization and engraftment of human islets posttransplantation [12, 15]. For
example, growth factor gene expression can significantly improve the islet
revascularization after transplantation [4, 8, 12], while anti-apoptotic protein expression
can increase the resistance of islet grafts to multiple posttransplantation challenges in
human islets [5, 6, 15]. The recent success in constructing bipartite viral vectors which
can simultaneously promote revascularization and increase the resistance of transplanted
islets may highlight the promising future of gene therapy [4, 8]. However, because of the
cluster-like property of islet, multiplicity of infection (MOI) of higher than 500 is usually
required to achieve optimal transduction efficiency as suggested from many reports [4, 6,
8, 16]. Therefore, despite its effectiveness, the clinical application of gene therapy is still
hindered by the high risk of immunogenicity of viral vectors.
How to improve the gene expression potency?
Gene expression potency involves two aspects, gene expression duration and gene
expression level. Gene expression duration is usually determined by the choices of
vectors while gene expression level is usually determined by the structure of vectors.
Previous studies suggested that the first two weeks is of critical important to the
success of the whole islet transplantation because most of the islet death or loss of
function happen in that time. Therefore, gene therapy must be able to generate
therapeutic proteins in human islets for no shorter than two weeks after gene transfer.
Plasmid has been demonstrated to be incapable to express therapeutic proteins for more
than 1 week, therefore unsuitable to promise the long term survival of human islets [13,
17]. Adenoviral vectors are the most frequently used gene transfer carriers for human
islet transplantation because 1) adenoviruses lead to a potent gene expression to ~ 2
weeks which is exactly what islet transplantation requires; 2) adenoviruses can be
generated in a higher titer and is easy to be manipulated and modified and 3)
adenoviruses causes less risk of insertional mutagenesis and subsequent tumorigenicity.
Lentiviral vectors or retroviral vectors have recently attracted some attentions because
these vectors promoted transgene expression up to months. But since these vectors will
insert genetic materials into host genome, precautions must be taken to avoid the risk of
insertional mutagenesis and consequent tumorigenicity.
Structure of vectors, especially the choice of promoters and enhancers, is critical
to the expression of therapeutic proteins. Although cytomegalovirus (CMV) promoter
drives considerable transgene expression in human islets, the discoveries of new isletspecific promotes and enhancers boost the expression of therapeutic proteins
significantly. For example, we previously reported that U6 promoter is transcriptionally
more effective than H1 promoter in human islets [6]. Sharma et al. demonstrated that
transgene expression can be drastically increased by incorporating an islets-specific
enhance into the construct [18]. Other factors such as the spacing within the construct
may also play a role. For example, we found out that insertion of a VEGF expression
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cassette between the CMV promoter and iNOS-shRNA significantly enhanced iNOS
gene silencing [19]. Since a majority of my work was done using adenovirus vectors
containing CMV promoter which drives optimal transgene expression in both human
islets and stem cells. The screening for new islet-specific promotes and enhancers is the
not the main scope of my work.
How to prevent the side effects of gene therapy?
The conflict between the potency and side effects of adenovirus mediated gene
therapy is in fact the conflicts between the transduction efficiency and the safety profile,
which is further exaggerated by the cluster-like nature of human islets. MOIs higher than
500 are usually required to achieve optimal transduction efficiency but even at this MOI,
the cells in the core of islet are hardly transduced. Further increase of MOI will cause
toxicity to the cells on the surface of human islets. Another problem with adenovirus
mediated gene therapy is that some proteins in the viral genome will be co-expressed
with therapeutic proteins though in a lesser extent. This phenomenon may lead to an
unwanted outcome; human islets transduced with adenovirus will be recognized and
cleared by the host immune system in a significantly faster manner.
To solve the side effects of adenovirus without significantly impaired its
transduction efficiency, modified adenovirus was proposed. Adenovirus is usually
modified in two manners, which are to reduce the immunogenicity or to increase the
transduction efficiency. For the formal purpose, more viral genome was deleted or
replaced with transgene to reduce the immunogenicity of adenovirus. The first generation
of adenovirus contained only E1 deletion. Recently adenoviruses with both E1 and E3
inserts to simultaneously express two therapeutic genes have been reported [8].
Moreover, adenoviruses with E1, E3 and E4 deletion and even “gutless” adenovirus have
been constructed to drive transgene expression [20, 21]. For the latter purpose,
researchers have been modifying the genome of adenovirus in such a way that some
transduction-assisting ligands can be expressed on the surface of the viral particles.
Arginine-Glycine-Aspartic acid (RGD) peptide is the most frequently used ligand for this
purpose because it binds with high affinity to several types of integrins present on the
surface of mammalian cells. Part of our work involved the construction of RGD modified
adenovirus. Detailed results are described in Chapter 4.
Stem Cell Therapy
Stem cells exist in all multicellular organisms and share two characteristic
properties. They have prolonged or unlimited self-renewal capacity and the potential to
differentiate into a variety of specialized cell types. The earliest stem cells in human life
are ESC cells, derived from the inner cell mass of the blastocyst and capable to
differentiate into all derivatives of the three primary germ layers: ectoderm, endoderm,
and mesoderm. Besides the ES cells which can only be isolated from early embryos, there
are other types of stem cells in the mature tissues of all aged mammals, the adult stem
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cells. Adult stem cells have unlimited self-renewal capacity and more restricted
differentiation potential. They multiply by cell division to replenish dying cells and
regenerate damaged tissues. The most famous adult stem cells are hematopoietic stem
cells (HSCs) which give rise to all the blood cell types and lymphoid lineages. Bone
marrow also contains a population of adult stem cells named MSCs.
Although bone marrow is considered as the primary source of MSCs, they can be
isolated from other tissues, including adipose tissue, trabecular bone, synovium, skeletal
muscle, deciduous teeth, and human umbilical cord blood [22-27], suggesting the diverse
distribution of MSCs in a body. However, MSCs derived from organs other than bone
marrow exhibit limited differentiation potential [28, 29]. Among all types of stem cells,
MSCs have attracted special attentions because of its wide application as regenerative
medicine. ES cells were first studied as regenerative medicine because of their selfrenewal capacity and differentiation potential. However, direct injection of highlypluripotent ES cells into ectopic organ often give rise to teratoma, a benign tumor
containing derivatives of all three germ layers [30]. MSCs are less potent to induce
teratoma or other malignant transformation as they only have restricted differentiation
potential [31]. Compared with other adult stem cells such as HSCs, mammary stem cells
or neural stem cells, MSCs have a well-characterized trophic effect and
immunomodulatory property, making them good candidates in treating degenerative
diseases. For example, intravenous transplantation of MSCs was reported to be successful
in treating systemic diseases such as graft versus host disease (GvHD) and osteogenesis
imperfecta in human [32, 33]. Wakitani et al. also reported several successful clinical
cases treating cartilage defects with MSCs [34]. Nevertheless, primary MSCs have also
been employed in regenerating hematocytes, tendon, bone marrow, muscle, and other
connective tissues [35-39].
Bone marrow derived mesenchymal stem cells (BMSC) are morphologically
defined as plastic, adherent, pluripotent fibroblast-like cells. BMSCs are stem cells
because of their stem cell-like properties such as unlimited self-renewal capacity and
potential for multilineage differentiation. Primary BMSCs can be expanded for 34~50
population doublings (PD) without losing their native characteristics. BMSCs can
differentiate into a variety of cell types including osteoblasts, chondrocytes, and
adipocytes under in vitro and in vivo conditions [40].
Progress in Stem Cell Therapy
There are two major directions of applying BMSCs to human islet transplantation,
as trophic mediators to support islet function or as immune modulators to prevent graft
rejection.
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BMSCs support islet function
In vivo studies using BMSCs to treat diabetes used to support a hypothesis that
BMSCs might differentiate into insulin-producing β cells or they might induce
endogenous progenitor proliferation/differentiation. Ezquer et al. demonstrated that
systemic administration of BMSCs increased β cell mass and reverted hyperglycemia in
streptozotocin (STZ) induced type 1 diabetic mice [41]. However, whether BMSCs can
directly replenish the loss of β cells is still under debate. The native β cells are derived
from neural crest cells during the process of neurulation, while BMSCs are derived from
mesoderm. Although the number of islets does not increase throughout human life,
insulin-producing β cells do proliferate according to several reports [41-43]. Hess et al.
first raised doubt that MSCs did not directly rescue the pancreatic injuries by in vivo
differentiation and migration but instead induced endogenous pancreatic tissue repair in
an unknown manner [44]. Lately, both Choi et al. [45] and Dor et al. [46] confirmed that
new pancreatic β-cells are derived from the expansion of pre-existing β cells rather than
exogenous stem cells through the convincing lineage tracing studies. Since then,
emerging evidence suggested that BMSCs supported islet function through a predominant
paracrine model, or in other words served as a “trophic mediator.”
BMSCs actively produced HGF, which is a potent mitogen to many cells
including pancreatic β-cells [47]. For example, in a study using human BMSCs to treat
STZ induced diabetic mice, Lee et al. demonstrated that the major effect of human
BMSCs treatment was to increase the number of mouse islets and mouse insulinproducing cells, which were most likely to arise from the proliferation, migration, and
neural differentiation of the nearby endogenous mouse neural stem cells [42].
Most studies suggested that BMSCs actively participate in angiogenesis of human
islets by secreting VEGF and HGF which are potent angiogenic factors [48]. Izumida et
al. reported that proliferative activity and differentiative response in the pancreatic ductal
cells were significantly raised once rats were treated with HGF positive BMSCs [49].
Sordi et al. found that BMSCs of bone marrow origin facilitated the restoration of
normoglycemia and the neovascularization of the islet graft [50]. which was confirmed
by a recently study by Rackham et al. that islets co-transplanted with BMSCs maintained
a morphology that more closely resembled that of islets in the endogenous pancreas both
in terms of size, endocrine and endothelial cell distribution [51]. We also demonstrated
that islet/BMSC co-transplantation under the kidney capsule of diabetic mice formed a
more intense and function vasculature [52]. Other studies suggested that BMSCs may
also differentiate into endothelial cells and directly assist the neo-vessel formation [53].
Silva et al. reported the transdifferentiation of BMSCs into an endothelial phenotype in a
canine ischemia model, which is supported by the report from Ito et al. that BMSCs
directly differentiate into a van-willebrand-factor-positive vascular endothelial cell type
to improve the islet graft morphology and function [54]. However, these results should be
explained cautiously because the new-formed vessels may arise from native BMSCs
instead of infused BMSCs.
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BMSCs prevent graft rejection
The allograft rejection from the host innate immune system is another major issue
for islet transplantation. The most potent antigen-presenting cells, dendritic cells (DCs)
play a key role in allograft recognition and rejection. Briefly, the precursor monocytes
migrated through the capillaries into tissue and differentiate into immature DCs. Once
encountering foreign cells, DCs process and present the allogeneic antigen through major
histocompatibility complex class II (MHC II) to the T cell receptor (TCR) of native T
cells (T0) and promote T cell activation into cytotoxic T cells (Tc), helper T cells (Th)
and memory T cells (Tm), while immature DCs themselves undergo maturation
simultaneously. Tc cells then mediate the acute immune attack to the allograft. Th cells
recruit and activate more immunocytes including Tc, macrophages and B cells and lead
to an enlarged immune response. Tm cells circulate in the host body and mediate the
long-term rejection.
BMSCs are hypoimmunogenic cells, expressing MHC1 but not MHC II. They
also lack co-stimulatory molecules including CD14, CD86, CD40L and CD95L (FasL)
[55]. Therefore, BMSCs can evade the alloreactive T cells and natural killer (NK) cells in
a similar manner like cancer cells [56, 57]. Most researchers believe that MSCs induced
immune tolerance by inhibiting T cell activation and proliferation. Two models have
been proposed: 1) BMSCs inhibited T cell activation through physical contact (the
direction inhibition model) and 2) BMSC produced immunosuppressive soluble factors to
reverse the maturation of antigen-presenting DCs and subsequently led to T cell
inactivation (the indirect inhibition model) (Figure 1-2).
The direct inhibition model proposed that the rate of T cell inhibition was
increased when cell contact between BMSCs and T cells was allowed [58]. Krampera et
al. showed that the inhibitory activity of BMSCs was abrogated when BMSCs were cocultured with T cells in a transwell system or when BMSCs were replaced by BMSC
culture supernatant [59]. Ding et al. supported the direct inhibition model by reporting
that the extracellular matrix proteins such as matrix metalloproteinase (MMP)-2 and
MMP-9 of BMSCs cleaved the IL-2 receptor from the surface of T cells and suppress T
cell responses [60]. However, overwhelming studies supported the indirect model,
showing BMSCs actively secreted multiple soluble immunosuppressive factors such as
indoleamine-pyrrole 2, 3-dioxygenase (IDO), HGF, transforming growth factor-β (TGFβ), prostaglandin E2 (PGE2) and inhibited the alloreactivity of T cells in recipients and
prolonged the allograft survival [58, 61-64].
However, it is worth noting that multiple discrepancies exist among these soluble
factors secreted by MSCs. For example, evidences from Beyth et al. showed that adding
neutralizing antibody to human TGF-β had no effect on the inhibitory activity of
MSCs[65], in contrast to the report by Di Nicola et al.[58]. Ryan et al. reported
constitutive expression of IL-10 by MSCs while Beyth et al. only detected IL-10 in
MLR/MSCs co-culture [55, 65]. Moreover, studies by Tse et al. showed that none of IL10, TGF-β or PGE2 produced by MSCs was responsible for the T-cell inhibitory effect
[66]. Although such discrepancies could be explained by the multiple sources and
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Figure 1-2. MSCs inhibit T cell activation
A. The allograft rejection mediated by T cells. Briefly, antigen-presenting Dendrite Cells
(DCs) present allogeneic antigen through MHC II to the TCR of T0 cells. With assist
from co-stimulatory molecules DCs become activated into mature DCs and
simultaneously promote T cell activation into Tc, Th and Tm. Then the activated T cells
lead to a cascade of immune responses to mediate acute graft rejection and long term
graft rejection. B. MSCs inhibit T cell activation through two mechanisms. (1) Direct T
inhibition, which is achieved by a so-far unknown cell-cell contract mechanism or
MMP2/MMP9 mediated CD25 cleavage on the surface of activated T cells. (2) Indirect T
cell inhibition, which is achieved by releasing soluble factors to inhibit and reverse DCs
maturation. The antigen presenting process through immature DCs which in lack of costimulatory molecules leads to inactivation of activated T cells, proliferation of
immunosuppressive Treg and allogeneic tolerance.
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lineages of MSCs and variation in culture conditions among the research groups, the
underlying signal transduction pathway between soluble factors released by BMSCs and
the antigen-presenting DC require further exploration. Moreover, most of these studies
are conducted using an in vitro cell culture instead of animal model. One goal of our
work is to resolve the mysteries of the immunomodulatory effect of BMSCs.
The immunomodulatory effect of BMSC makes them good candidate in organ
transplantation. Ding et al. reported that BMSCs co-transplanted under the kidney
capsule of immune competent mice protected islet grafts by inhibiting the alloreactivity
of infiltrating T cells [60]. Longoni et al. reported that BMSCs induced a reduction of
inflammatory cytokines and improved the viability of islets infused into the portal vein of
diabetic rats [67]. Li et al. reported reduced Th1/Th2 ratio, Tc cells and Tm cells number
and suppressed DCs maturation once BMSCs were co-transplanted with allograft islets
under the kidney capsules of diabetic C57LB/6 mouse [68]. Kim et al. reported the
combined use of autologous BMSCs and low-dose cyclosporine A to further prolong
graft survival after allogeneic rat islet transplantation [69]. BMSCs were also used to
prevent the allograft rejection in the transplantation studies of other organs including
kidney,[61, 70] skin[71] and heart [62, 72, 73] (Table 1-4).
Stem Cell Based Gene Therapy
In the last decade, gene therapy and stem cell therapy are frequently combined
together to enhance the therapeutic effect, unusually referred as stem cell based gene
therapy. Stem cell based gene therapy can be applied on human islet transplantation from
two directions: 1) Stem cells were used as gene delivery vehicles to express therapeutic
gene in the target sites and 2) stem cells were reprogrammed or transdifferentiated by
genetic modification to replenish the defect cells or tissues (regenerative medicine).
Traditional gene therapy requires direct transduction on targeted tissue so that
transgene can be introduced and expressed afterward. The gene transfer process normally
takes 16~24 hours and has several drawbacks in human islet transplantation. The first is
the loss of islet viability and function during the transduction process. One extra day of in
vitro culture can make a big difference in the function, viability and quantity of islets
needed for optimal transplantation outcome. The second issue is the toxicity and
immunogenicity of adenoviral vectors. Adenoviral at high MOI will kill islets. Even at a
moderate MOI which is not toxic to human islets, adenovirus will increase the
immunogenicity of human islets and consequently induce strong immune rejection.
Therefore for some soluble factors whose effect can be exerted from outside of the
cytoplasm, use stem cells as nursing cells to deliver therapeutic genes can be a smart
strategy to overcome the issues with direction transduction (Figure 1-3). Part of our work
focused on the feasibility of using BMSC as a gene delivery vehicle to support the
survival of human islets after transplantation and the detailed results are presented in
Chapter 5.
BMSCs not only regenerate mesenchymal tissues such as chondrocytes,
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Table 1-4.

BMSCs improve solid organ transplantation

Organs
Kidney

Experimental design
Human of 14 subjects. In vitro MLR study of donor
BMSCs against recipients lymphocytes.
Human of 2 subjects. Autologous BMSCs were injected
IV into recipients at day 7 posttransplantation.

Therapeutic effects of BMSCs
BMSCs inhibit the proliferation of Th and Tc from the
recipients by cell-cell contact and IL-10 and IDO. No effect
on B or NK cells [61].
BMSCs inhibit the proliferation of Tm and Tc. Increase
Treg percentage [70].

Skin

Baboons study. Donor BMSCs from MHC mismatched
donor were injected IV into recipients on the day of
transplantation.

BMSCs inhibit lymphocyte reactivity and prolong the graft
survival and suppress the proliferation. IL-2 partially
reverse the effects of BMSCs [71].

Heart

Rat. In vitro expanded BMSCs were injected IV 1 week
before and on the day of transplantation.
Mice. In vitro expanded BMSCs were injected IV before
transplantation.

BMSCs reduce the alloreactivity of recipient’s T cells and
shift the Th1/Th2 balance to immunosuppressive Th2 [72].
BMSCs induce donor-specific Treg proliferation and
impaired Th1 alloreactivity. Donor-specific Treg do not
lead to immune tolerance of allograft from third-party [73].
BMSCs induce tolerance by secretion IDO and interaction
with DCs [62].

Rat. BMSCs were injected IV with a short course of lowdose mycophenolate.
Islet

Rat. In vitro expanded BMSCs co-infused into liver.
Rat. In vitro expanded BMSCs were co-transplanted into
omental pouch.
Mice. In vitro expanded BMSCs were co-transplanted
beneath the kidney capsule
Monkey. BMSCs from donor and third party were coinfused into portal vein and injected IV thrice at day 4, 5
11 after transplantation.
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Reduce islet number needed for reversal of diabetes
promote revascularization [54].
Inhibit Th1 cell activation promote IL-10 producing CD4+
T cells [74].
BMSCs secreted MMP2 and MMP9 to cleave CD25 from
IL-1R and thus lead to interleukin-2 hyporesponsiveness in
T-cells [60].
BMSCs prolong graft viability and function, probably by
increasing Treg proliferation in peripheral blood [75].

Figure 1-3. Gene therapy and stem cell based gene therapy
In vivo gene transfer involves direct administration of the vector in the tissue of interest.
Ex vivo gene transfer requires collection of cellular targets from the patient. The cells are
treated in culture with the vector. Cells expressing the therapeutic transgene are harvested
and given back to the patient.

18

osteoblasts, and adipocytes but also undergo transdifferentiation into cells from other
lineages upon proper induction, indicating plasticity of these adult stem cells. Gene
transfer into primary BMSCs may greatly promote their transdifferentiation into insulinproducing cells even islet-like cluster, which may replenish the current shortage in the
supply of donor islets. Chen et al. first reported in vitro transdifferentiation of rat MSCs
into functional insulin-producing islet-like cells that actively controlled blood glucose
level in diabetic rats [76]. Then Karnieli et al. and Li et al. independently reported the
generation of insulin-producing cells from human MSCs which were genetically
manipulated to overexpress Pdx-1 with retrovirus and adenovirus, respectively [77, 78].
The research in this area provided new insights and has bright future in human islet
transplantation. However, we just initiate our work in this area and it is out of the scope
of this thesis.
Diabetic Humanized Animal Model
Immune deficient animal models are most frequently used for the research in
human islet transplantation. These models provide optimal environment for the
engraftment of islets from multiple sources because of the absence of immune rejection.
However, these models can only be used to study the function of islets against the nonimmune challenges such as hypoxia, inflammatory cytokines and early graft apoptosis,
which is the PNF of islets.
To understand the physiology of islet grafts under the immune rejection of the
recipient, a humanized mouse model was introduced. Lenny Schultz first introduced the
idea of humanized mouse in which human immune system was rebuilt in mouse by
injecting and settling human peripheral blood mononuclear cells (PBMCs) [79, 80]. The
success in building human immunity in mice relies on the species and strain of mouse.
For example, human immunity can be readily built by injecting PBMCs into NOD.CgPrkdcscidIL2rgtm1Wjl/SzJ (NSG) mice but not Nonobese diabetic severe combined immune
deficient (NOD-SCID) mice. This may be a result of the knock-out of IL-2rgamma,
which has great impact on the settlement of PBMCs, in the NSG mice. Another mouse
model was NOD.Cg-Rag1tm1MomIns2AkitaIl2rgtm1Wjl/SzJ (NRG-Akita) mice, which
spontaneously develop diabetes from 5-7 weeks. However, the difficulty of using NRG
mice is that not all mice develop similar extent of diabetes at a same pace. To control the
extent of diabetes, we choose STZ induced NSG mice for islet transplantation studies.
The risk of GvHD is another factor need to be taken into consideration. The
mature PBMCs has the potential to recognize and attack the xenogeneic organs after
infusion. GvHD is usually characterized by the weight loss, hunched posture, ruffled fur,
reduced mobility, extremely low blood glucose and tachypnea and will lead to animal
death in one day or two. To avoid GvHD, Dose of PBMCs used for infusion is important.
The most frequently reported dose is 5x106 PBMCs/mouse, which is enough to build
human immunity but less potent to induce GvHD. However, even at such a low dose,
GvHD is only pended but not avoided. GvHD will occur at 5~10 weeks after infusion in
most cases, therefore we only buy ourselves a limited window to evaluate the immune
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rejection of human islets even at the safety dose of PBMCs. Recently, a lot of efforts
have been put onto the maturation of human immunity in mice using hematopoietic stem
cells. It was recently demonstrated that the immunocytes matured inside the body of
mouse has less potential to attack organs of mouse and therefore less likely to induce
GvHD like symptoms.
Induce diabetes in humanized mice or vice versa (humanize diabetic mice) are
both tricky task. We chose the latter strategies because of two reasons: 1) it provides
direct contrast of the responses of animals to transplanted human islets in the absence and
presence of human islets and 2) the chemical used to induce diabetes, STZ is strong
immune activation drug and the injection of STZ into humanized mouse will elicit a fast
and strong GvHD and cause animal death in less than 2 weeks. NRG-Akita mouse was
not used in this study purely due to cost considerations. Because mice develop diabetes at
different pace but islets always come together and vary from preparation to preparation.
We need a strategy which is capable of develop suitable extent of diabetes in most mice
in the same day so all of them are suitable for human islet transplantation.
To generate diabetic humanized mouse, we first induce diabetic in NSG mice by
intraperitoneally injection of STZ. We wait 3~4 week until all mice showed similar
extent of diabetes (blood glucose 300~500mg/dL). Then islets were transplanted with or
without BMSCs. After additional 4 weeks, PBMCs were injected to introduce human
immunity. Detail experiments are described in Chapter 6.
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CHAPTER 2.

SPECIFIC AIMS

Aim I. Adenovirus Mediated XIAP Expression to Prevent the Early Graft Apoptosis
in Human Islet Transplantation
The main objective of this part of research is to find the best anti-apoptotic gene
to prevent the early apoptosis in human islet transplantation. Our formal lab members
identified several target genes in the apoptotic pathway of human islet. For example,
Feng Li silenced iNOS gene while Guofeng Cheng silenced caspase 3 using RNA
interference for in vitro protection of human islets from inflammatory cytokines [5, 6].
Ravikiran Panakanti blocked IL-1 pathway by overexpressing IL-1 receptor antagonist
(IL-1Ra) to prevent the early graft loss after islet transplantation into NOD-SCID mice
[4, 8]. All these previous work inspired our research and hereby we hypothesized that
XIAP over expression can be a more effective strategy to prevent the early graft
apoptosis in human islet transplantation. We propose several objectives in this part of
research and discuss in detail in Chapter 3.
1) Learn the techniques in the culture of rat insulinoma cells (INS-1E) and
human islets.
2) Learn the techniques in the generation, amplification, tittering and storage of
adenovirus.
3) Test the transgene expression of XIAP in genetically modified human islets.
4) Test whether XIAP expression improves the outcome of human islet
transplantation in immunodeficient NOD-SCID mice.
Aim II. RGD Peptide Modified Adenovirus Encoding XIAP and HGF to
Simultaneously Prevent Early Graft Apoptosis and Promote Revascularization to
Improve the Outcome of Human Islet Transplantation
The main objective of this research is to improve the transduction efficiency of
traditional adenoviral vectors. In 2004, when we first initiated gene therapy project, we
used plasmid and lipid-mediated transfection to introduce gene of interest into human
islets [12]. However, the gene transfer efficiency of this strategy was extremely low. In
2006 we converted the plasmids to adenoviral vectors, which significantly improved the
gene transfer efficiency [7]. However, the titer of adenovirus must be strictly controlled
because high titer of virus is known to induce toxicity in human islets. After that we
designed several bipartite adenoviral vectors so that two therapeutic genes can be coexpressed simultaneously without increase the viral titer [4, 8]. But this strategy was
incompetent to reduce the viral titer for optimal transgene expression. Hereby we were
trying to modify the surface of adenovirus so that less viral particles can be used to
transduce human islets without compromising the transduction efficiency. We propose
several objectives in this part of research and discuss in detail in Chapter 4.
1) Learn the techniques in the induction of moderate diabetes in mice.
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2) Compare the transduction efficiency of unmodified adenovirus and RGD
modified adenovirus.
3) Test the transgene expression of XIAP and HGF in genetically modified
human islets.
4) Test whether genetically modified human islets improve the outcome of
human islet transplantation in immunodeficient NOD-SCID mice.
Aim III. Use BMSCs as Gene Delivery Vehicles to Express HGF and IL-1Ra to
Improve the Outcome of Human Islet Transplantation
The main objective of this study is to determine whether gene therapy can be
achieved without the direct gene transfer into human islet. We successfully decreased the
viral titer for optimal transgene expression in the previous study. However, the use of
virus, at whatever titer, will raise safety concerns such as immunogenicity and
tumorigenicity. Moreover, before islet transplantation can be performed, gene transfer
into human islets will cost one extra day, which makes great difference in the viability
and function of islets and thus the outcome of islet transplantation. We hypothesized that
BMSC can be genetically modified by adenovirus before the arrival of islet preparations
and co-transplanted with fresh human islets to treat type 1 diabetes. We propose several
objectives in this part of research and discuss in detail in Chapter 5.
1) Test the transduction efficiency of adenovirus on BMSCs.
i. Test whether the adenoviral transduction affects the gene expression prolife
and stem cell like properties of BMSC.
ii. Test the duration and level of transgene expression in genetically modified
BMSCs.
2) Test the protection of genetically modified BMSCs to human islets in islet
perifusion study in vitro.
3) Test whether islet/BMSCs cotransplantation improve the outcome of human
islet transplantation in immunodeficient NOD-SCID mice.
Aim IV. Use BMSCs to Prevent the Immune Rejection of Islet Allografts in
Humanized NSG Mice
Gene therapy is incompetent to prevent the immune rejection, while stem cells
can be an effective strategy to overcome the immune rejection. In this study, we
borrowed an up-to-date humanized animal model to determine immunomodulatory effect
of BMSC to protect human islets in the presence of human immunity. We propose
several objectives in this part of research and discuss in detail in Chapter 6.
1) Build human immunity in STZ-induced diabetic NSG mice through
intraperitoneal injection of human PBMCs.
2) Determine the immunomodulatory effects of BMSCs in vitro.
i. Characterize the surface markers of BMSCs.
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ii. Test whether BMSCs can suppress the proliferation and activation of
PBMCs in the mixed lymphocyte reaction (MLR).
iii. Test whether BMSCs can promote the regulatory T cells in MLR.
3) Determine the mechanism underlying the immunosuppressive effect of
BMSCs.
i. Determine whether BMSC alone can suppress the proliferation and
activation of PBMCs.
ii. Determine the role of IL-10 in the immune modulation mediated by
BMSCs.
iii. Determine the sources of IL-10 production in the MLR/BMSC mixture.
4) Test the tropic effect of BMSCs in vitro.
i. Test the gene expression profile of BMSC.
ii. Test whether BMSC can improve the insulin production of islets under the
challenges by inflammatory cytokines.
5) Test whether BMSCs prevent the graft rejection in human islet transplantation
in a humanized immune-competent mice model.
i. Test whether BMSCs prevent T cell infiltration into the transplantation site.
ii. Test whether BMSCs increase Tregs.
iii. Test whether BMSCs improve early engraftment and revascularization of
human islet transplantation.
Aim V. Use Small Molecular Compound Drug to Prevent the Immune Rejection of
Islet Allografts in Humanized NSG Mice
BMSCs were capable to prevent the immune rejection of human islets in
humanized mouse model. However, BMSCs will be sequestered in the lung after
intravenous injection, making them unsuitable for repeated dosing. Despite the
hypoimmunogenic nature, BMSCs from a third party, if used in large quantity, will raise
safety concerns about the immunogenicity and tumorigenicity. In this study, we
synthesized a compound drug (E)-2,3,5-trihydroxy-5-(propylcarbamoyl)cyclohexyl 6-(4ethoxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4enoate (JP-3-110) by conjugating anti-apoptotic compound 1,3,4,5-tetrahydroxy-Npropylcyclohexanecarboxamide (KZ41) and immunosuppressive compound MPA. We
hypothesized that this new compound can exert the immunosuppressive effect through
intravenous injection while avoiding the toxicity associated with MPA. We propose
several objectives in this part of research and discuss in detail in Chapter 7.
1) Synthesis and characterization of a compound drug JP-3-110 which is
composed of MPA, an immunosuppressive drug and KZ-41, a novel antiapoptotic compound for human islet transplantation.
2) Compare the anti-apoptotic effect of JP-3-110 and KZ41 against the
inflammatory cytokines.
3) Compare the immunosuppressive effect of JP-3-110 and MPA on PBMCs.
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CHAPTER 3. XIAP OVEREXPRESSON MEDIATED BY ADENOVIRUS TO
PREVENT APOPTOSIS OF ISLET TRANSPLANTATION
Introduction
The loss of function of transplanted human islets is usually accompanied with the
apoptosis of insulin-producing β cells. The apoptosis of β cells can be caused by many
reasons including lack of supplies of oxygen and nutrition, poor revascularization,
inflammatory cytokines, and reactive oxidative species. In most cases, islet loss occurs in
the first two weeks after transplantation, and will decrease significantly due to successful
revascularization thereafter [81, 82]. Therefore, expression of an antiapoptotic gene in β
cells timely may be an effective strategy to improve islet viability post transplantation
[17]. We previously reported ex vivo transduction of islets with adenoviral vector
encoding human interleukin-1 receptor antagonist (IL-1Ra) to prevent IL-1β induced
apoptotic cell death of islets [3]. We also demonstrated that the inhibition of caspase-3
pathway helped to protect human islets from apoptosis caused by inflammatory cytokines
in vitro [6]. However, the apoptosis of islets usually involved multiple inflammatory
cytokines and a network of signal transduction pathways (Figure 3-1). The therapeutic
effect gained from the inhibition in a single factor or pathway was limited and not
capable to reverse the apoptosis of islets in a whole picture. For example, IL-1Ra
expression was not able to address the apoptosis of islets caused by hypoxia and ROS. A
target gene with more ubiquitous anti-apoptotic effect was needed.
In this study, we identified XIAP as a target gene. XIAP is a well characterized
inhibitor of apoptosis by inhibiting three types of caspase at the same time (Figure 3-1).
The BIR2 domain of XIAP inhibits caspase 3 and caspase 7, while BIR3 domain inhibits
caspase 9 [83-85]. Besides, XIAP is also capable of address the apoptosis from death
receptor pathway and mitochondria pathway. Therefore, XIAP holds great potential to
inhibit the apoptosis of human islets caused by hypoxic environment, ROS and
inflammatory cytokines together.
XIAP overexpression minimizes the injury in pancreatic β-cells caused by
hypoxia and reperfusion [86]. Hui and colleagues demonstrated the reversal of the
negative effects of immunosuppressive drugs by XIAP overexpression on human islets
[87]. XIAP has also been proven to improve the murine islet viability after isolation [88].
However, the mechanism underlying the protective effect of XIAP was also not
thoroughly understood and promising long term data normoglycemic control in animal
experiments is still needed. Therefore, in this study, we transduced INS-1E cells and
human islets with replication deficient adenovirus encoding XIAP to determine whether
XIAP overexpression protects β cells and islets from cytokine induced cell death.



Reprinted with permission from American Chemical Society. Wu, H, Panakanti, R, Li,
F, and Mahato, RI (2010). XIAP gene expression protects beta-cells and human islets
from apoptotic cell death. Molecular Pharmaceutics 7: 1655-1666.
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Figure 3-1. Schematic diagram showing the role of XIAP in the apoptotic
pathway of human islets
XIAP inhibits caspase 3, caspase 7 and caspase 9 simultaneously. XIAP also inhibits the
apoptosis caused by the mitochondria pathway (hypoxia, reactive oxygen species (ROS),
and ultraviolet radiation) and death receptor pathway (inflammatory cytokines) at the
same time. Therefore, we hypothesized that the anti-apoptotic effect of XIAP
overexpression should be better than the gene silencing of caspase 3 or iNOS and the
blocking of IL-1R.
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Materials and Methods
Materials
The replication deficient (ΔE1/ΔE3) adenoviral vector encoding human XIAP
(Adv-hXIAP) was purchased from Vector Biolabs (Philadelphia, PA). RPMI 1640
medium was purchased from Invitrogen (Carlsbad, CA). CMRL-1066 medium was
purchased from Sigma Aldrich (St. Louis, MO). Fetal bovine serum (FBS) was purchased
from MediaTech Cellgros (Herndon, VA). Phosphate buffer solution (PBS) was
purchased from GIBCO-BRL (Gaithersburg, MD). Human XIAP enzyme-linked
immunosorbent assay (ELISA) kits and cytokines such as IL-1β, TNF-α, and interferon
(IFN)-γ were purchased from R&D Systems (Minneapolis, MN). Human Insulin ELISA
kits were purchased from Alpco Diagnostics (Windham, NH). RNA extraction kit and
Caspase-Glo 3/7 assay kit, DeadEnd Colorimetric terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) system, and APO-DIRECT TUNEL system were
purchased from Promega (Madison, WI). SYBR Green real-time PCR master mix and
reverse transcription reagents were purchases from Applied Biosystems (Foster city, CA).
Virus amplification and titer determination
Adv-hXIAP was transduced into 293 cells. At 48h post transduction, almost 90%
of the cells were detached from the flask. Then, the cells were collected, centrifuged and
freezed and thaw three times to release Adv-hXIAP viral particles. Then, the viral
solution was used to determine the viral titer using an Adeno-X rapid titer kit from
Clontech (Mountain View, CA). Briefly, different dilutions of Adv-hXIAP was taken and
transduced to 293 cells, using untransduced cells as a control. After 48h posttransduction, 293 cells were fixed and incubated with Anti-Hexon antibody, followed by
a secondary horse radish peroxidase (HRP)-conjugated antibody. Then the cells were
stained with 3, 3’ diaminobenzidine tetrahydrochloride (DAB) substrate and positively
stained cells were counted under a microscope, and the titer was determined.
Cell and islet culture and transduction
INS-1E cells, a gift from Professor Claes B. Wolheim (University Medical
Center, Geneva, Switzerland) were seeded at a density of 106 cells per 24-well plate.
After 24h, INS-1E cells were transduced with Adv-hXIAP of indicated MOI for 3h
followed by washing and further culturing for 2 days. Human islets were received from
one of the several Islet Cell Resource (ICR) Centers through ICR services for Basic
Science Applications, in culture media at 4°C. On receiving, the islets were cultured in
CMRL-1066 medium containing 10 % FBS and 1 % Penicillin Streptomycin. INS-1E
cells and human islets were transduced with Adv-hXIAP, while nontransduced human
islets as well as the islets transduced with Adv-LacZ were used as controls. To determine
the optimal MOI of Adv vectors in terms of plaque forming units (pfu) per IE, 1000 IE
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were incubated with diluted Adv-hXIAP in 300μl media in a 96 well plate for 12 h,
followed by washing and further culturing in 1ml of media in 24-well plates for 2 days.
Quantitative real-time PCR
INS-1E cells were collected to determine XIAP mRNA level by quantitative
Real-time PCR post-transduction. Briefly, INS-1E cells were collected and total RNA
was isolated using RNAeasy mini isolation kit from Promega (Madison, WI) 3 days posttransduction. RNA concentration was measured by UV spectrophotometer. Then 170 ng
of extracted RNA was converted into cDNA using MultiScirbe reverse transcriptase and
random hexamers (Applied Biosystems, Inc., Foster City, CA) by incubation at 25°C for
10 min, followed by reverse transcription at 48°C for 30 min and enzyme inactivation at
95°C for 5 min. Then 2 μl cDNA was used as a template and analyzed by SYBR Green-I
dye universal PCR master mix on a LightCycler 480 Instrument. Caspase 3 mRNA
expression was also determined by the same method. β-actin was used as an internal
control. All samples were run in triplicates. The primer sequences were as follows:
human XIAP (forward) 5’-TGT TTC AGC ATC AAC ACT GGC ACG-3’, (reverse) 5’TGC ATG ACA ACT AAA GCA CCG GAC-3’; rat caspase 3 (forward) 5’-CAT GAC
CCG TCC CTT GAA-3’, (reverse) 5’-CCG ACT TCC TGT ATG CTT ACT CTA-3’; rat
β actin (forward) 5’-AGT CAT GTA CGT AGC CAT-3’, (reverse) 5’-CTC TCA GCT
GTG GTG GTG-3’.
ELISA and western blot
At the indicated time post-transduction, INS-1E cells or human islets were
collected to determine XIAP protein level by ELISA or Western Blot. Total protein was
extracted by lysing INS-1E cells or human islets with RIPA buffer (Sigma) and stored in
-80 oC for ELISA and Western Blot study. For ELISA, XIAP levels were measured as
per the manufacturer’s protocol (R&D Systems, Minneapolis, MN). For Western Blot
analysis, the samples were mixed with 6 × Laemmli sodium dodecyl sulfate (SDS) buffer
(Boston BioProducts) and then boiled for 5 min to denature the protein. Then groups of
samples were loaded to 4%-15% Tris-HCl Precast Polyacrylamide Gel (Bio-Rad,
Hercules, CA) for electrophoresis and subsequently transferred to Immobilon
Polyvinylidene Fluoride (PVDF) membrane (Millipore). After blocking with 3% bovine
serum albumin in 1× PBST (PBS containing 0.05% Tween-20) for 1 h at room
temperature, the membranes were further incubated with goat polyclonal IgG to XIAP
and actin (Santa Cruz) primary antibodies (1:500) overnight at 4 °C. Membrane was then
incubated with HRP-conjugated rabbit polyclonal antibody to goat (1:10000) (Abcam)
for 1 h at room temperature. Target proteins were detected by enhanced
chemiluminescence (ECL) detection kit (GE Healthcare Life Sciences, Pittsburgh, PA).
Total protein concentration of INS-1E cells and islet extracts was also determined using
the bicinchoninic acid (BCA) protein assay kit to normalize the results. Actin was used as
an internal control for Western Blot.
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Caspase detection
Caspase-Glo 3/7, 8 and 9 assay kits were used to analyze caspase 3/7, 8 and 9
activities, respectively, as per the manufacturer’s protocol (Promega). This assay kit
provides a proilluminescent caspase substrate, DEVD, when cleaved by caspases, will
release luciferin to quantitatively determine caspase concentration. Briefly, 48h following
transduction and cytokine cocktail treatment for additional 3h, 100 μl Caspase-Glo
reagent was added to 100 μl of culture supernatants in 96-well plates and incubated at
room temperature for 1h. The contents were then transferred into culture tubes and
luminescence was determined using a luminometer (Berthold, Germany).
Cell viability
Cell viability was determined using MTT assay. Briefly, following transduction
with adenoviral vectors at MOI=2, INS-1E cells were further incubated with cytokine
cocktail, including 5ng/ml IL-1β, 25ng/ml TNFα, and 25ng/ml IFNγ, for indicated time.
At the end of the cytokine treatment, INS-1E cells were further cultured with medium
containing 0.5mg/ml 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT, Sigma) for 2h in 37oC. Then the medium was removed and 200ul DMSO was
added into each well to dissolve the formazan crystals. The absorbance was measured in
550 nm using a microplate reader (Bio-Rad, Hercules, CA). The relative cell viability (%)
was calculated.
TUNEL assay
To determine the apoptotic cell death, following transduction for 3h, INS-1E cells
were incubated with cytokine cocktail for 48h. Apoptotic cells were dark stained using
DeadEnd Fluorometric TUNEL System from Promega (Madison, WI) as per the manual.
To quantitatively determine the effect of XIAP expression on cytokine induced INS-1E
cell apoptosis, APO-DIRECT kit (Promega, Madison, WI) was used to detect apoptotic
cells. Briefly, following transduction for 3h and incubation with the cytokine cocktail for
additional 48h, INS-1E cells were made to single cell suspension by trypsin digestion as
described above. The cells were fixed in 1% paraformaldehyde in PBS (pH 7.4) and then
treated with ice-cold 70% ethanol and stained with FITC-dUTP and propidium iodide.
Fluorescent intensity was measured by flow cytometry and analyzed using CELLQUEST
software (BD Bioscience). Nontransduced cells without cytokine treatment were served
as a negative control. Three sets of independent transduction experiments were carried
out for each assay.
Static insulin release
In vitro function of INS-1E cells and human islets after transduction with AdvhXIAP was determined by the static incubation method. Briefly, after transduction media
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was carefully removed with pipette, INS-1E cells and human islets were sequentially
incubated in the media containing 2.5mM (basal) and 22mM glucose (stimulated) at 37ºC
for 1h. Supernatants were collected and analyzed for insulin release by Insulin
Ultrasensitive EIA kit (Alpco Diagnostics, Salem, NH). Insulin secretion was expressed
as µU/ml and the ratio of insulin levels at 22mM to 2.5mM glucose was used to calculate
the stimulation index.
Islet transplantation studies
Animal experiments were performed as per the NIH
(http://grants1.nih.gov/grants/olaw/references/phspol.htm) and institutional animal care
and use guidelines using the approved protocol. To induce diabetic animal model, STZ
(40 mg/kg) was administered to NOD-SCID mice by intraperitoneal injection for 5
consecutive days. Animals were considered to be diabetic after two consecutive
measurements of blood glucose ≥ 300 mg/dl using a One Touch Ultra Glucometer
(LifeScan, Inc.). Before transplantation, human islets were grouped in four and
transduced with blank vehicle, Adv-hXIAP, Adv-LacZ, and Adv-hXIAP with 50 ng/ml
embelin at the dose of 1,000 MOI for 12 h and washed with PBS. About 1,000
transduced or non-treated islets were transplanted under the left kidney capsules of
diabetic mice. The nonfasted glucose levels were measured from the snipped tail of each
animal up to 42 days post-transplantation. Then the mice were anesthetized to collect
blood to measure serum c-peptide level by ELISA; Alpco Diagnostics (Windham, NH),
and the graft-bearing kidneys were removed from some animals to confirm the function
of islet grafts by the return of blood glucose levels to ≥ 300 mg/dL for two consecutive
days. Since most mice developed high blood glucose level ≥ 600mg/dL after STZ
treatment and long time after transplantation, all mice were subjected to daily
intraperitoneal administration of 10U/kg insulin to maintain mice survival. To minimize
the interference to blood glucose measurement by insulin injection, all the measurement
were done at least 5h after insulin injection.
To determine the effect of ex vivo Adv-hXIAP transduction prior to
transplantation on insulin production of human islets post transplantation, transplanted
mice were sacrificed at day 43 and kidneys bearing islets were isolated, washed with
PBS, fixed in 4% paraformaldehyde overnight, and embedded in paraffin as described
before[12]. Sections of 5–7 μm thickness were cut and immune-stained with rabbit antiinsulin first antibody (Abcam) 1:500 overnight. Then immune-reactivity was detected
using goat anti-rabbit IgG, H& L chain specific peroxidase conjugate (Abcam) and
subsequent incubated with DAB substrate. Sildes were further counter-stained
Haematoxylin (Sigma).
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Results
XIAP gene expression in INS-1E cells and human islets
As shown in Figure 3-2, real-time PCR results showed increase in XIAP mRNA
level of INS-1E cells by 3000 folds and 100,000 folds after transduction of INS-1E cells
with Adv-hXIAP at MOI of 1 and 10, respectively. Similarly, XIAP protein
concentration increased by 13 folds (from 0.54 ng/μg to 6.94 ng/μg) and 28 folds (from
0.54 ng/μg to 12.59 ng/μg) for INS-1E cells after transduction with Adv-hXIAP at MOI
of 1 and 10. In human islets, dose-dependent XIAP gene expression was also observed
after Adv-hXIAP transduction. XIAP protein level increased from the basal level of
16.17 ng/μg to 28.87, 75.58, and 95.55 ng/μg when 1000 IEs were transduced with AdvhXIAP at MOI of 200, 1000, and 2000, respectively. These results were in good
agreement with our Western Blot analysis, where XIAP band density increased with
increasing MOI, suggesting increase in XIAP protein expression after transduction.
XIAP improves INS-1E cells viability and function against inflammatory cytokines
Following transduction, INS-1E cells were further incubated with inflammatory
cytokine cocktail for 48h. INS-1E cell viability decreased after cytokine treatment, as
determined by the MTT assay (Figure 3-3). However, transduction of INS-1E cells with
Adv-hXIAP showed only 14% decrease in cell viability, compared with untransduced
INS-1E cells (37%) and INS-1E cells transduced with Adv-LacZ (55%), suggesting the
protective effect of XIAP. INS-1E cell function was determined by insulin stimulation
test. Following transduction and cytokine treatment for 12h, INS-1E cells were
sequentially incubated with 2.5 nM and 22.5 nM glucose medium and secreted insulin
was determined by ELISA. The results showed that under cytokine treatment, AdvhXIAP transduced INS-1E cells did produce more insulin than untransduced INS-1E
cells and Adv-LacZ transduced INS-1E cells, suggesting the protective effect of XIAP on
INS-1E cell function.
XIAP inhibits INS-1E cell apoptosis against inflammatory cytokines
One crucial step in apoptosis is DNA fragmentation, resulting from the activation
of endonucleases during the apoptotic process [89]. Therefore, the analysis of DNA
fragmentation with TUNEL assay is a useful approach to gain information regarding cell
apoptosis (Figure 3-4). After 48h of incubation with cytokine cocktail post-transduction,
Adv-hXIAP transduced INS-1E cells showed significant decrease in the number of
apoptotic cells, which were stained dark brown, compared with untransduced INS-1E
cells, and Adv-LacZ transduced INS-1E cells. In a parallel experiment, all cells were
fixed, stained with FITC, and run through flow cytometry to count the relative ratio of
apoptotic cells. Adv-hXIAP transduced INS-1E cells showed an average of 5.7% of
apoptosis, significantly lower than 27.9% and 32.8% of untransduced INS-1E cells and
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Figure 3-2. Adenovirus mediated overexpression of XIAP in INS-1E cells and
human islets
Overexpression of XIAP in 106 INS-1E cells and 1000 IEs at 2 days after Adv-hXIAP
transduction at indicated MOI as determined by Realtime PCR, ELISA and western blot.
Realtime PCR was not done for human islets because of the difficulty of isolating mRNA
from islet clusters. MOI describes the number of adenoviral particles capable to transduce
each INS-1E cells or each islet cluster. *p<0.05 under one way ANOVA compared with
untransduced group. Data are presented as the mean + SD. n = 3.
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Figure 3-3. Beneficial effect of XIAP overexpression on INS-1E cell viability and
function
A. Higher viability of Adv-hXIAP transduced 106 INS-1E cells was observed in the
presence of inflammatory cytokine cocktail, compared with untransduced cells and AdvLacZ transduced cells. B. More insulin production by INS-1E cells transduced with AdvhXIAP was observed under cytokine treatment. n = 3. Data are presented as the
mean±SD. *p<0.05 under t test compared with Adv-XIAP group.
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Figure 3-4. Anti-apoptotic effect of XIAP overexpression on INS-1E cells
Left panel, dark stain of apoptotic INS-1E cells under cytokine treatment, as determined
by DeadEnd Fluorometric TUNEL System. Right panel, apoptotic cell number counted
by flow cytometry following fluorescent labeling by APO-DIRECT. The values indicate
the percentage of apoptotic cells. A.D. Untransduced INS-1E cells. B.E. Adv-LacZ
transduced INS-1E cells. C.F. Adv-hXIAP transduced INS-1E cells. Data are presented
as the mean + SD of n = 3. *p<0.05 under one way ANOVA compared with
untransduced group.
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Adv-LacZ transduced INS-1E cells, respectively.
XIAP inhibits caspase activity in INS-1E cells and human islets
XIAP binds to caspase 3 and caspase 7 with its BIR2 domain and caspase 9 with
its BIR3 domain [90], and is known to inhibit their activities [91]. Since caspase 3/7 was
the converging point of apoptotic pathways, we determined the effect of XIAP gene
expression on caspase 3/7 activity. XIAP overexpression led to dose dependent caspase
inhibition under cytokine treatment (5ng/ml IL-1β, 25ng/ml TNFα, and 25ng/ml IFNγ for
3h) (Figure 3-5). Caspase 3/7 activity decreased up to 40% post transduction of both
INS-1E cells and human islets with Adv-hXIAP. Similarly, XIAP expression also
inhibited caspase 8 and caspase 9 activities in human islets, resulting in a total inhibition
of 45% and 40%, respectively.
Prolonged normoglycemic control of diabetic mice by Adv-hXIAP transduced
human islets
The effect of XIAP gene expression on the islet survival and function posttransplantation was determined in terms of blood glucose, animal weight gain, and insulin
production, by comparing mice transplanted with Adv-hXIAP transduced human islets
and mice transplanted with untransduced human islets, Adv-LacZ transduced human
islets, and Adv-hXIAP with embelin co-transduced human islets. Following
transplantation, blood glucose level decreased to around 200 mg/dL for all transplanted
mice (Figure 3-6), suggesting the immediate reversal of diabetic hyperglycemia by islet
transplantation. However, the blood glucose level of the mice transplanted with untransduced islets, Adv-LacZ transduced islets, and Adv-hXIAP plus embelin cotransduced islets gradually increased after the first week post transplantation, and was
maintained to the diabetic level (~600 mg/dL) since 2 weeks post transplantation (Figure
3-6), suggesting the impaired normoglycemic control caused by the impaired islet
viability and function. This result is also consistent with previous reports [4, 8, 92]. In
contrast, the mice transplanted with Adv-hXIAP showed prolonged normoglycemic
control till 6 weeks post transplantation, probably due to the improvement in transplanted
islet viability and function by XIAP overexpression. It should be noted that since most
mice became highly diabetic after STZ treatment and the experiment last for more than 6
weeks, all mice were subjected to daily intraperitoneal administration of 10U/kg insulin
from the second week post transplantation. To minimize the interference of insulin
injections to blood glucose measurement, all the measurement were made 5h after insulin
injection.
As listed in Table 3-1, the mice transplanted with Adv-hXIAP transduced human
islets showed significant increase in average body weight six weeks after transplantation,
probably due to the prolonged normoglycemic control by XIAP overexpression. To
further monitor the long-term islet function following transplantation, the kidney bearing
Adv-LacZ transduced islets and Adv-hXIAP transduced islets were isolated at the end of
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Figure 3-5. XIAP overexpression inhibits caspase activities of INS-1E cells and
human islets after cytokine treatment
XIAP expression significantly inhibited activities of caspase 3/7, 8, and 9 in a dose
dependent manner as determined by Caspase Glo Kit. A. Caspase 3/7 activity in INS-1E
cells. B. Caspase 3/7 activity in human islets. C. Caspase 8 and caspase 9 activities in
human islets *p<0.05 under one way ANOVA compared with untransduced group. Data
are presented as the Mean + SD. n = 3.
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Figure 3-6. Effect of Adv-hXIAP transduction on the outcome of islet transplantation
Blood glucose level of STZ-induced diabetic NOD-SCID mice transplanted with 1000 Adv-hXIAP transduced IEs under the kidney
capsule The mice transplanted with Adv-LacZ transduced and nontransduced IE were used as controls. Embelin was also used as
negative control since it can reverse the effect of XIAP overexpression. The nonfasting glucose levels were measured in each animal
up to 42 days post-transplantation. At day 43 after transplantation, the islet graft-bearing kidney was removed and mice were
sacrificed. Data are presented as the Mean±SD. n = 5.

36

Table 3-1.

Mouse weight measurements after human islet transplantation

Weight
Control
Adv-LacZ
Adv-hXIAP
Adv-hXIAP+Embelin

Day 0
18.06±1.01
17.93±1.33
18.39±0.69
18.18±0.93

Day 7
17.90±2.43
17.20±2.35
17.83±1.85
18.07±2.70

Day 28
18.90±1.99
18.87±2.28
20.49±2.36*
18.76±2.07

Day 42
19.21±2.05
18.93±2.40
22.33±2.43*
19.13±3.07

*p<0.05 under one way ANOVA test. Data are presented as the Mean±SD. n = 5.
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experiment and subjected to immunohistochemical analysis. The right kidneys without
islet transplantation were also isolated and used as the negative control (Figure 3-7). The
positive staining of insulin was more evident in kidney section bearing Adv-hXIAP
transduced islets, while only rare insulin staining was observed in the kidney section
bearing Adv-LacZ transduced islets (Figure 3-7), suggesting the maintenance of insulin
secretion. The serum of mice was also collected to measure serum c-peptide level by
ELISA. Result showed that c-peptide level in the mice transplanted with Adv-hXIAP
transduced islets was significantly higher than the other group, indicating improved islet
function in Adv-hXIAP transduced human islets post transplantation (Figure 3-7).
Protective effect of Adv-hXIAP transduction will be reversed by XIAP inhibitor
embelin
As shown in Figure 3-8, embelin cytotoxicity was first determined ex vivo by
MTT. Embelin does not show significant toxicity on INS-1E cells in 24 h treatment when
concentration is below 200 nM, and 50 nM was selected as a proper concentration of
embelin to inhibit XIAP expression. XIAP expression in human islets was greatly
inhibited after embelin treatment, even lower than the basal XIAP expression in normal
islets, which was consistent with the literature [93, 94]. The cytoprotective effect of
XIAP overexpression was impaired by XIAP inhibitor embelin. Adv-hXIAP transduced
INS-1E cell viability was decreased to 44% after incubation with cytokine cocktail and
50nM embelin for 24h, compared with 88% viability with just cytokine cocktail. Caspase
3/7 activity was restored to the untransduced level after embelin treatment, suggesting the
inhibitory effect of XIAP gene expression on caspase activity can be reversed by
embelin. The prolonged normoglycemic control of diabetic mice by Adv-hXIAP
transduced human islets can also be impaired by additional embelin incubation before
transplantation, in which the duration of normoglycemia was significantly decreased
from 6 weeks to 2 weeks (Figure 3-6), suggesting the loss of islet viability and function
by XIAP inhibition.
Discussion
Human islet transplantation has great potential to provide type 1 diabetic patients
with sustained and improved normoglycemic control and a period of insulin
independence. However, most islet grafts get destroyed in the early days posttransplantation due to inflammatory cytokines, ROS and failure to revascularize induced
by immune rejection, let alone the islet loss in islet isolation, transportation and
transplantation processes [95, 96]. Although the use of immunosuppressant to the
transplant recipient can partially relieve graft rejection by the host immune system, these
drugs have significant toxicity including nephrotoxicity, ulcers, hyperglycemia,
osteoporosis, and increased risk of infection and neoplasms [97-100]. Therefore, islets
from two to four donors are generally necessary for successful islet transplantation [101].
Since the limited islet supply nowadays cannot meet the increasing islet need for
transplantation, improving islet graft viability and function post transplantation is one of
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Figure 3-7. Immunohistochemical staining of kidney sections at 42 days after
transplantation
A. Kidney section bearing no islet graft. B. Kidney section bearing Adv-hXIAP
transduced islet grafts. C. Kidney section bearing Adv-LacZ transduced islet grafts.
Insulin was stained in brown color. Nuclear was stained in purple by haematoxylin. D.
Increasing C-peptide level in Adv-hXIAP group was observed in the serum collected at
42 days after transplantation. *p<0.05 under one way ANOVA compared with
untransduced group. Data are presented as the Mean±SD. n = 5.
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Figure 3-8. Beneficial effect of XIAP overexpression on INS-1E cells can be
reversed by XIAP inhibitor embelin
A. Cytotoxicity study of embelin on 106 INS-1E cells/well for 24 h. B-C. Embelin can
inhibit XIAP expression as illustrated by ELISA and western blot. D. Embelin reversed
the cytoprotective effect of XIAP overexpression on 106 INS-1E cells against cytokine
treatment. E. Embelin reversed the caspase inhibition effect of XIAP overexpression on
INS-1E cells. *p<0.05 under one way ANOVA compared with zero embelin
concentration. Data are presented as the Mean±SD. n = 3.
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the major barriers to overcome for successful islet transplantation.
As we mentioned before, the first two weeks post islet transplantation is crucial
for graft survival. This makes adenoviral vector a good candidate for ex vivo gene
therapy because of its high transduction efficacy and stable expression ability up to eight
weeks [102, 103]. In our group, we have been working on the adenovirus mediated gene
therapy method to improve the islet viability and function against graft rejection post
transplantation for years. Briefly, besides the growth factor gene delivery to reduce
apoptotic β-cell death and promote β-cell proliferation post transplantation, we also
demonstrated that proapoptotic gene silencing such as iNOS silencing and caspase 3
silencing by siRNA and shRNA respectively, could reduce the apoptotic β-cell death
caused by inflammatory cytokines [5, 6, 8, 17].
Compared with other gene therapy methods, XIAP gene delivery holds its own
merits. The major problem with growth factor gene therapy was that growth factors were
secreted protein, whose effects were determined by microenvironment concentration.
Therefore, in Adv-transduced human islet clusters, growth factor concentration in
extracellular microenvironment could not be uniformly distributed and finely regulated.
Accumulation of microenvironmental VEGF in the outer layer of human islets may
finally lead to aberrant angiogenesis and islet loss [10, 104].
XIAP is strictly localized in the cytoplasm in a granular supranuclear pattern
[105]. Therefore, after Adv-hXIAP transduction, the outer layer of human islets which
will be more exposed to the inflammatory cytokines and hypoxic environment, will
express higher level of XIAP and achieve an optimal defense mechanism against
cytokine and hypoxia challenge in the early stage of graft survival. Transduction of INS1E cells and human islets with Adv-hXIAP resulted in significant increased XIAP
expression (Figure 3-2). With adenovirus mediated XIAP overexpression method, we
can easily reach the caspase inhibition effect in human islets without inducing acute
immune response by ex vivo transduction. Adv-hXIAP ex vivo transduction also led to
~40% inhibition of caspase 3/7, caspase 8, and caspase 9 activities in both INS-1E cells
and human islets (Figure 3-5). The protective effect of Adv-hXIAP transduction on
human islets was lasted for more than six weeks after transplantation. Another advantage
of XIAP expression, though not discussed in this paper, is its ability to reverse the islet
loss caused by hypoxia [16, 106], which made it a good candidate for ex vivo
transduction of islets prior to transplantation.
As a result of caspases inhibition, we also observed the protective effect of XIAP
expression on INS-1E cells against cytokine cocktail treatment. Compared with
untransduced INS-1E cells, Adv-XIAP transduced INS-1E cells showed significant
improved cell viability, decreased apoptotic cells and increased insulin production under
cytokines treatment. One interesting point we observed in this experiment is that AdvLacZ transduced INS-1E cells showed decreased cell viability and decreased insulin
production under cytokines treatment, despite the fact that Adv-LacZ at such low MOI
(MOI=2) has no significant effect on INS-1E cell viability (data not shown), suggesting
the cytotoxic or proapoptotic effect of inflammatory cytokines could be possibly
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exaggerated by viral transduction. But since XIAP expression effectively blocked the
caspases activation, it reversed the cytotoxic or proapoptotic effect of cytokines.
Our in vivo data showed the prolonged normoglycemia control of highly diabetic
NOD-SCID mice and increasing insulin production after transplantation with AdvhXIAP transduced human islets for six weeks, which was much longer than the previous
reports [8, 17, 86], probably due to the protective effect of XIAP in the first two weeks
after transplantation. However, when transplanted with human islets in which XIAP
expression was almost silenced by co-culturing with its inhibitor embelin, the blood
glucose level of the diabetic NOD-SCID mice was decreased (Figure 3-6). This result
suggested XIAP level played a crucial role in determining islet viability after
transplantation in highly diabetic patients. However, it should also be addressed that all
mice were subjected to daily intraperitoneal administration of 10U/kg insulin from the
second week post transplantation because it was necessary to keep the mice survival in all
the other three groups except the one transplanted with Adv-hXIAP transduced human
islets or these mice might not have survived for six weeks with such high blood glucose
levels. To minimize the interference of insulin injection to blood glucose measurement to
the lowest extent, all the measurement were made at least 5h after insulin injection.
Adv-hXIAP transduced INS-1E cells and human islets, when exposed to small
molecular XIAP inhibitor embelin, had greatly decreased XIAP activity and therefore
decreased cell viability and insulin production under inflammatory cytokines. Our data
suggest that embelin inhibited XIAP activity by blocking protein synthesis, which is in
good agreement with the previous report that embelin regulated apoptotic related gene
expression [107], not by structure based protein-protein interaction as described before
[93]. Embelin could inhibit XIAP expression to an extremely low level which was even
lower than the basal XIAP level in normal INS-1E cells and human islets, and hence
reversed the protective effect of XIAP in INS-1E cells and human islets against cytokine,
suggesting the important role of XIAP expression in graft viability and function post
transplantation.
The therapeutic range of Adv-hXIAP transduction is very hard to determine. The
MOI of Adv vector used for transduction must be carefully selected to achieve optimal
transduction efficacy, with little toxicity. Our data showed that Adv-hXIAP could elevate
XIAP expression in human islets in a dose dependent manner (Figure 3-2) without
significant toxicity, and this result was in good agreement with previous reports [4, 6, 8,
16, 17].
Taken together, these data confirm that XIAP overexpression in human islets
enhances islet viability and function against inflammatory cytokines and in doing so
helped to achieve prolonged normoglycemic control in diabetic mice, suggesting that
clinical application of this protocol could immediately and greatly enhance the
availability and long-term outcome of islet transplantation for type I diabetes.
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CHAPTER 4. RGD MODIFIED ADENOVIRUS ENCODING XIAP AND HGF
TO SIMULTANEOUSLY PREVENT EARLY GRAFT APOPTOSIS AND
PROMOTE REVASCULARIZATION TO IMPROVE THE OUTCOME OF
HUMAN ISLET TRANSPLANTATION
Introduction
In the previous study, we get a proof of concept that anti-apoptotic gene delivery
effectively prevented the early graft apoptosis of human islet transplantation. However,
several issues were unsolved.
First, the transduction efficiency of traditional adenovirus to human islet is low
therefore a high MOI is needed to achieve sufficient transgene expression. In the previous
study, to achieve optimal XIAP expression, human islet was transduced with Adv-XIAP
at MOI 2000. A high MOI could lead to two unwanted outcomes, difficulties in washing
off the free viral particles and the coexpression of a significant portion of viral proteins,
which raised safety concerns of adenovirus-based gene therapy and increased the
immunogenicity of human islets, respectively. The low transduction efficiency and high
MOI of traditional adenovirus called for the construction of more efficiency vectors.
Second, anti-apoptotic gene transfer is incapable to assist the revascularization of
human islets. Insulin producing β cells in human islet need anti-apoptotic gene expression
to overcome the challenges after transplantation. They also need supplies of oxygen and
nutrition as well as the channels to export the insulin. Failure to revascularization led to
hypoxia and starvation in human islets and subsequently caused a significantly portion of
islet loss after transplantation. Previous studies demonstrated that a functional
revascularization in the first two weeks after human islet transplantation is critical to the
survival and engraftment of transplanted islets [17]. Therefore, co-expression of antiapoptotic proteins with angiogenesis factors could be a reasonable strategy to address this
issue.
Last but not the least, the diabetic animal model we used for human islet
transplantation needed immediate improvements because most mice became overdiabetic with current protocol of streptozotocin injection. Insulin must be injected to
maintain the euglycemia besides the human islet transplantation which significantly
clouded the outcome of transplantation surgery and the results of functional analysis of
transplanted islets. A better protocol to induce diabetes in NOD-SCID mice was needed
to generate moderate level of diabetes, which is similar to clinical cases and reversible by
the islet transplantation only. By doing this, we will have an important standard to
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determine whether islet transplantation is successful or not by rendering the diabetic
animals insulin-independent, an important clinical criterion of human islet transplantation.
Therefore, in this study we tried to improve the traditional gene therapy on human
islet transplantation from three aspects. First, we inserted an Arg-Gly-Asp (RGD) peptide
expression cassette into the adenoviral genome encoding HI fiber knob so that an RGD
modified fiber knob can be expressed on the surface of viral particles. We hypothesized
this RGD modified adenovirus would have high transduction efficiency against human
islets because RGD was known to bind with high affinity to several types of integrins
present on the surface of mammalian cells. Second, instead of using adenovirus with one
transgene insertion within E1 deletion, we used adenovirus with two inserts (XIAP and
HGF) within E1 and E3 deletions. We hypothesized co-expression of anti-apoptotic gene
and angiogenic factor would have significant advantage in the outcome of human islet
transplantation to the previous studies in which one gene was expressed at a time. Third,
we revaluated the methodology to generate diabetic mice and found out that the manner
of STZ injection had great impact on the extent of diabetes. Because the optimal blood
glucose level was within 300~500mg/dL for human islet transplantation, we developed a
new manner of STZ injection so that >80% of mice will develop an optimal level
diabetes which can be reversed to insulin-independence by the islet transplantation only.
Materials and Methods
Culturing islets
Human islet preparations were received from the Integrated Islet Distribution
Program funded by the National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) and with support from the Juvenile Diabetes Research Foundation International
(JDRFI). Upon arrival, islet preparations were subjected to quality control assessment for
viability by using calcein AM/propidium iodide staining and for purity by using dithizone
staining. Dithizone binds zinc ions present in the beta cells of islets, and therefore stains
the islets red. Other exocrine tissue also present in the preparations does not bind
dithizone, and is therefore not stained[108]. Islet preparations with purity and viability >
90% were cultured in CMRL-1066 medium (Sigma Aldrich, St. Louis, MO) containing
10% FBS (Gibco, Gaithersburg, MD) in a 37°C incubator.
Construction of RGD-modified Adv
RGD-Adv-GFP was a kind gift from Dr. Hiroyuki Mizuguchi, Osaka University,
Japan. Adv-GFP was constructed and passaged in our lab. To generate RGD-modified
Adv, the genome encoding the fiber in Ad5 (from 28592 to 30470) was cloned into the
SacII-KpnI site of pBluescript II SK(+) (Stratagene, La Jolla, CA), creating pSK5543,
and the genome encoding the fiber in Ad5 (from 32123 to 32836) was cloned into the
EcoRI-HindIII site of pSP72 (Promega, Madison, WI), creating pSP72(713). For ease of
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incorporating the RGD epitope between the HI-loop
(LNVTQETGDTTPSAYSMSFSWD) of the fiber knob, immediately downstream of the
following the 11th threonine, new BamHI and MroI sites were added by PCR-mediated
site-directed mutagenesis. For PCR-mediated site-directed mutagenesis, the following
primer set was used: 5’- GAA ACA GGA GAC ACA GGA TCC GCG TCC GGA ACT
CCA AGT GCA TAC -3’ as the sense primer and 5’- GTA TGC ACT TGG AGT TCC
GGA CGC GGA TCC TGT GTC TCC TGT TTC -3’ as the antisense primer. After PCR
amplification, the resulting mutated PCR product, containing BamHI and MroI sites
(underlined) to make pSP72 [713-BM], was verified using an ABI PRISM 337 automatic
DNA sequencer (Applied Biosystems, Foster City, CA). To construct a vector encoding
the RGD epitope between the HI-loop of the fiber knob, two complementary
oligonucleotides were synthesized and annealed to form a DNA duplex. This DNA
duplex was designed to contain a BamHI overhang 5’ end and an MroI overhang 3’ end,
so that the fragment could be inserted into the BamHI and MroI sites of the pSP72[713BM] vector. The RGD epitope consisted of a nine-amino acid sequence, CDCRGDCFC.
Sequences of the oligonucleotides were 5’- GA TCC TGT GAC TGC CGC GGA GAC
TGT TTC TGC T -3’and 5’- CC GGA GCA GAA TCA GTC TCC GCG GCA GTA
ACA G-3’. These oligonucleotides encoded the RGD epitope (boldface and italicized).
The resulting plasmid was then digested with NcoI and MfeI and cloned into pSK5543 to
generate an Adv fiber shuttle vector, pSK[5543-RGD]. To generate the RGD-modified
Adv, the newly constructed Adv fiber shuttle vector pSK[5543+RGD] was digested with
SacII and XmnI, and the viral vector dl324 was digested with SpeI for homologous DNA
recombination in E. coli BJ5183.
Generating RGD-Adv-hHGF-hXIAP
To generate an Adv encoding HGF and XIAP at the E1 and E3 regions,
respectively, we first constructed an E3 shuttle vector expressing XIAP. The XIAP gene
was cloned from pSport6-XIAP by using 5’-CG GGATCC ATG ACT TTT AAC AGT
TTT GAA GGA TCT AAA-3’ and 5’-CG GGATCC TTA AGA CAT AAA AAT TTT
TTG CTT GAA AGT-3’ primers and subcloned into the Adv E3 shuttle vector, pSP72E3[109], generating a pSP72-XIAP. The newly constructed pSP72-XIAP shuttle vector
was linearized with XmnI digestion and then co-transformed with a replicationincompetent Adv, dl324-RGD, into E. coli BJ5183. It was then digested with SpeI for
homologous recombination, yielding Adv-encoding plasmid, dl324-XIAP (E3)-RGD.
Structures of the resulting recombinant vectors were then confirmed by restriction
enzyme digestion and PCR analysis.
In addition, to construct an Adv E1 shuttle vector expressing HGF, HGF gene was
excised from pCDNA3.1-HGF by using BamHI and XbaI and subcloned into the
replication-incompetent E1 shuttle vector, pCA14 (Microbix, Ontario, Canada). Then, the
Adv E1 shuttle vector was linearized with XmnI digestion and co-transformed into E. coli
BJ5183 with the BstBI-digested dl324-XIAP-RGD for homologous recombination,
generating dl324-HGF-XIAP-RGD. Recombinant Adv encoding plasmid was digested
with PacI and transfected into 293 cells to generate the replication-incompetent Adv,
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RGD-Adv-hHGF-hXIAP (Figure 4-1). The propagation, purification, titration, and
quality analysis of all Adv used were performed as previously described [110].
Transduction efficiency
Human islets were first transduced with Adv-GFP and RGD-Adv-GFP at equal
MOI to determine the effect of RGD modification on the transduction efficiency of Adv.
To determine the optimal MOI for RGD-Adv-hHGF-hXIAP, 500 hand-picked human
islets were transduced with serial dilutions of RGD-Adv-hHGF-hXIAP in 24-well plates
for 12 h and incubated for additional 48 h. Medium were collected. Human islets were
washed with PBS and dispersed into a single-cell suspension by incubation with 0.25%
trypsin/EDTA (Gibco, Gaithersburg, MD) at 37°C for 5 min followed by passage through
a narrow-gauge pipette. Total protein was extracted with RIPA buffer (Sigma Aldrich, St.
Louis, MO) and stored at -80oC. HGF concentration in the cultured medium and XIAP
concentration in the total protein extract of human islets was measured by ELISA (R&D
Systems, Minneapolis, MN).
Caspase detection
Caspase-Glo 3 assay kits were used to analyze caspase 3 activities as described
before [6]. Briefly, 48 h following transduction, a single-cell islet suspension was
generated by 0.25% trypsin/EDTA digestion. Then, 100 μl Caspase-Glo were added to
100 μl of the single-cell suspension of 104 cells in 96-well plates and incubated at room
temperature for 1 h. The contents were then transferred to culture tubes, and
luminescence was determined using a luminometer (Berthold, Germany).
Western blot
Five hundred human islets were transduced with RGD-Adv-hHGF-hXIAP at 500
MOI in 24-well plates for 12 h and incubated for additional 48 h. A single-cell islet
suspension was generated by 0.25% trypsin/EDTA digestion. The total protein samples
were extracted with RIPA buffer supplemented with a protease inhibitor cocktail (Sigma
Aldrich, St. Louis, MO), mixed with 6 × Laemmli sodium dodecyl sulfate (SDS) buffer
(Boston BioProducts) and then boiled for 5 min to denature the protein. Then, a 20μgsample was loaded onto a 4%-15% Tris-HCl precast polyacrylamide gel (Bio-Rad,
Hercules, CA) for electrophoresis and subsequently transferred to an immobilon
polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA). After blocking
with 3% BSA in 1× PBST (PBS containing 0.05% Tween-20) for 1 h at room
temperature, the membranes were incubated with goat polyclonal IgG to XIAP, BAX,
BCL-2, p-AKT, AKT and GADPH (Abcam, Cambridge, MA) primary antibodies (1:500)
overnight at 4°C. The membrane was then incubated with HRP-conjugated rabbit
polyclonal antibody to goat (1:10000) (Abcam, Cambridge, MA) for 1 h at room
temperature. Target proteins were detected by enhanced chemiluminescence (ECL)
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Figure 4-1. Construction of RGD modified Adv genome encoding HGF and XIAP
in E1 and E3 deletion
RGD epitope expressing cassette, hXIAP cDNA and hHGF cDNA were sequentially
incorporated into the Ad5 genome by homologous DNA recombination.
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detection kit (GE Healthcare Life Sciences, Pittsburgh, PA).
Apoptosis study
A cytokine cocktail of recombinant TNFα (5ng/ml) and IL-1β (5ng/ml) was used
to mimic the in vivo challenge to the INS-1E cells and human islets by the inflammatory
cytokines. INS-1E cells were transduced with Adv for 3 h, stimulated with cytokine
cocktail for an additional 48 h and characterized by DeadEnd™ Colorimetric TUNEL
system (Promega, Madison, WI), in which fragmented DNA from apoptotic cells was
labeled with biotinylated nucleotide and detected using hydrogen peroxide and
diaminobenzidine (DAB). Human islets were transduced with Adv for 12 h and incubated
with cytokine cocktail for an additional 3 days. Then islet cells were digested with 0.25%
trypsin/EDTA into a single-cell suspension, stained with Annexin V-FITC Apoptosis
Detection Kit (Abcam, Cambridge, MA) and analyzed with flow cytometry. Annexin V
binds to phosphatidylserine on the cell surface, which is a feature found in apoptotic
cells. Fluorescent intensity was analyzed using CELLQUEST software (BD Bioscience,
Franklin Lakes, NJ). Nontransduced cells without cytokine treatment served as a negative
control. Three sets of independent transduction experiments were carried out for each
assay.
Dynamic insulin release
We designed and constructed an islet perifusion set for dynamic analysis of the
function of human islets (Figure 4-2). Compared with static insulin release method, this
method gives a real-time monitoring of the islet function against difference stimuli.
Briefly, after being stimulated with a cytokine cocktail of IL-1β (5 ng/ml) and TNF-α (5
ng/ml) for 3 days, 50 islets from each group were handpicked and loaded onto a Swinnex
13 chamber (Millipore, Burlington, MA) and perifused with Krebs Ringer-bicarbonate
(KRB) buffer containing basal glucose (2.5 mM). The flow rate was maintained at 2
ml/min with a peristaltic pump (Themo Fisher, Waltham, MA) and the temperature was
maintained at 37 °C with a solution heater (Warner Instruments, Hamden, CT). Islets
were first perifused with basal glucose (2.5 mM) for 45 min and stimulated with glucose
(22.5 mM) for 15 min and at last perifused with basal glucose (2.5 mM) until insulin
release reversed to basal level. Samples were collected through a fraction collector
(Waters, Milford, MA) and analyzed for insulin content by ELISA (Calbiotech, Spring
Valley, CA).
Generate moderate diabetic nod-scid mice
To find out the best protocol to induce diabetes in NOD-SCID mice with
moderate extent of blood glucose levels for human islet transplantation, several manners
and doses of STZ injection were tested. In the first protocol, two shots of STZ were
injected intraperitoneally into NOD-SCID mice at a dose 70mg/kg for two consecutive
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Figure 4-2.

Islet perifusion set for dynamic analysis of function of human islets
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weeks. If the mice developed moderate level of diabetes (blood glucose 300~500 mg/dL)
in the first week, the second shot can be skipped. In the second protocol, one shot of STZ
was injected intraperitoneally into NOD-SCID mice at a fixed dose 150mg/kg. In the
third protocol, STZ was injected intraperitoneally into NOD-SCID mice at a dose of 40
mg/kg for 5 consecutive days. The levels of blood glucose of all mice were determined
by a glucometer at 3 weeks after last STZ injection. A boxplot of the minimum, the 10
percentile, the median, the 90 percentile, and the maximum was draw for each protocol.
Since the measurable glucose concentration of our glucometer is 50~600mg/dL, if a
measurement gives a reading HI (high) or LOW, it would be recorded as 600mg/dL and
50mg/dL respectively.
Islet transplantation
Animal experiments were performed by approved protocol following NIH and
institutional animal care and use Institutional Animal Care and Use Committee guidelines
using an approved protocol. To induce diabetes, STZ (70 mg/kg) was administered to
NOD-SCID mice by intraperitoneal injection for 2 consecutive days. Animals were
classified as diabetic after two consecutive measurements of blood glucose ≥ 400 mg/dl
with a glucometer. Upon receiving human islets from the Integrated Islet Distribution
Program (IIDP) distribution centers, they were immediately transduced with RGD-AdvhHGF-hXIAP at 500 MOI for 12 h. Then islets were washed three times to remove free
virus. Then 500 islets were carefully hand-picked and transplanted under the kidney
capsule of each STZ-induced diabetic NOD-SCID mouse. Three shots of insulin (5U/kg)
were given to each mouse on the first 3 days after transplantation to relieve the
hyperglycemic stress to the newly transplanted islets and no insulin was given afterwards.
The nonfasted glucose levels of all the mice were measured from the snipped tail of each
animal at 2 p.m. during the first week after surgery and then weekly. At the end of study,
the mice were anesthetized to collect blood to measure serum insulin and c-peptide levels
by ELISA. The graft-bearing kidneys were then removed from some animals to confirm
the function of islet grafts by the return of blood glucose levels to ≥ 400 mg/dL.
Intraperitoneal glucose tolerance test
Thirty days after islet transplantation, glucose tolerance was determined in
overnight-fasted mice as described by Garcia-Ocana et al. [9]. Briefly, the mice were
subjected to intraperitoneal injection of glucose at 2 g/kg of body weight. Blood samples
were obtained from the snipped tail at 15, 30, 60, 90 and 120 min after injection and
analyzed for glucose levels with a glucometer.
Immunofluorescence staining
In an independent study, 500 hundred handpicked islets were transplanted under
the kidney capsule of STZ-induced diabetic NOD-SCID mice. Six mice from each group
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(mice receiving untransduced human islets and mice receiving RGD-Adv-hHGF-hXIAP
transduced human islets at 500 MOI) were sacrificed 30 days after transplantation.
Another six from each group was sacrificed at 200 days after islet transplantation. The
kidneys bearing islets were isolated, washed with PBS, fixed in 4% paraformaldehyde
overnight, and embedded in optimal cutting temperature compound. Frozen sections of
10 μm thickness were cut. To detect insulin-positive human islets, the slides were stained
with guinea pig anti-insulin primary antibody (1:200) at 4°C overnight and Alexa Fluor
568-conjugated goat anti-guinea pig secondary antibody (1:500) at room temperature for
1 h. To detect revascularization, the slides were stained with rabbit anti-von-Willebrand
factor (vWF) primary antibody (1:500) at 4°C overnight and Dylight 488-conjugated goat
anti-rabbit secondary antibody (1:500) at room temperature for 1 h. Slides were counterstained with DAPI.
Results
Construction of RGD-Adv-hHGF-hXIAP
To improve the transduction efficiency of Adv on human islets, we chose to
introduce an RGD peptide, which is known to bind with high affinity to several types of
integrins present on the surface of mammalian cells, into the HI loop of the fiber knob.
An RGD-modified Adv was generated by sequentially incorporating and RGD epitopeexpressing cassette, hXIAP cDNA and hHGF cDNA, into the genome of adenovirus
serotype 5 through homologous DNA recombination (Figure 4-1). Structures of the
resultant recombinant vectors were then confirmed by restriction enzyme digestion and
PCR analysis. A proper amount of recombinant plasmid was digested with PacI and
transfected into 293 cells, thereby generating the replication-incompetent Adv, RGDAdv-hHGF-hXIAP.
Transduction efficiency of RGD-Adv-hHGF-hXIAP on human islets
The transduction efficiency of traditional Adv-GFP and RGD-Adv-GFP was compared.
Results showed that the RGD modification increased the expression of GFP in human
islets, suggesting improved transduction efficiency (Figure 4-3). Optimal MOI of RGDAdv-hHGF-hXIAP was determined by transducing human islets with serial dilutions of
RGD-Adv-hHGF-hXIAP. Results showed that HGF and XIAP expression were
upregulated in a dose-dependent manner. At 500 MOI, RGD-Adv-hHGF-hXIAP could
upregulate HGF and XIAP to the extent usually requiring MOI >2000 for traditional Adv
[8, 111]. The gene expression profile of RGD-Adv-hHGF-hXIAP-transduced human
islets over 2 weeks indicated the transient manner of Adv-mediated gene expression. The
amount of HGF and XIAP produced by RGD-Adv-hHGF-hXIAP transduced human
islets peaked 2 days after transduction and decreased gradually in the following 14 days.
However, the levels of HGF and XIAP were still much higher compared with the
endogenous expression of these two therapeutic genes.
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Figure 4-3. Transduction efficiency of RGD-Adv-hHGF-hXIAP into human islets
A. GFP expression in human islets transduced with Adv-GFP and RGD-Adv-GFP. B.
Dose dependent expression of HGF and XIAP in RGD-Adv-hHGF-hXIAP and AdvhHGF-hXIAP transduced human islets. C. Time dependent expression of HGF and
XIAP in RGD-Adv-hHGF-hXIAP transduced human islets at 500 MOI.
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Pro-apoptotic gene inhibited and anti-apoptotic gene elevated
Both HGF and XIAP hold antiapoptotic effect. HGF inhibited the apoptotic
pathway via activating AKT kinase while XIAP was well known for its inhibition of
caspase activities [112, 113]. Results showed that the activity of caspase 3 was
significantly decreased in RGD-Adv-hHGF-hXIAP-transduced human islets over 14 days
after transduction (Figure 4-4). Western blot results showed the upregulation of p-AKT
at 2 days after Adv transduction. These results suggested anti-apoptotic effect of RGDAdv-hHGF-hXIAP on human islets. We also observed elevated anti-apoptotic protein
BCL-2 and suppressed pro-apoptotic protein BAX, which might be a result of XIAP
overexpression and degradation as suggested by the reports from Deveraux et al. and
Bratton et al. [114, 115].
Protection of RGD-Adv-hHGF-hXIAP on human islets
TUNEL assay was used to determine the apoptotic cell death under cytokine
treatment. We first test the anti-apoptotic effect of RGD-Adv-hHGF-hXIAP on insulinproducing INS-1E cells because it is relatively easier to stain and detect the dead cell in
monolayer. Numerous apoptotic cells were observed in untransduced INS-1E cells after
cytokine treatment, while much fewer apoptotic cells were observed in RGD-Adv-hHGFhXIAP-transduced INS-1E cells (Figure 4-5). Similarly, the ratio of apoptotic cells was
significantly reduced in RGD-Adv-hHGF-hXIAP-transduced islets compared with
untransduced islets (Figure 4-5). However, it should be addressed that since flow
cytometry did not differentiate insulin-producing β cells from other cell types in human
islets, these results only suggested that the whole islet can be protected from cytokine
induced cell death. Another glucose perifusion experiment is needed to determine the
viability and function of insulin-producing β cells of human islets.
Human islets were first transduced with RGD-Adv-hHGF-hXIAP and then
stimulated with a cytokine cocktail of IL-1β and TNF-α. Results showed that insulin
secretion by human islets was significantly impaired after treated with the cytokine
cocktail (Figure 4-6). However, the insulin secretion of RGD-Adv-hHGF-hXIAP
transduced human islets was not significantly impaired under cytokine treatment (Figure
4-6), suggesting improved viability and function of the insulin-producing β cells of RGDAdv-hHGF-hXIAP transduced human islet.
Generation of diabetic NOD-SCID mice for human islet transplantation
Fifteen NOD-SCID mice were used for each protocol. STZ was injected at 40
mg/kg for 5 shots, 150mg/kg for 1 shot, and 70mg/kg for 2 shots. The blood glucose level
was determined by a glucometer at 3 weeks after last STZ injection. A boxplot of the
minimum, the 10 percentile, the median, the 90 percentile, and the maximum as draw for
each protocol as shown in Figure 4-7. The box area between the 10 percentile and 90
percentile indicated the expected glucose levels for 80% of mice. The blood glucose level
of 600mg/dL was the maximum for all three protocols because it is the maximum
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Figure 4-4. HGF and XIAP expression led to inhibition of pro-apoptotic gene and
elevation of anti-apoptotic gene
A. Caspase 3 activity in RGD-Adv-hHGF-hXIAP transduced human islets was measured
up to 14 days after transduction by Caspase 3 Glo kit. B. Expressions of proapoptotic
marker BAX and antiapoptotic markers BCL-2, p-Akt were determined by western blot.
MOI: 0, 5, 10, 50, 100, 500, left to right.
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Figure 4-5. Transgene expression of HGF and XIAP protected INS-1E cells and
human islets from inflammatory cytokine induced apoptotic cell death
After transduction with RGD-Adv-hHGF-hXIAP, INS-1E cells and human islets were
incubated with a cytokine cocktail of IL-β (5 ng/mL) and TNF-α (5 ng/mL) for 48 h and
3 days, respectively. A. Apoptotic INS-1E cells were stained dark brown using
DeadEnd™ Colorimetric TUNEL System. B. Islet was dispersed with trypsin into single
cell suspension. Apoptotic cells were stained with annexin V-FITC and counted by flow
cytometry. P3 indicated the percentage of apoptotic cells. All experiments were
performed in triplicate and at least twice with similar results. Results are presented as
mean ± SD. *, P < 0.05 as determined by Student t test.
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Figure 4-6. Effect of HGF and XIAP gene expression on islet function
Briefly, after transduction with RGD-Adv-hHGF-hXIAP and further stimulation with a
cytokine cocktail of IL-β (5 ng/mL) and TNF-α (5 ng/mL) for 3 days, 50 islets from each
group were sequentially perifused with basal glucose (2.5mM) for 45 min and stimulated
with glucose (22.5mM) for 15 min and at last perifused with basal glucose (2.5mM) till
insulin release reverse to basal level. The flow rate was maintained at 2ml/min. Samples
were collected through a fraction collector and analyzed for insulin content by ELISA.
All experiments were performed in triplicate. Results are presented as Mean±SD. n=3.
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Figure 4-7. The manner and dose of STZ injection has great impact on the
diabetic level of NOD-SCID mice
In the first protocol, two shots of STZ were injected intraperitoneally into NOD-SCID
mice at a dose 70mg/kg for two consecutive weeks. If the mice developed moderate level
of diabetes (blood glucose 300~500 mg/dL) in the first week, the second shot can be
skipped. In the second protocol, one shot of STZ was injected intraperitoneally into
NOD-SCID mice at a fixed dose 150mg/kg. In the third protocol, STZ was injected
intraperitoneally into NOD-SCID mice at a dose of 40 mg/kg for 5 consecutive days. The
levels of blood glucose of all mice were determined by a glucometer at 3 weeks after last
STZ injection. A boxplot of the minimum, the 10 percentile, the median, the 90
percentile, and the maximum was draw for each protocol.
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measurement level for the glucometer. The NOD-SCID mice receiving two shots of STZ
at 70mg/kg developed a moderate level of diabetes with 80% of them at 300~500mg/dL
and a median of 400mg/dL. The NOD-SCID mice receiving one shot of STZ at
150mg/kg were slightly more diabetic with 80% of them at 300~550mg/dL. But the
median glucose was increased to 500mg/dL. Most NOD-SCID mice receiving 5 shots of
STZ at 40mg/kg were over diabetic, which was consistent with our previous study that
constant insulin injection was needed for glucose control besides islet transplantation.
We gathered a lot of useful information from this study. First, mice responded in a
drastically different manner to STZ injection. For example, half of the mice developed
moderate level of diabetes after the first shot of STZ at 70mg/kg. But the other half were
not diabetic (<200mg/dL) before the second shot. Therefore, we developed a flexible
protocol in which the blood glucose of all mice could be measured in the middle of STZ
injection and the non-diabetic mice would receive a second shot. Secondly, some mice
developed a pre-diabetes symptom with blood glucose at 180~250m/dL after the first
shot of STZ. These mice had a chance back to normoglycemia without any treatment. But
the mice with blood glucose higher than 300mg/dL hardly reversed normoglycemia.
Therefore a blood glucose level of 300mg/dL was used to determine whether the mouse
was “truly” diabetic and ready for the following islet transplantation.
RGD-Adv-hHGF-hXIAP transduction prolonged islet survival after transplantation
Islet transplantation reversed diabetes in every subject (Figure 4-8). However, the
mice transplanted with RGD-Adv-hHGF-hXIAP-transduced islets showed clearly better
transplantation outcome in terms of average blood glucose level, duration of
normoglycemia, and insulin independent ratio (Figure 4-8). These results demonstrated
the improved viability and function of human islets genetically modified with RGD-AdvhHGF-hXIAP.
Intraperitoneal glucose tolerance test was performed 30 days after islet
transplantation to determine whether ex vivo transduction of islets with RGD-AdvhHGF-hXIAP helped islet grafts engraft and respond to elevated blood glucose in real
time. Prior to glucose injection, all mice displayed similar baseline blood glucose levels
following overnight fasting. Blood glucose levels increased immediately following
glucose (2 g/kg) injection, peaked at 15 min in all groups, and decreased over time
(Figure 4-9). Results showed faster and better response to the glucose boost in those
mice receiving RGD-Adv-hHGF-hXIAP-transduced human islets relative to the mice
receiving untransduced islets (Figure 4-9). These results demonstrated that RGD-AdvhHGF-hXIAP-transduced human islets had a better engraftment outcome and led to
superior glucose control and to tolerance as compared with untransduced islets.
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Figure 4-8. Effect of RGD-Adv-hHGF-hXIAP transduction on the outcome of
islet transplantation
A-B. The blood glucose level of every single mouse after receiving 500 untransduced (A)
or RGD-Adv-hHGF-hXIAP-transduced islets (B). C. The average blood glucose level of
mice after islet transplantation. D. Reversed-diabetes ratio of the NOD-SCID mice after
islet transplantation. Blood glucose≤200 mg/dL (dashed line in a, b) was identified as
reversed-diabetes. Data are presented as the mean ± SD, n=10. *P < 0.05 as determined
by Student t test.
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Figure 4-9. Intraperitoneal glucose tolerance test of the mice at 30 days after islet
transplantation
Results from non-treated diabetic mice and non-diabetic mice were used as negative and
positive controls, respectively. Data are presented as the mean ± SD, n=6. *P < 0.05 as
determined by Student t test compared with mice receiving untransduced human islets.
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RGD-Adv-hHGF-hXIAP transduction improved islet revascularization after
transplantation
As shown in Figure 4-10, immunofluorescence staining showed the successful
engraftment of insulin-positive islets under the kidney capsule 30 days after islet
transplantation. Untransduced islets and RGD-Adv-hHGF-hXIAP-transduced islets both
showed proper engraftment and function at this time. At 200 days after transplantation,
the clear insulin staining in the kidney bearing RGD-Adv-hHGF-hXIAP transduced islets
indicated morphological integrity and appropriate function of transplanted islets (Figure
4-11). In addition, the potent staining of vWF in proximity to these islets indicated the
functional revascularization of islet grafts under the kidney capsule. However, in the
kidney bearing untransduced islets, only scarce vWF staining was seen and weak insulin
staining indicated poor morphology and function of transplanted islets.
Discussion
PNF is the major reason leading to islet loss after transplantation except immune
rejection. PNF is mostly caused by the inflammatory cytokines and poor
revascularization. Dinarello et al. summarized that IL-1 and TNF are the two most
important effectors in autoimmune diseases [27]. Donath et al. concluded that antiinflammatory therapeutic approaches to block β-cell apoptosis could be an important
strategy in treating type 1 and 2 diabetes [28]. We previously reported that IL-1Ra
expression in human islets effectively blocked the IL-1β-mediated apoptotic islet death [8,
29], but it did not stop the apoptosis caused by other inflammatory cytokines such as
TNFα and IFNγ. We also reported that XIAP expression in human islets repressed
apoptotic islet death by inhibiting caspase activation [30], but its effect is limited because
of low transduction efficiency. In the current study, we genetically engineered Adv with
an RGD peptide to improve transduction efficiency and co-expressed HGF and XIAP,
both of which hold anti-apoptotic effect but through different pathways [21, 31]. Our
results demonstrated that the levels of HGF and XIAP were significantly upregulated and
gradually decreased 14 days after Adv transduction (Figure 4-3C), which accords with
the transient property of Adv-mediated gene expression. Consequently, a high HGF level
activated the PI3K-Akt pathway and a high XIAP level suppressed caspase 3 activity in
the first 14 days after Adv transduction (Figure 4-4). In an inflammatory condition
mimicked by a cytokine cocktail of IL-1β and TNFα, TUNEL assay and islet perifusion
study indicated that overexpression of HGF and XIAP gene prior to cytokine treatment
effectively protected islet viability and function from apoptotic cell death (Figures 4-5,
4-6). The in vivo viability and function were further confirmed by immune fluorescence
analysis (Figure 4-10).
Revascularization is another crucial factor for successful islet transplantation.
Islets are a cluster of heterogeneous cell types with extensive intra-islet vessels. These
vessels get disrupted during islet isolation, leading to the collapse of vasculature, the
accumulation of endothelial fragments, and the compromised perfusion in the core of the
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Figure 4-10. Immunofluorescence staining of the kidney section bearing RGD-AdvhHGF-hXIAP-transduced human islets at 30 days after islet transplantation
A. Untransduced human islets. B. RGD-Adv-hHGF-hXIAP-transduced human islets.
Human insulin was stained in red. Slides were back-stained with DAPI. Scale bar
represents 100 μm.
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Figure 4-11. Immunofluorescence staining of the kidney section bearing RGDAdv-hHGF-hXIAP-transduced human islets at 200 days after islet transplantation
Insulin was stained in red (first column) and vWF factor was stained in green (second
column). A-B. Kidney section bearing untransduced human islets under 10x and 40x
magnification. C-D. Kidney section bearing RGD-Adv-hHGF-hXIAP-transduced human
islets human islets under 10x and 40x magnification.
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islets [32]. Therefore, extensive and functional revascularization is required to promote
the survival of islet grafts posttransplantation [33]. VEGF is a popular angiogenic factor,
but its effect is so potent that caution should be exercised to avoid aberrant angiogenesis
[34]. Recently, HGF has been seen as a more favorable growth factor because it can
prevent apoptotic islet death and can promote the proliferation of pancreatic β-cells [12].
In this study, we demonstrated that HGF expression of human islets can be upregulated
over 14 days after Adv transduction (Figure 4-3) Consequently, extensive
revascularization was observed in the mice transplanted with RGD-Adv-hHGF-hXIAPtransduced human islets in the immune fluorescence study (Figure 4-11).
Islet destruction following transplantation can be greatly reduced by gene therapy
[35]. Since islet is a compact cluster of about 1000 non-dividing cells, it is difficult to
transfect intact islets by the available non-viral approaches, such as cationic liposomes
and polymer-based systems, which are also toxic at high doses [36]. In contrast,
replication deficient (E1, or E3 deleted) Adv vectors are known to efficiently transduce
islets. In addition, adenoviral vectors can be produced in high titers and there is no risk of
insertional mutagenesis as they do not integrate into host genome. However, Adv
transduction of human islets leads to increasing immune responses, because some viral
genomes co-express with therapeutic genes and elicit increased immune response and
allograft rejection [37, 38]. This problem may be exaggerated when a relatively higher
MOI is required to achieve optimal transduction efficiency on solid organs like human
islets [13, 14].
We incorporated an RGD peptide sequence into the Adv fiber knob to interact
with αvβ integrins to facilitate Adv transduction into human islets [39]. Our results
indicated that the transduction efficiency on human islets could be significantly improved
using RGD-modified Adv (Figure 4-1). Transduction efficiency could be further
increased when MOI was increased to 1000 and 5000 (data not shown). However, we
decided not to transduce islets with an MOI higher than 500 to avoid any toxic side
effects. The insulin perifusion study demonstrated that there was no decrease in insulin
production from RGD-Adv-hHGF-hXIAP-transduced islets (Figure 4-6). RGD
modification of Adv may be of significant importance to the development of new viral
vectors, which can be genetically redirected to specialized cells as gene delivery vehicles.
A similar RGD sequence placed in the virus hexon coat protein increased gene transfer to
cells that were normally refractory to Adv transduction [40]. Similarly, adding a cationic
polylysine sequence (pK7) to the fiber knob COOH terminus, which facilitates viral
binding to negatively charged cell surface molecules such as heparan sulfates, increased
transduction to macrophages, endothelial cells, smooth muscle cells, fibroblasts, and T
cells [41, 42]. In this study, we also evaluated a bipartite Adv vector for multiple gene
delivery to human islets for promoting revascularization and inhibiting inflammatory
cytokine-mediated destruction. Because transfection with the bipartite plasmid encoding
hHGF and hXIAP (dI324-hHGF-hXIAP-RGD, Figure 4-1) produced very little hHGF or
hXIAP (data not shown), viral vector seems to be the only choice for gene therapy on
human islets. Bipartite Adv vectors are usually constructed with one therapeutic gene and
another marker gene, especially GFP [43, 44]. Using a bipartite vector not only simplifies
the amplification and purification process of Adv vectors but also decreases the use of
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total Adv backbone, compared to the use of two single Adv vectors. This procedure is
expected to minimize the immunogenicity and toxicity of Adv vectors.
Islet isolation and preparation is another state-of-the-art in clinical islet
transplantation. Unlike other species from which islets can be isolated with little
contamination, human islet preparations are usually composed of a majority (50~60%) of
β cells and many other cell types including duct cells, acinar cells, α cells, and lymph
node cells [45, 46]. Regardless of their origin, all cells within an islet preparation may
contribute to the immune response induced after transplantation. Therefore, purity and
viability of islets used for transplantation have a significant impact on the outcome of
islet transplantation. Dithizone staining is carried out to discriminate between endocrine
and non-endocrine cells to increase the purity of the islet preparation to 70–95% [46, 47].
Using hand-picked islets helped to further improve islet purity by discarding other tissues
such as acinar cells and lymph nodes [48]. However, further purification of the islet
preparations remains a challenge because of a remarkable loss of insulin-producing cells.
To summarize, our study demonstrated that RGD modification is a useful tool to
improve the transduction efficiency of Adv. Ex vivo transduction of islets with RGDAdv-hHGF-hXIAP decreased apoptotic islet death and improved islet revascularization
and eventually improved the outcome of human islet transplantation.
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CHAPTER 5. BMSC AS GENE DELIVERY VEHICLE TO EXPRESS HGF
AND IL-1RA TO IMPROVE THE OUTCOME OF HUMAN ISLET
TRANSPLANTATION
Introduction
Traditional gene therapy directly transfers genetic materials into human islet using
viral or nonviral vectors to generate genetically modified human islets. This strategy is
promising because the resistance of islet to a specific challenge can be selectively
enhanced by overexpression of a specific gene but holds some weakness because 1)
human islets will be subjected to gene transfer for at least 1 day before transplantation
causing inevitable PNF in the transduction process and 2) the co-expression of transgenes
with viral genes could increase the immunogenicity of transduced human islets and make
them easily recognized and cleared by the host immune system.
MSC are adult progenitor cells with differentiation potential and self-renewal
capacity. MSCs have great promise in repairing injured tissues including pancreatic islets
[42]. MSCs also hold hypoimmunogenic property [55], since they are in lack of major
histocompatibility complex II (MHC-II) and co-stimulatory molecules, such as CD14,
CD86, CD40L and CD95L. MSCs suppress inflammation, either by receptor-mediated
signal-transduction, probably through MMP2/MMP9-CD25 signal pathway [60], or the
secretion of immunosuppressive factors such as TGF-β1, interleukin 10 (IL-10) and
PGE2. Therefore, MSCs are unlikely to cause inflammation at the transplant site. These
characteristics make MSCs attractive vehicles for virus-based gene therapy.
BMSC was selected for several reasons. First, BMSC can be readily isolated from
bone marrow and many other tissues. Secondly, BMSC is an adult stem cell with limited
expansion and differentiation potential. Therefore the tumorigenicity of BMSC was low.
Thirdly, BMSC was accessible to a wide spectrum of genetic modifications, which were
not reported to affect the stem-cell-like properties of BMSC. Fourthly, BMSC actively
secreted multiple growth factors as a trophic mediator which can help the engraftment of
human islets after transplantation. We hypothesized that BMSC genetically modified to
express soluble factors can be a competent strategy to help human islet transplantation
without direct transduction of human islets (Figure 5-1). However, it should be noted
that BMSCs alone, through systemic administration or local transplantation, were less
competent to prevent the islet loss immediately after transplantation, which accounts for
more than 70% of islet loss in the first week after transplantation [95, 96]. This
phenomenon probably explains the inadequate control of the blood glucose level in the
early stage (< 3 weeks) after transplantation in most islet/MSC co-transplantation studies
[54, 116].



Reprinted with permission from Springer. Wu, H, Lu, W, and Mahato, RI (2011).
Mesenchymal stem cells as a gene delivery vehicle for successful islet transplantation.
Pharmaceutical Research 28: 2098-2109.
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Figure 5-1. A schematic demonstration of Adv-hHGF-hIL-1Ra-transduced
BMSCs co-transplantation with human islets
A. BMSCs were transduced with Adv-hHGF-hIL-1Ra prior to islet transplantation. B.
After co-transplantation with human islets under the kidney capsule of diabetic NODSCID mice, BMSCs expressed HGF and IL-1Ra into the surrounding microenvironment
to support islet viability and function.
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Because traditional gene transfer into human islets is less efficient and time
consuming and BMSC mediated cell therapy is less competent to prevent the acute graft
loss, we planned to utilize BMSC mediated gene therapy in this study. We hypothesized
that adenovirus mediated gene therapy can prevent the acute graft loss while the BMSC
can support the islet function for long term. We selected genes encoding HGF and IL1Ra, both of which were soluble factors, as the therapeutic genes in this study. The antiapoptotic effect of IL-1Ra expression may not be able to compete with XIAP because ILRa blocked the islet apoptosis caused by death receptor pathway but XIAP blocked the
islet apoptosis in a more ubiquitous manner (Figure 3-1). But we avoided the toxicity
associated with direct transduction and the viral expression in human islets. Moreover the
gene transfer efficiency on BMSC which can be seeded in a tissue culture flask is
significantly higher than human islets. BMSC can also be transduced and expanded
before we received islet preparations, therefore we can save one day of gene transfer into
human islets and it may significantly prevent the loss of islet due to PNF. Other benefit of
this study is that BMSC was known to maintain its stem cell properties after transduction.
Therefore when the transgene expression mediated by adenovirus diminished in 2 weeks,
the growth factors produced by BMSC, though in a lesser extent, may help islet survival
for a long duration. We were trying to test these hypotheses in the following study.
In this study, we evaluated the capability of primary BMSCs as gene delivery
vehicles to protect the graft viability of human islets in a STZ induced NOD-SCID mice
model. Adv-hHGF-hIL-1Ra-transduced BMSCs served as gene delivery vehicles to
express HGF to promote islet revascularization, and IL-1Ra to reduce acute islet loss
from inflammatory cytokines. We also determined the capability of BMSCs as nursing
cells to prevent long-term islet graft rejection.
Materials and Methods
Materials
The replication-deficient (ΔE1/ΔE3) Adv-hHGF-hIL-1Ra containing a CMV
promoter, hHGF cDNA, and rabbit β-globin poly A in the E-1 region, and a CMV
promoter, hIL-1Ra cDNA, and rabbit β-globin poly A in the E-3 region was constructed
amplified and the titer measured in our lab as previously described (Figure 5-2) [8]. The
control virus encoding green fluorescent protein (Adv-GFP) was constructed and kept in
our lab. Primary BMSCs, HyClone Advanced Stem Cell Medium and Medium
Supplement were purchased from Thermo Fisher Scientific (Waltham, MA), passaged,
and frozen in our lab. Human islets were received from Integrated Islet Distribution
Program (Duarte, CA). CMRL-1066 medium for islet culture and 6-diamidino-2phenylindole (DAPI) were purchased from Sigma Aldrich (St. Louis, MO). FBS was
purchased from MediaTech Cellgro. (Herndon, VA). PBS was purchased from GIBCOBRL (Gaithersburg, MD). Human HGF ELISA kits, IL-1Ra ELISA kits, IL-10 ELISA
kits, VEGF ELISA kits, Stem cell factor (SCF) ELISA kits and recombinant IL-1β were
purchased from R&D Systems (Minneapolis, MN). Human insulin and c-peptide ELISA
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Figure 5-2. Construction of bipartite Adv-hHGF-hIL-1Ra using AdenoQuick
cloning system
Shuttle plasmids pE 3.1 which contains IL-1Ra gene and pE 1.2 which contains HGF
gene were cloned into AdenoQuick plasmid 13.1 to generate a cosmid containing genes
of interest and the entire sequence of recombinant adenovirus by homologous
recombination. After transfection into 293 cells, recombinant adenovirus Adv-hHGF–
hIL-1Ra was produced.
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kits were purchased from Alpco Diagnostics (Windham, NH). The primary antibodies for
hHGF, hIL-1Ra, insulin, vWF, and the Dylight 488-conjugated secondary antibody were
purchased from Abcam (Cambridge, MA). The Alexa Fluor 568-conjugated secondary
antibody and 0.25% trypsin was purchased from Invitrogen (Carlsbad, CA). 8-well LabTek Chamber Slides were purchased from Nalge Nunc. (Rochester, NY). Ultrasensitive
One Touch glucose test strips and One Touch Ultra glucometer were purchased from
LifeScan (Milpitas, CA). Tissue-Tek O.C.T. compounds were purchased from Sakura
Finetek (Torrance, CA).
Adv transduction of BMSCs
Primary BMSCs were seeded at a density of 5 × 105 cells per well with 2 ml
HyClone Advanced Stem Cell Medium in a 6-well plate and allowed 24 h for adherence.
Prior to transduction, morphology of BMSCs was checked under a bright field
microscope. To determine the optimal MOI for Adv transduction, primary BMSCs were
transduced with Adv-GFP at 60 MOI and 120 MOI for 3 h followed by washing three
times. The GFP expression was determined under a fluorescent microscope at 2 days
after transduction. Primary BMSCs were then transduced with Adv-hHGF-hIL-1Ra at
120 MOI for 3 h followed by washing three times. The expressions of HGF, IL-1Ra, IL10, VEGF, and SCF were measured by ELISA at 0, 2, 4, 6, 8, 10, 12, 14 days after
transduction according to the manufacturer’s instructions. The protein concentration was
normalized using the number of cells in each well.
Islet viability study
After transduction with Adv-hHGF-hIL-1Ra at 120 MOI for 3 h, 5 × 105 primary
BMSCs were digested with 0.25% trypsin and co-culture with 500 IEs in a 10 cm dish of
CMRL-1066 medium with 10% FBS for 2 days. Then, the islet/BMSC co-culture was
stimulated with 5μg/ml IL-1β for 4 days and stained with 5 μg/ml calcein-AM and 2
μg/ml propidium iodide for 30 min. Cell viability was monitored under a fluorescent
microscope. Viability of human islets was also determined by staining with dithizone, a
zinc chelating agent. Briefly, at 4 weeks after cultured alone or co-cultured with AdvhHGF-hIL-1Ra-transduced primary BMSCs, human islets were stained with dithizone as
described previously [12]. The insulin production of human islets was quantified by the
static insulin release method. Briefly, five hundred IEs were cultured alone or with 5 ×
105 untransduced primary BMSCs or with 5 × 105 Adv-hHGF-IL-1Ra-transduced
primary BMSCs (120 MOI) in a 10-cm dish of CMRL-1066 medium with 10% FBS for
10 days. At day 10, 5 μg/ml IL-1β was added to the medium and the islet/BMSC coculture was incubated with IL-1β for 4 days. Insulin release from islets was measured at
day 0, 10 and 14 by sequentially stimulated islets with the media containing 2.5 mM
(basal) and 22 mM glucose (stimulated) at 37ºC for 1 h.
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Islet transplantation
Animal experiments were performed following NIH
(http://grants1.nih.gov/grants/olaw/references/phspol.htm) and institutional animal care
and use guidelines using an approved protocol. To induce diabetes, STZ (70 mg/kg) was
administered to NOD-SCID mice by intraperitoneal injection for 2 consecutive days.
Animals were considered to be diabetic after two consecutive measurements of blood
glucose ≥ 400 mg/dl using a glucometer. Primary BMSCs were transduced with AdvhHGF-hIL-1Ra at 120 MOI and labeled with Qdot 565 prior to transplantation according
to the manufacturer’s instructions. Then islets were transplanted into the kidney capsule
of diabetic NOD-SCID mice alone or with Adv-hHGF-hIL-1Ra-transduced primary
BMSCs at constant ratio (islet: BMSC = 1:100). The nonfasted glucose levels and body
weights of all the mice were measured from the snipped tail of each animal up to 15
weeks after transplantation. Then the mice were anesthetized to collect blood to measure
serum insulin and c-peptide levels by ELISA. The graft-bearing kidneys were then
removed from some animals to confirm the function of islet grafts by the return of blood
glucose levels to ≥ 400 mg/dL for 2 consecutive days.
Intraperitoneal glucose tolerance test
Two weeks after islet transplantation, glucose tolerance was analyzed in overnight
fasted mice as described by Garcia-Ocana et al [9]. Briefly, the mice were subjected to
intraperitoneal injection of glucose at 2 g/kg of body weight. Blood samples were
obtained from the snipped tail at 15, 30, 60, 90, 120, and 180 min after injection and
analyzed for glucose levels using a glucometer.
Immunofluorescence staining
For Adv-hHGF-hIL-1Ra-transduced BMSCs, primary BMSCs were seeded at the
density of 5×104 each well into an 8-well chamber slide. After 24 h, these cells were
transduced with Adv-hHGF-hIL-1Ra at 120 MOI for 3 h followed by washing three
times and culturing an additional 48 h. The slides were then detached from the media
chamber and fixed with ice-cold methanol. To detect HGF expression, the slides were
stained with rabbit anti-HGF primary antibody (1:200) at 4 °C overnight and Alexa Fluor
568-conjugated goat anti-rabbit secondary antibody (1:500) at room temperature for 1 h.
To detect IL-1Ra expression, slides were stained with rabbit anti-IL-1Ra primary
antibody (1:200) at 4 °C overnight and Dylight 488-conjugated goat anti-rabbit secondary
antibody (1:500) at room temperature for 1 h. Slides were counter-stained with DAPI.
For the kidney section, 1000 IEs were mixed with Adv-hHGF-hIL-1Ratransduced BMSCs and co-transplanted under the kidney capsule of STZ-induced
diabetic NOD-SCID mice. Mice receiving islets alone and islets co-transplanted with
primary BMSCs were sacrificed 4 weeks after islet transplantation. Mice receiving islets
co-transplanted with Adv-hHGF-hIL-1ra transduced BMSCs were sacrificed at 4 weeks
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and 15 weeks after islet transplantation. Kidneys bearing islets were isolated, washed,
fixed in 4% paraformaldehyde overnight, and embedded in optimal cutting temperature
compound. Frozen sections of 5 μm thickness were cut. To detect insulin-positive human
islets, the slides were stained with guinea pig anti-insulin primary antibody (1:200) at 4
°C overnight and Alexa Fluor 568 conjugated goat anti-guinea-pig secondary antibody
(1:500) at room temperature for 1 h. To detect revascularization, the slides were stained
with rabbit anti-vWF primary antibody (1:500) at 4 °C overnight and Dylight 488conjugated goat anti-rabbit secondary antibody (1:500) at room temperature for 1 h.
Slides were counter-stained with DAPI. Images were analyzed using the Measure RGB
function of ImageJ to quantify the relative intensity of protein expression.
Statistical analysis
Statistical significance of the difference between the two groups was determined
by unpaired t-test and between several groups by one-way ANOVA.
Results
Characterization of Adv-hHGF-hIL-Ra-transduced BMSCs
As shown in Figure 5-3, primary BMSCs exhibit a spindle-shaped fibroblastic
morphology after ex vivo expansion. The optimal MOI was determined by transduction
of BMSCs with Adv-GFP at 60 MOI and 120 MOI. Results showed that the Adv
transduction efficiency into primary BMSCs is >30% at 60 MOI and >80% at 120 MOI.
Then 120 MOI was selected for optimal transduction of Adv-hHGF-hIL-1Ra. Results
showed that primary BMSCs transduced with Adv-hHGF-hIL-Ra at 120 MOI produced
significantly elevated levels of hHGF and hIL-1Ra since two days after transduction. The
expressions of HGF and IL-1Ra by Adv-hHGF-hIL-1Ra transduced primary BMSCs
decreased with time but were still significantly higher than the expressions by
untransduced BMSCs at 14 days after transduction. The exogenous expressions of HGF
and IL-1Ra by Adv-hHGF-hIL-1Ra transduced primary BMSCs were validated by
immunofluorescence staining. Primary BMSCs produced IL-10 in picogram level and
VEGF in nanogram level and the native expressions of IL-10 and VEGF were not
changed by Adv transduction (data not shown). As in previous reports [117, 118], we did
not detect expression of SCF from primary BMSCs (data not shown). In summary, these
results indicated that primary BMSCs simultaneously expresses the target exogenous
gene after transduction by Adv-hHGF-hIL-1Ra without losing their native characteristics.
Protection of human islets by Adv-hHGF-hIL-Ra-transduced BMSCs
Primary BMSCs participated extensively in organ repair [119]. HGF and IL-1Ra
were widely reported to hold anti-apoptotic ability [120, 121]. We tested the protection of
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Figure 5-3. Transduction efficiency of Adv-hHGF-hIL-1Ra into BMSCs
A. Primary BMSCs exhibit a spindle-shaped fibroblastic morphology after ex vivo
expansion. B. GFP expression in primary BMSCs after the transduction of Adv-GFP at
60 MOI. C. GFP expression in primary BMSCs after the transduction of Adv-GFP at 120
MOI. D. Time profile of HGF gene expression in primary BMSCs after the transduction
of Adv-hHGF-hIL-1Ra at 120 MOI as determined by ELISA. E. Time profile of IL-1Ra
gene expression in primary BMSCs after the transduction of Adv-hHGF-hIL-1Ra at 120
MOI as determined by ELISA. F-G. Expression of HGF and IL-1Ra in BMSCs after the
transduction of Adv-hHGF-hIL-1Ra at 120 MOI as determined by immunofluorescence
staining. Data are represented as the mean ± SD. n = 3. *P < 0.05 under t test.
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human islets against inflammatory cytokine from Adv-hHGF-hIL-1Ra transduced
primary BMSCs in an ex vivo co-culturing study. Results showed that after stimulated
with 5 ng/ml recombinant human IL-1β for 4 days, the cluster-like structures of islets
were destroyed and viability of islets decreased (Figure 5-4). However, the viability
andmorphological integrity were better preserved in the islets co-cultured with AdvhHGF-hIL-1Ra transduced primary BMSCs. The protection on cultured human islets
from Adv-hHGF-hIL-1Ra transduced primary BMSCs even lasted to 4 weeks. To
determine whether this protection effect was a result of the Adv-hHGF-hIL-1Ra
transduction on BMSCs or the organ repairing function of primary BMSCs, the insulin
release profiles over time from islets cultured alone, islets cultured with untransduced
primary BMSCs and islets cultured with Adv-hHGF-hIL-1Ra transduced primary
BMSCs were monitored (Figure 5-4). Results showed that the insulin releases from islets
cultured with primary BMSCs were significantly higher than the islets cultured alone at
day 10 of culture, indicating that BMSCs did help to protect islets viability. However,
untransduced BMSCs did not provide sufficient protection against the apoptotic islet
death caused by IL-1β. Results showed that insulin releases from islets cultured with
untransduced primary BMSCs decreased dramatically (75.1 ± 9.7%) in 4 days after
stimulating with 5 ng/ml recombinant human IL-1β. However, insulin releases from islets
cultured with Adv-hHGF-hIL-1Ra-transduced BMSCs decreased only slightly (23.4 ±
5.6%).
In summary, these results demonstrated that primary BMSCs supported islet
viability and function, but primary BMSCs alone failed provide islets with sufficient
protection against inflammatory cytokines in the physiology condition. Adv-hHGF-hIL1Ra-transduced primary BMSCs effectively prevented the apoptotic islet death caused by
inflammatory cytokines.
Co-transplantation of islets with Adv-hHGF-hIL-Ra-transduced BMSCs improved
outcome of islet transplantation
Transplantation of islets under the kidney capsule of diabetic NOD-SCID mice
reversed diabetes in every subject. As shown in Figure 5-5, the mice transplanted with
1000 IEs all reverted to diabetes after only 4 weeks. However, the diabetic mice receiving
1000 IEs and Adv-hHGF-hIL-Ra-transduced BMSCs maintained the blood glucose level
≤250 mg/dL for 15 weeks, suggesting prolonged protection of islets by Adv-hHGF-hILRa-transduced primary BMSCs. Results also showed that increasing islet mass from 1000
IEs to 2000 IEs effectively improved the outcome of islet transplantation (Figure 5-5),
although rapid increase in blood glucose level was still observed when no additional
BMSCs were co-transplanted. We considered mice with blood glucose ≤250 mg/dL as
the reversed-diabetes mice to determine the cumulative outcome of islet transplantation.
Co-transplantation of islets with Adv-hHGF-hIL-1Ra-transduced BMSCs significantly
increased the reversed-diabetes ratio, suggesting the positive role of Adv-hHGF-hIL-Ratransduced primary BMSCs after islet transplantation. To determine the islet function at
15 weeks after islet transplantation, the mice were anesthetized to collect blood to
measure serum insulin and c-peptide level by ELISA. Results showed that the levels of

74

Figure 5-4. Adv-hHGF-hIL-1Ra-transduced BMSCs helped to preserve islet
viability against IL-1β stimulation
A. Viability of naked islets after IL-1β stimulation for 4 days, as determined by calceinAM/PI double staining. B. Viability of islets co-cultured with Adv-hHGF-hIL-1Ratransduced BMSCs after IL-1β stimulation for 4 days, as determined by calcein-AM/PI
double staining. C. Glucose-stimulated insulin release from islets alone, islets co-cultured
with primary BMSCs and islets IEs co-cultured with Adv-hHGF-hIL-1Ra-transduced
BMSCs at day 0, day 10, and day 14 after co-culturing, as determined by ELISA. 5μg/ml
IL-1β was added at day 10 (arrow) and incubated with islets for 4 days. Data are
presented as the mean ± SD, n = 3. *P < 0.05 under one-way ANOVA test. D-F. Viability
of human islets cultured for 4 weeks alone (bottom left) or with Adv-hHGF-hIL-1Ra
transduced primary BMSCs (bottom right) as determined by dithizone staining. Fresh
islets were used as positive control (bottom center).
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Figure 5-5. Outcome of islet transplantation after being cotransplanted with AdvhHGF-hIL-1Ra-transduced BMSCs
A-D. The blood glucose level of every single mouse after receiving 1000 IEs (A), 1000
IEs co-transplanted with Adv-hHGF-hIL-1Ra-transduced BMSCs (B), 2000 IEs (C) and
2000 IEs co-transplanted with Adv-hHGF-hIL-1Ra-transduced BMSCs (D). Blood
glucose ≤ 250 mg/dL was identified as reversed-diabetes (dashed line). E. Reverseddiabetes ratio of the NOD-SCID mice after islet transplantation. White triangles = mice
receiving 1000 IEs, white squares = mice receiving 1000 IEs co-transplanted with AdvhHGF-hIL-1Ra-transduced BMSCs, black triangles = mice receiving 2000 IEs, black
squares = mice receiving 2000 IEs co-transplanted with Adv-hHGF-hIL-1Ra-transduced
BMSCs. F. Average serum insulin level of the mice receiving 1000 IEs and 1000 IEs cotransplanted with Adv-hHGF-hIL-1Ra-transduced BMSCs 15 weeks after islet
transplantation, as determined by ELISA. G. Average serum c-peptide level of the mice
receiving 1000 IEs and 1000 IEs co-transplanted with Adv-hHGF-hIL-1Ra-transduced
BMSCs 15 weeks after islet transplantation, as determined by ELISA. Data are presented
as the mean ± SD, n = 7. *P < 0.05 under t test.
76

insulin and c-peptide of the mice transplanted with 1000 IEs co-transplanted with AdvhHGF-hIL-1Ra-transduced primary BMSCs were significantly higher than those of the
mice transplanted with islets alone. The body weight was also measured to validate the
blood glucose measurement (Figure 5-6). The increases in body weight were
significantly slower in mice receiving islets alone since their blood glucose reverted to
diabetes sooner after transplantation. However, this phenomenon was not observed in
mice receiving islets and Adv-hHGF-hIL-1Ra-transduced primary BMSCs.
Intraperitoneal glucose tolerance test was used to determine islet engraftment and
function 2 weeks after transplantation. Results showed faster and better response to the
glucose boost in mice receiving 1000 IEs co-transplanted with Adv-hHGF-hIL-1Ratransduced primary BMSCs compared with mice receiving islets alone (Figure 5-7).
These results demonstrated the improvement in islet engraftment and function after cotransplantation of islets with Adv-hHGF-hIL-1Ra-transduced primary BMSCs and agreed
with recently published results [60].
Adv-hHGF-hIL-Ra-transduced BMSCs promoted islet engraftment and
revascularization
As shown in Figure 5-8, immunofluorescence staining showed the engraftments
of insulin-positive islets under the kidney capsule. Qdot labeled BMSCs were detected in
proximity of human islets, suggesting a protective role. As shown in Figure 5-9, the
staining of vWF was undetectable in the kidney sections bearing islets alone and sparse in
the kidney sections bearing islets and untransduced primary BMSCs. However, evident
vWF staining in the kidney sections bearing islets co-transplanted with Adv-hHGF-hIL1Ra-transduced primary BMSCs was detected at both 4 weeks and 15 weeks after islet
transplantation. After analyzed the relative vWF intensity from three independent regions
using ImageJ, these results suggested increased revascularization by Adv-hHGF-hIL1Ra-transduced primary BMSCs.
Discussion
The purpose of this study was to combine MSC based cell therapy with
adenovirus based gene therapy to improve the outcome of islet transplantation. We have
been working on Adv based gene therapy for years. Replication-deficient Adv vectors are
extensively reported to be effective in blocking the inflammatory cytokine pathway and
increasing the islet resistance to post-transplantation challenges [4]. HGF is known to
induce angiogenesis, promote β-cell proliferation and protect islets from apoptosis and
eventually helps to improve the transplantation outcome in STZ-induced diabetic mice [9,
122]. IL-1Ra binds to the cell surface interleukin-1 receptor and prevents IL-1 from
sending a signal to that cell. Ex vivo transduction of human islets with Adv-hIL-1Ra has
been reported to prevent IL-1β cell induced apoptotic cell death in islets [3]. We
previously reported the improved islet transplantation using Adv-hHGF-hIL-1Ra
transduced human islets [8]. However, most Adv vector failed to support the long-term
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Figure 5-6. Body weight and blood glucose after human islet transplantation
A-B. The average blood glucose level (A) and average body weight (B) of mice receiving
1000 IEs and 1000 IEs co-transplanted with Adv-hHGF-hIL-1Ra-transduced BMSCs (B).
C-D. The average blood glucose level (C) and average body weight (D) of mice receiving
2000 IEs and 2000 IEs co-transplanted with Adv-hHGF-hIL-1Ra-transduced BMSCs (D).
Decreasing average weight gain was observed in the mice receiving islets alone sooner
after the average blood glucose reversed back to diabetic level (arrow). However, this
phenomenon was not observed in mice receiving islets and Adv-hHGF-hIL-1Ratransduced BMSCs.
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Figure 5-7. Intraperitoneal glucose tolerance test of the mice receiving 1000 IEs
and 1000 IEs co-transplanted with Adv-hHGF-hIL-1Ra-transduced BMSCs at 2
weeks after islet transplantation
Data are presented as the mean ± SD, n = 7. *P < 0.05 under t test.
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Figure 5-8. Immunofluorescence staining of the kidney section bearing islets and
Adv-hHGF-hIL-1Ra-transduced BMSCs
A.B. Images under 20x magnification from bright field (A) and fluorescent microscope
(B). C.D. Images under 100x magnification from bright field (C) and fluorescent
microscope (D). Insulin was stained in red to indicate the functional human islets. Qdot
565 labeled BMSCs were green “blinking” dots in close proximity of transplanted islets
(white arrows).
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Figure 5-9. Adv-hHGF-hIL-1Ra-transduced BMSCs promoted revascularization
of the transplanted islets
A-D. Representative staining of vWF factor (green) in the kidney bearing islets alone at 4
weeks after transplantation (A), the kidney bearing islets co-transplanted with
untransduced primary BMSCs at 4 weeks after transplantation (B), the kidney bearing
islets co-transplanted with Adv-hHGF-hIL-1Ra-transduced primary BMSCs at 4 weeks
after transplantation (C) and the kidney bearing islets co-transplanted with Adv-hHGFhIL-1Ra-transduced primary BMSCs at 15 weeks after transplantation (D). E. vWF
fluorescent intensity was quantified using ImageJ from three independent regions. Data
are presented as the mean ± SD, n = 3, *P < 0.05 under t test.
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survival of islet grafts, probably due to the short expression profile of Adv. For example,
the expression of HGF and IL-1Ra drastically decreased at 14 days after Adv
transduction (Figure 5-3). Lentivrus could be an alternative solution for long term gene
therapy. But since lentivirus integrates into the host genome and has the potential for
generation of replication competent lentivirus and oncogenesis [123], great caution
should be used before starting in this area.
Another problem with Adv based gene therapy is the viral genome, more or less,
co-expressed with target genes may trigger an increasing immune response to the
transplanted organs. Some reports suggested that Adv transduction led to immune
reaction to the Adv-bearing organs and made them more susceptible to attack from the
recipient’s immune system with potentially dangerous consequences [124, 125].
Therefore, how to find the perfect vehicles to provide prolonged protection to islet grafts
with less immunogenicity is a critical question to be answered by traditional gene
therapy.
BMSCs seem to be one of these perfect vehicles for gene delivery. BMSCs are
pluripotent adult stem cells with the property of self-renewal and the potential to
differentiate into many types of cells [40]. They are open to genetic manipulation and
capable of secreting endogenous growth factors to promote engraftment of human islets
[58, 126]. They are also hypoimmunogenic, probably by releasing anti-inflammatory
cytokines and inhibiting T cell proliferation and activation [127, 128]. All these
characteristics make BMSCs good nursing cells to advance current clinical studies of islet
transplantation by combining gene therapy with cell therapy.
However, probably because of the lack of standard operating protocols for
isolating, preserving, and culturing BMSCs, the supporting role of BMSCs is still under
discussion. The secretion of growth factors such as HGF, VEGF, and stem cell factor by
BMSCs is controversial. We did not detect SCF expression by primary BMSCs, and the
basal expression of HGF and VEGF from primary BMSCs was too low to support an
optimal revascularization for islet graft survival (Figure 5-8) as noted in previous reports
[129]. We demonstrated that exogenous expression of HGF by Adv-hHGF-hIL-1Ratransduced primary BMSCs could be maintained for at least 2 weeks and may eventually
lead to the notable increasing revascularization of islet grafts after transplantation
(Figure 5-3).
Despite many reports on hypoimmunogenic nature of BMSCs, its mechanism is
unclear. There are two hypotheses: 1) through the secretion of immunosuppressive
cytokines, such as IL-10 and TGFβ [130]; and 2) through cell surface molecules of
BMSCs to inhibit T cell activity and proliferation [71]. Previous reports showed that the
co-transplantation of islets with primary BMSCs prevented the allogeneic rejection and
helped engraftment of islets, but one common feature in all these studies was that the
BMSCs were incompetent to reverse the blood glucose levels of recipients in the acute
stage (<3 weeks) after transplantation, suggesting the slow engraftment of transplanted
islets [43, 54, 116]. To make the situation even worse, the hyperglycemia caused by slow
engraftment in turn accelerated the apoptotic islet cell death [95]. We hypothesized that
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this phenomenon was probably due to the incapability of primary BMSCs to protect islets
against the inflammatory-cytokine induced apoptotic cell death. In consistence with
previous report [131], we demonstrated that the native secretion of IL-10 by BMSCs was
insufficient to support islet survival against the inflammatory cytokine (Figure 5-4). We
also demonstrated that Adv-hHGF-hIL-1Ra transduced primary BMSCs has clear
advantaged in preventing inflammatory-cytokine induced islet death compared with
untransduced primary BMSCs (Figure 5-4).
BMSCs are hypoimmunogenic cells in lack of the major histocompatibility
complex class II (MHC II) [56], making them capable of escaping the recognition by
Natural Killer cells and alloreactive T cells. This is an important feature for the gene
therapy to improve islet transplantation because 1) adding primary BMSCs into islets will
not significantly raise allogeneic rejection, and 2) BMSCs could serve as gene delivery
vehicles to avoid the notable immunogenicity of Adv vectors. Primary BMSCs were also
capable of repairing injured tissues in long term [132]. We demonstrated that when islets
were co-transplanted with Adv-hHGF-hIL-Ra transduced primary BMSCs, the blood
glucose levels of diabetic NOD-SCID mice were maintained ≤ 250 mg/dL for more than
15 weeks (Figure 5-5), significantly longer than most reported islet transplantations
using genetic modified islets [4, 16, 133]. These results indicated the advantage of
primary BMSCs as gene delivery vehicles to improve the outcome of islet
transplantation. Although an immunocompetent animal model should be used to further
validate the benefit of hypoimmunogenic primary BMSCs as gene delivery vehicles, our
work provided useful information for further research.
The differentiation capability of BMSCs is another interesting feature worthy of
mentioning. The capacity of BMSCs to differentiate into a variety of cells including
osteoblasts, adipocytes and chondrocytes and so on is one of most important mechanisms
underlying its capability of tissue repair [132]. Moreover, viral transduced BMSCs still
retained their differentiation capacity [134, 135]. This tissue repairing capacity of
primary BMSCs, as supported by majority of reports, may eventually lead to the long
term protection on human islets and was further supported by the fact that BMSCs were
in close proximity to the islet grafts (Figure 5-8). Other reports showed that BMSCs have
the potential to differentiate into vascular endothelial cells [136]. This is also possible
because revascularization was observed mostly around islet grafts where most BMSCs
settled (Figure 5-9). However, whether the neoforming blood vessels in the kidney
bearing islet grafts is from BMSCs alone or other cell types remains to be clarified.
In agreement with other reports on islets/BMSCs co-transplantation [67, 137], our
results indicated that the co-transplantation of islets with Adv-hHGF-hIL-1Ra-transduced
primary BMSCs into diabetic NOD-SCID mice promoted local revascularization,
improved islet viability and reversed diabetes in long term. We are the first group to
report the combination strategy of Adv-based gene therapy and BMSC-based cell therapy
to improve the outcome of islet transplantation. Our data indicated that BMSCs were
efficient gene delivery vehicles to improve the outcome of islet transplantation, as they
did to treat other diseases [138, 139]. Adv-hHGF-hIL-1Ra-transduced primary BMSCs
secreted elevated levels of HGF and IL-1Ra and retained their protective capability for
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the long-term survival of islet grafts. Since current gene therapy approaches still focus on
the expression of endogenous growth factors in human islets, our report provides a novel
direction for future exploration of other factors and cells for co-transplantation. Our
studies in rodents also provide useful information on the future studies on the
immunocompetent animal model. However, several issues still need clarification before
this approach can be clinically applicable, including the immunogenicity and in vivo fate
of Adv-transduced BMSCs, mechanism underlying the long-term protection of BMSCs,
and the optimal ratio between islet and BMSC numbers.
In our previous and present studies [6, 8], most transplanted human islets survived
only up to 4~6 weeks in diabetic NOD-SCID mice without any treatment. We can also
find out similar length of islet survival in other reports [140, 141]. We are aware of
several reports of islet survival beyond 60 days post-transplantation. This discrepancy is
due to the fact that islet survival and function post-transplantation depends on multiple
factors, including donor condition, islet purity, immunocytes, hyperglycemia, hypoxia
and inflammation after transplantation. The degree of diabetes and variability in mice
used for transplantation also greatly affect the length of islet survival and function. The
other reason may be the pre-transplantation treatment after islet isolation. When handpicked islets were used for transplantation, the length of islet survival was significantly
improved, possibly due to discarding of lymph nodes in the hand-picking process as the
existence of lymph nodes is detrimental to the survival of islets after transplantation.
However, we are not personally in charge of the isolation process and we do not prefer to
use hand-picked islets for transplantation.
In summary, co-transplantation of islets and BMSCs promoted revascularization,
protected islet viability, and significantly reduced the islet mass required for reverse
diabetes. The production of HGF and IL-1Ra by Adv-hHGF-hIL-1Ra-transduced primary
BMSCs and the protective capability of BMSCs synergistically helped to improve the
islet survival in the early stage and graft function in the long term run after
transplantation.
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CHAPTER 6. BMSC PREVENTS ALLOGRAFT REJECTION OF HUMAN
ISLET TRANSPLANTATION IN HUMANIZED MOUSE MODEL
Introduction
We marched a long trip to find the best ways to induce diabetes, to purify human
islets and to transplant human islet under the kidney capsule of diabetic mice. However,
the absence of human immunity in all the animal experiments has rendered all the
previous efforts far from clinical human islet transplantation. In fact, human islets can
only settled in immunodeficient animals for longer time (>4 weeks) and the absence of
human immunity is a common weakness of all studies involving human islet
transplantation in diabetic animals. These studies were actually focused on the PNF,
which is the loss of human islets caused by non-immune challenges including
inflammatory cytokines, hypoxia, ROS and poor revascularization, instead of immune
rejection.
To introduce immune rejection into preclinical studies regarding human islet
transplantation, some groups have been using immunocompetent rodents [60, 142].
However, the immune responses from mice and human are drastically different and the
results from these studies must be interpreted with caution. Recently, the development of
humanized mouse marked a huge advance in the animal models used for human islet
transplantation [79]. First, it is a perfect model to study the development of type 1
diabetes, which is an autoimmune disease. Second, the interaction between transplanted
islets and the adoptively transferred human immunity provide useful information about
immune rejection after human islet transplantation. The human immunity can be
established in several specialized mouse strains by injection of human immunocytes
validated by the presence of human IgG in the blood steam and CD3+ T cells in the
mouse spleen [79]. The adoptively transferred human immunity posed a challenge, which
is similar to the clinical immune rejection, to the transplanted human islets.
Compared with previous studies using immunodeficient animals [52, 54], the
duration of insulin independence in humanized mice was significantly reduced [79],
suggesting the existence of immune rejection. However, the introduction of human
immunity also led to GvHD, a fetal disease characterized by the attack to the recipient’s
major organs by the infused xenogeneic immunocytes. The risk of GvHD can be
controlled by reducing the amount of the infused immunocytes and even eradicated by
generating humanized mice using hematopoietic stem cells [79].
The potential of BMSC as a novel personalized medicine has inspired us to
explore its potential as an immune modulator. Although the recent improvements in the



Reprinted with permission from Nature Publishing Group. Wu, H, Wen, D, and Mahato,
RI (2013). Third-Party Mesenchymal Stem Cells Improved Human Islet Transplantation
in a Humanized Diabetic Mouse Model. Molecular Therapy, (in press).
85

regimen of immunosuppressive drugs such as tacrolimus, sirolimus and MPA have
greatly reduced their side effects, these drugs are still toxic to the viability and function of
transplanted islets. BMSC on the other hand, which can be easily isolated from a diabetic
patient and expanded in vitro, does not cause such concerns.
Unlike Gene therapy, which is incapable to prevent the immune rejection, stem
cell therapy has recently met great success as a novel regenerative medicine to support
solid organ transplantation including human islet transplantation [52, 143]. Among all
types of stem cells, BMSCs are given special interest for their self-renewal potential,
multi-lineage capacities, paracrine effects (trophic mediator) and immune modulatory
effects [40, 55], making it a great candidate for improving human islet transplantation.
MSC-based therapy has been used to improve human islet transplantation from
several aspects. Ding et al. reported the immunosuppressive effects of MSCs by secreting
soluble factors [60]. Korbutt et al. reported that co-culture with MSCs improved islet
viability and function against inflammatory cytokines [144]. Ito et al. and other
researchers reported that MSCs were capable of promoting the revascularization of islets
in vivo [52, 54]. However, the translation to a real clinical breakthrough is slow and the
data from limited clinical trials seems vague and controversial, probably due to the lack
of the human immunity in most of the previous studies. Hereby we evaluated the
effectiveness of BMSCs from a third party donor to improve the outcome of human islet
transplantation in a diabetic humanized NSG mouse model. We plan to answer two
questions by this study: 1) the interaction of BMSCs with adoptively-transferred human
immunity to protect islets in vivo; 2) the tropic effect of BMSCs to support islet function.
Materials and Methods
Materials
NSG and NOD-SCID mice were purchased from Jackson Laboratory and housed
in pathogen-free microisolator cages. Human PBMCs were isolated from fresh buffy
coats (Lifeblood South, Memphis, TN) by gradient centrifugation using Ficoll-Paque (GE
Healthcare, Little Chalfont, UK). Before use, the preparations of PBMCs were
characterized by FlowCellect™ Human Lymphocyte ZAP-70 Characterization Kit
(Millipore, Billerica, MA). To establish human immunity, PBMCs were injected
intraperitoneally into NSG mice (5x106/mouse) as described before [145]. The settlement
of T cells in the spleen was assessed two weeks after injection by immunofluorescence
staining. The function of B cells was assessed by measuring human IgG concentration in
the mouse blood. Human islets were received from Integrated Islet Distribution Program
(Duarte, CA). Primary BMSCs were purchased from Thermo Fisher Scientific (Waltham,
MA), passaged, and frozen in our lab. Before use, BMSCs were characterized of the
surface markers including human leukocyte antigens (HLA)-DR, HLA class I, CD14,
CD80, CD86 and Fas Ligand (FasL or CD95L) (Abcam, Cambridge, MA).
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Mixed lymphocyte reaction (MLR)
The proliferation of PBMCs was determined using CFSE proliferation assay.
CFSE passively diffuses into cells, retained by the cells throughout division and can be
used to differentiate the successive generations from the parental generations. Briefly,
CFSE-labeled PBMCs (1x106) were stimulated with phytohaemagglutinin (PHA,
1μg/mL) for 24h and co-cultured with BMSCs (5x104) in the same well or in a transwell
system for indicated time. In the transwell system, the BMSCs were adherent to the
bottom of the cell culture plate while the PBMCs were cultured in a 0.4µm transwell cell
culture inserts (Corning, Tewksbury, MA). The media was carefully monitored to rule
out the penetration of the PBMCs from the inserts. The division history of PBMCs was
analyzed by flow cytometry. The percentage of proliferated cells was calculated by
dividing the number of cells undergoing divisions with the number of total cells in the
cultures. The total number of PBMCs was measured using T4 Automatic Cell Counter
(Nexcelom, Lawrence, MA). The extent of T cell activation was determined by
measuring the level of IL-2, IL-2sRa and IFN-γ in the medium using ELISA. IL-10 level
in the medium was also determined by ELISA. Total T cells, CD4+ T cells, CD19+ B
cells and CD14+ monocytes were isolated or depleted from PBMCs using specific
Dynabeads for each population, respectively (Invitrogen, Carlsbad, CA). The mRNA
levels of IL-10 in each subpopulation were determined by Realtime PCR and normalized
by the levels of β-actin. The percentage of CD4+CD25+FoxP3+ Tregs was determined
by Human Regulatory T cells 3-color kit (RnD System, Minneapolis, MN) using flow
cytometry. To study whether a direct contact between BMSCs and PBMCs was required
for the immunosuppression of BMSCs, a transwell system was set up.
Islet viability study
Primary BMSCs (5×105) were co-cultured with 500 islets in a 10 cm dish of
CMRL-1066 medium with 10% FBS for 2 days. Then, the islet/BMSC co-culture was
stimulated with cytokine cocktail of TNFα (50 ng/mL), IL-1β (5ng/mL) and IFN-γ (50
ng/mL) for 4 days and the insulin secretion from human islets was quantified using a
dynamic islet perifusion assay. Briefly, 50 islets from each group were handpicked and
loaded onto a Swinnex 13 chamber (Millipore, Burlington, MA, USA) and perifused with
Krebs-Ringer bicarbonate HEPES buffer of the following composition (in mM): 129
NaCl, 5 NaHCO3, 4.8 KCl, 1.2 KH2PO4, 1.2 MgSO4, 2.5 CaCl2, and 10 HEPES at pH
7.4. The flow rate was maintained at 1 ml/min with a peristaltic pump (Themo Fisher,
Waltham, MA) and the temperature was maintained at 37°C with a solution heater
(Warner Instruments, Hamden, CT). Islets were first perifused with basal glucose
(1.67mM) for 60 min and stimulated with glucose (16.7mM) for 30 min and finally
perifused with basal glucose (1.67mM) until insulin release reversed to the basal level.
Samples were collected once per two minutes through an automatic fraction collector
(Waters, Milford, MA) and analyzed for insulin content by ELISA.
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Islet transplantation
A long-term low-dose STZ injection was used to induce diabetes in NSG mice.
Briefly, STZ (70 mg/kg) was injected intraperitoneally to NSG mice in the first day the
first and third week. Animals were mostly diabetic after three weeks as indicated by two
consecutive measurements of blood glucose ≥ 400 mg/dl using a glucometer. Then 500
handpicked human islets (150~300μm in diameter) were co-transplanted with primary
BMSCs at serial ratios (islet: BMSC = 1:0, 1:50, 1:100 and 1:200) under the kidney
capsule of diabetic NSG mice. The nonfasted glucose levels and body weights of all the
mice were measured from the pricked tail of each animal up to 15 weeks after
transplantation. PBMCs (5x106/mouse) were infused intraperitoneally into these mice at
4 weeks after islet transplantation. At the end of study (17 weeks after islet
transplantation), the graft-bearing kidneys were removed from some mice to confirm the
function of islet grafts by the return of blood glucose levels to ≥ 400 mg/dL for 2
consecutive days and all mice were subjected to euthanasia. Serum was collected serum
to measure the level of human insulin and c-peptide by ELISA. Whole blood was
collected and human CD4+ T cells were isolated using Dynabeads. The percentage of
CD4+CD25+FoxP3+ Tregs was determined by flow cytometry.
Intraperitoneal glucose tolerance test
Two weeks after islet transplantation, glucose tolerance was analyzed in overnight
fasted mice as described by Garcia-Ocana et al. [9]. Briefly, the mice were subjected to
intraperitoneal injection of glucose at 2 g/kg of body weight. Blood samples were
obtained from the snipped tail at 15, 30, 60, 90, 120, and 180 min after injection and
analyzed for glucose levels using a glucometer.
Immunofluorescence staining
Mice receiving islets alone and islets co-transplanted with primary BMSCs were
sacrificed 4 weeks after transplantation. The kidneys bearing islets were isolated, washed
with PBS, fixed in 4% paraformaldehyde overnight, and embedded in optimal cutting
temperature compound. Frozen sections of 5 μm thickness were cut. To detect insulinpositive human islets, the slides were stained with guinea pig anti-insulin primary
antibody (1:200) at 4 °C overnight and Alexa Fluor 568 conjugated goat anti-guinea pig
secondary antibody (1:500) at room temperature for 1 h. To detect CD3+ T cells, the
slides were stained with rabbit anti-CD3 primary antibody (1:500) at 4 °C overnight and
Dylight 488-conjugated goat anti-rabbit secondary antibody (1:500) at room temperature
for 1 h. Slides were counter-stained with DAPI. Three independent images were analyzed
using ImageJ to quantify the fluorescence intensity.
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Statistical analysis
Statistical significance of the difference between the two groups was determined
by unpaired t-test and between several groups by one-way ANOVA.
Results
Generation and characterization of humanized NSG mice
Human PBMCs were isolated from human buffy coat using Ficoll Paque and
gradient centrifugation. Typically 1x109 of PBMCs can be isolate from 60 mL of buffy
coat. A detailed isolation protocol is listed in the appendix. PBMCs isolated from
concentrated human buffy coat was composed of T lymphocytes (~55%) and B
lymphocytes (~40%) (Figure 6-1A). To further isolate a subpopulation of PBMCs,
specific dynabeads for each population can be used. Potent human IgG in the mouse
blood stream and evident human CD3+ T cells in the spleen sections were detected at
around two weeks after the intraperitoneal injection of PBMCs (5x106/mouse),
suggesting the successful establishment of human immunity (Figure 6-1B-C). In
contrast, human IgG and CD3+ T cells were not detected in NOD-SCID mice because
NOD-SCID mice expelled the xenogeneic immunocytes constantly [79].
BMSCs are fibroblast like adult stem cells
Primary BMSCs exhibit a spindle-shaped fibroblastic morphology after ex vivo
expansion. To understand the immunomodulatory effects of BMSCs, we decided to
characterize the surface markers of BMSCs. HLA Class I and HLA-DR (class II) were
tested because BMSCs might act as antigen presenting cells. We also tested CD14, CD80
and CD86 which are important co-stimulatory factors. Besides, FasL was also tested
because they might participate in the apoptosis of T cells [146]. The BMSCs maintained
in our lab were positive for HLA class I and negative for HLA-DR, FasL, CD14, CD80
and CD86 (Figure 6-2). However, the lack of co-stimulatory molecules such as CD80
and CD86 suggested that the antigen presentation through BMSCs led to the reversal of T
cell maturation and subsequent immune tolerance as suggested by previous literatures
[147].
BMSCs suppressed the activation and proliferation of PBMCs
PBMCs were isolated from human buffy coats. We first tested the
immunomodulatory effect of BMSCs on PBMCs in a MLR. Carboxyfluorescein diacetate
succinimidyl ester (CFSE), a fluorescent dye retained within cells for a long period, was
used to stain PBMCs before co-culturing with BMSCs. The PBMC/BMSC co-culture
was stimulated with phytohaemagglutinin (PHA) (5μg/mL) and allowed to proliferate for
2 days. The daughter cells were determined by the progressive halving of CFSE
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Figure 6-1. Establish human immunity in NSG mice using human PBMCs
A. Isolation and characterization of PBMCs from fresh buffy coat. B-C. The serum
human IgG concentration (B) and the staining of human CD3+ T cells in the spleen
sections (C) of NSG mice and NOD-SCID mice at 2 weeks after the injection of PBMCs
(5x106/mouse).

Figure 6-2. Characterization of human BMSCs
A. BMSCs are spindle-shaped adult stem cells under bright field. B. BMSCs are positive
for HLA class I and negative for HLA-DR, FasL, CD14, CD80 and CD86. Open circle
represents the isotype control.
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fluorescence following each division. The co-incubation with BMSCs strongly inhibited
the proliferation of PBMCs as indicated by the area of successive generations at 24h after
co-incubation (Figure 6-3A). The total number of PBMCs in the co-culture was also
significantly less than the PBMCs cultured alone (Figure 6-3B). Moreover, less IFN-γ,
IL-2 and IL-2sRα (a soluble subunit of IL-2 receptor) were detected in the co-culture,
suggesting less T cell activation (Figure 6-3C). We then determined whether the
inhibition required direct contact between PBMCs and BMSCs. Surprisingly, BMSCs
were equally potent to inhibit the proliferation of PBMCs and the expression of IFN-γ,
IL-2 and IL-2sRα in a transwell system, suggesting a predominant paracrine model. Or in
other words, BMSCs inhibited PBMCs by secreting soluble factors.
IL-10 is a well-documented immunosuppressive factor by suppressing T cell
activation, preventing antigen presenting process and inhibiting inflammatory cytokines.
We previously reported marginal IL-10 expression (~20pg/mL) in the medium of primary
BMSCs [52]. However, IL-10 expression was significantly boosted (300~400pg/mL) in
the PBMC/BMSC co-culture, despite the existence of PHA-stimulation (Figure 6-4A).
The inhibition of IL-10 pathway partially restored the production of IFN-γ, IL-2 and IL2sRα by the stimulated T cells in the presence of BMSCs (Figure 6-4B), indicating the
crucial role of IL-10 in the immunomodulatory effects of BMSCs. We next determined
which subpopulation of PBMCs produced IL-10. Neither T cells nor B cells have been
reported to produce potent IL-10. We found that CD14+ monocytes were required for IL10 expression in the PBMC/BMSC co-culture since CD14+ monocyte depleted PBMCs
produced significantly less IL-10 (Figure 6-4C). Realtime PCR also demonstrated that
IL-10 transcription was activated in CD14+ monocytes instead of T cells or B cells,
suggesting that the signal transduction between BMSCs and monocytes might be the first
step toward the production of IL-10 and subsequent immune suppression.
Other literatures showed positive expression of FasL on the surface of BMSCs
and hypothesized that BMSCs promoted the apoptosis of T cells and subsequent immune
tolerance [58, 146]. However, we did not detect FasL expression on the surface of
BMSCs maintained in our lab (Figure 6-1). Annexin V staining demonstrated that
BMSCs had no effect on the apoptosis of T cells in the co-culture (data not shown). Our
results was supported by the results from Ryan et al [55].
BMSCs improved islet function
Bedsides immune rejection, islets also suffers from the PNF which is the loss of
islet function by non-immune reactions. Although still in debate, inflammatory cytokines
seem to play important roles in the PNF of human islets because raised inflammatory
cytokines was accompanied with most post-transplantation challenges including hypoxia
in the core of islet grafts, inflammation in the transplantation site and the disruption of
vasculature [17]. In this study, we used a cocktail of inflammatory cytokines (TNFα 50
μg/mL, IL-1β 5μg/mL and IFN-γ 50 μg/mL) to mimic the PNF related challenges to
human islets. Without inflammatory cytokines, the presence of BMSCs in the co-culture
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Figure 6-3. Human BMSCs prevent the proliferation and activation of PBMCs
A. The percentage of successive generations of PBMCs when stimulated with
phytohaemagglutinin (PHA, 1μg/mL) for 1 day and allowed to proliferate for 2 more
days. PBMCs were labeled with CFSE and subjected to analysis using flow cytometry.
Left, PBMCs alone; right, PBMCs with BMSCs. B. The total amount of PBMCs as
determined by an automatic cell counter. C. The levels of IL-2, IL-2sRα and IFN-γ in the
medium as determined by ELISA. D-F. Repeat of the previous experiments (a-c) using a
transwell system. n=3.
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Figure 6-4. CD14+ monocytes and IL-10 were required for the
immunomodulatory effect of BMSCs
PBMCs were stimulated with phytohaemagglutinin (PHA, 1μg/mL) for 1 day and cocultured with BMSCs for 2 more days. A. IL-10 was highly expressed by the
PBMC/BMSC co-culture but not by PBMCs alone. B. The inhibition of PBMCs
mediated by BMSCs can be reversed by adding IL-10sR. C. Monocyte depleted PBMCs
(PBMCsΔMono) failed to produce high level of IL-10 in the PBMC/BMSC co-culture. D.
IL-10 mRNA was highly expressed in CD14+ monocytes but not B cells and T cells in
the PBMC/BMSC co-culture. n=3.

93

did not affect insulin release from human islets when exposed to stimulatory glucose.
Inflammatory cytokines significantly impaired the first-phase (the first peak appears
immediately after stimulatory glucose) and the total insulin release of human islets after 4
days (Figure 6-5A). However, the presence of BMSCs in the co-culture significantly
ameliorated the impairment caused by inflammatory cytokines (Figure 6-5B), suggesting
a protective effect of BMSCs.
BMSCs improved islet transplantation in humanized NSG mice
The co-administration of STZ and PBMCs usually led to strong T cell
alloreactivity and subsequent GvHD and death. In this study, we first used a long term
injection of low doses of STZ to induce diabetes. Mice were mostly diabetic after three
weeks. Then, 500 handpicked human islets were transplanted under the kidney capsule of
each diabetic NSG mouse with BMSCs at serial ratios (islet: BMSC = 1:0, 1:50, 1:100
and 1:200). At 4 weeks after successful islet transplantation, PBMCs (5x106/mouse) were
injected intraperitoneally to establish the human immunity. This strategy helped us to
identify the settlement of human immunity by comparing blood glucose before and after
PBMC injection and to avoid STZ-stimulated GvHD. Glucose measurement showed that
all mice restored normoglycemia during the first 4 weeks after islet transplantation,
indicating successful islet engraftment and function (Figure 6-6A). However, the blood
glucose of some mice reversed to hyperglycemia after PBMC infusion, probably due to
the destruction of islet grafts by the established human immunity. Briefly, 11/11 mice
receiving islets only were back to diabetes in the first two weeks after PBMC infusion. In
contrast, 10/11, 6/12 and 2/10 mice were back to diabetes when the islets were
transplanted with BMSCs (islets: BMSCs=1:50, 1:100, 1:200), respectively (Figure
6-6B). Dose dependent improvement of the outcome of human islet transplantation was
observed by increasing the ratio of BMSCs, suggesting the protective role of BMSCs
against the adoptively transferred human immunity.
Intraperitoneal glucose tolerance test was performed 2 weeks after the PBMC
injection to determine the function of islets in real time. Despite the difference in the nonfasted blood glucose level between different groups, all mice displayed similar baseline
blood glucose levels following overnight fasting. Blood glucose levels increased
immediately following glucose (2 g/kg) injection, peaked at 15 min in all groups, and
decreased over time (Figure 6-6C). The mice receiving islet/BMSC co-transplantation
showed faster and better response to the stimulatory glucose compared to the mice
receiving islets alone (Figure 6-6C), suggesting a better glucose control. At the end of
study, the mice were anesthetized to collect blood to measure serum insulin and c-peptide
level by ELISA. The levels of insulin and c-peptide of the mice receiving islet/BMSC cotransplantation were significantly higher than those of the mice transplanted with islets
alone (Figure 6-6D).
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Figure 6-5. Human BMSCs protected the function of human islets against the
inflammatory cytokines
A. The dynamic insulin release from human islets. Briefly, 50 islets from each group
were perifused with basal glucose (1.67mM) for 60 min, stimulatory glucose (16.7mM)
for 30 min and finally basal glucose until the insulin release reversed to the basal level.
The flow rate was maintained at 1 ml/min and the temperature was maintained at 37°C.
Samples were collected once per two minutes and analyzed for insulin concentration. For
the cytokine treatment groups, islets, alone or with BMSCs, were stimulated with a
cytokine cocktail (TNFα 50 μg/mL, IL-1β 5μg/mL and IFN-γ 50 μg/mL) for 4 days prior
to perifusion. B. Cumulative insulin release calculated from dynamic insulin release
profile on the left. n=3.
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Figure 6-6. The outcome of human islet transplantation with BMSCs in diabetic
humanized NSG mice
A. The blood glucose levels of all mice after successful islet transplantation. For each
mouse, 500 handpicked islets ((150~300μm in diameter) were transplanted alone or with
BMSCs at serial ratios (islet: BMSC =1:50, 1:100 and 1:200) under the kidney capsule of
STZ induced diabetic NSG mice. The blood glucose level of each mouse was monitored
using a glucometer weekly. An intraperitoneal injection of PBMCs (5x106/mouse) was
given 4 weeks after islet transplantation. At 17 weeks after islet transplantation, the graftbearing kidneys were then removed from some mice to validate the function of islet
grafts by the return of blood glucose levels to ≥ 400 mg/dL. B. The Kaplan–Meier plot
for the percentage of insulin-independent mice of each group after PBMC injection. The
mouse with blood glucose level < 200mg/dL for two consecutive measurements was
identified as insulin-independent. P value was calculated as compared to the islet-alone
group using R version 2.15.2. C. Intraperitoneal glucose tolerance test was done with the
mice receiving islet alone and islet/BMSC cotransplantation (islet: BMSC =1:200) to
determine the islet function at 2 weeks after the injection of PBMCs. D. The serum
insulin and c-peptide of the mice receiving islet alone and islet/BMSC cotransplantation
(islet: BMSC =1:200) at the end of study. Data are presented as Mean±SD, n=9.
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BMSCs prevented T cell infiltration and increased Tregs
The kidney bearing islets was isolated at the end of study and subjected to
immunofluorescence staining. The location and function of islet grafts were identified by
staining for insulin. Insulin signal in the kidney capsule bearing islet/BMSC was
significantly higher than those bearing islets only (Figure 6-7A). However, CD3+ T cells
were significantly less in the kidney capsules bearing islet/BMSC than those bearing
islets only. Taken together, these data suggested that BMSCs prevented T cell infiltration
into the transplantation site and prevented the destruction of islets in vivo.
The expansion of Tregs might play an important role in the immune tolerance of
transplanted organs in vivo [148]. Moreover, BMSCs were recently reported to increase
the proportion of Tregs [149, 150]. To further explore whether such mechanism can
explain the reduced infiltration and destruction by alloreactive T cells into the
transplantation site, we isolated all CD3+ T cells and detected the percentage of Tregs
from the blood stream of NSG mice. Despite the low cell recovery, significantly higher
percentage of CD3+CD25+Foxp3+Tregs was detected in the blood stream (Figure
6-7B), which was consistent with the BMSC/T cells co-culture study in vitro (Figure
6-7C). Taken together, these results suggested that BMSC mediated increase in the
proportion of Tregs might contribute to the immune tolerance of islet transplantation.
Discussion
Edmonton protocol for human islet transplantation, which was developed more
than 20 year ago, failed to maintain insulin independence in the long term in most
patients. Despite the development of new immunosuppressive regimens and new
combination therapy, graft rejection remains a major challenge for human islet
transplantation. Other challenges are summarized as PNF caused by the hypoxic
environment, secretion of inflammatory cytokines and apoptosis of islet cells during
isolation, transportation and storage process.
MSC-based cell therapy has attracted wide attention in regenerative medicine and
tissue engineering. There are two major strategies of using MSCs for islet transplantation:
1) direct the differentiation of MSCs to replenish the lost islets; 2) use MSCs to nourish
islet grafts and mitigate immune response. For the first strategy, several groups have
reported the generation of islet-producing cells and islet-like clusters by the in vitro
transdifferentiation of MSCs [76, 77]. However, this strategy usually required long-term
in vitro induction and failed to generate enough islets for clinical study and the risk of
tumorigenicity was somehow overlooked. For the second strategy, MSCs constitutively
secreted multiple factors, which are capable of regulating insulin production,
revascularization, immune rejection and apoptosis of human islets. This strategy does not
require in vitro transdifferentiation and huge amount of MSCs. Most importantly, MSCs
can be isolated from and infused back into the same patient to exert the therapeutic
potential as indicated by several clinical studies [39]. Therefore, in this study, we selected
the second strategy for improving human islet transplantation.
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Figure 6-7. Human BMSCs prevent the T cell infiltration into the transplantation
site
A. The immune fluorescence staining of the kidney section bearing human islets alone
(left) or with BMSCs (right). Briefly, three mice in each group were sacrificed at 2 weeks
after the injection of PBMCs (5x106/mice), or 6 weeks after islet transplantation. Insulin
was stained in red to identify the transplanted human islets, while CD3+ T cells were
stained in green. All experiments were done in triplicates and an representative picture
was shown. B. The percentage of CD4+CD25+FoxP3+ regulatory T cells (Tregs)
recovered from the blood stream of NSG mice at 2 weeks after the injection of PBMCs.
Briefly, the total CD4+ T cells was isolated and purified from the total blood of NSG
mice using Dynalbeads at the end of study. The percentage of CD25+FoxP3+ Tregs
among the total CD4+ T cells was determined by flow cytometry. Q2 represents the
Tregs. C. The percentage of Tregs of the total CD3+ T cells when co-culture with
BMSCs in vitro.
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The pattern of the surface markers has great impact on the function of BMSCs
and provided useful information to the following studies. Our BMSCs were positive for
HLA class I and negative for CD14 (Figure 6-2), which concurred with previous report
and suggested BMSCs can be recognized and destroyed by the cytotoxic T cells [55].
BMSCs were also negative for costimulatory factors such as CD80 and CD86, which
might explain why BMSCs were unable to stimulate the multiplication of helper T (Th)
cells and the subsequent antibody production. Generally, the lack of co-stimulatory
factors (CD80 and CD86) led to an immature antigen presenting to the Th cells and
subsequent immune tolerance [151]. Despite that some groups showed that BMSCs
expressed FasL and promoted the apoptosis of T cells through direct contact [146, 152],
our BMSCs were negative for FasL (Figure 6-2), which was supported by the results
from other groups [55, 153] and confirmed by the MLR that BMSCs did not promote the
apoptosis of T cells (data not shown). The expression of HLA class II on the surface of
BMSCs is still unclear. While some groups demonstrated that BMSCs were positive for
HLA class II [151], the studies from our and other groups suggested that BMSCs were
negative for HLA class II which explained the hypoimmunogenicity of MSCs (Figure
6-2) [55]. This discrepancy is probably due to the difference in culture conditions and the
sources of BMSCs and can only be solved if a standard operating protocol is developed
and maintained among all research groups.
T cells are the most important cells mediating the recognition and destruction of
human islets. T cells can be activated by PHA and the activation of T cells is
characterized by the production of IL-2, IL-2R and IFNγ. In the MLR, BMSCs prevented
PHA-induced proliferation and activation of PBMCs by secreting the soluble factors,
among which IL-10 may play an important role (Figures 6-3, 6-4). However, despite
potent IL-10 expression in the PBMC/BMSC co-culture, significantly less IL-10 was
expressed by BMSCs or PBMCs when they were cultured alone [52], suggesting that the
communications between BMSCs and a subpopulation of PBMCs were required for the
production of immunosuppressive IL-10 [63, 65]. We identified CD14+ monocytes as the
prerequisite of the BMSC-mediated immune suppression (Figure 6-4), which is
consistent with previous reports that monocytes or monocyte-derived dendritic cells were
deeply involved in the BMSC-mediated T cell inhibition [154, 155]. First, BMSCs
secreted soluble factor(s) and activated CD14+ monocytes to express IL-10. Then IL-10
suppressed the subsequent proliferation and activation of T cells. Such two-step
immunosuppression could be an important feature for the co-transplantation of human
islets and BMSCs as the BMSCs only exert a local effect to protect human islets without
impairing the host immunity systemically. However, these results should be interpreted
with caution because 1) the role of IL-10 in the BMSC-mediated immunosuppression is
controversial as some groups observed IL-10 inhibition did not reverse and even further
suppressed T cell proliferation [63, 154] and 2) the soluble factors secreted by BMSCs in
this process remained unknown. Besides IL-10, other immunosuppressive factors such as
HGF, TGFβ and PGE2 may also play important roles in the BMSC-mediated
immunosuppression [52, 55, 156]. It is highly possible that the immunomodulatory effect
of BMSCs is mediated through a network of molecular pathways instead of a single
pathway.
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Next we evaluated the interactions of BMSCs with human islets and human
immunity in vivo. In fact, several groups have previously shown the improvement of islet
transplantation using MSCs, either through co-transplantation or intravenous infusion.
For example, Ito et al. reported that MSCs improved the outcome of islet transplantation
by promoting the revascularization of islet grafts [54]. Ding et al. reported MSCs
prevented the rejection of allogeneic islets by matrix metalloproteinase-2 and -9 (MMP2
and MMP9) [60]. Yeung et al. reported that MSCs protected human islets from
inflammatory cytokines [144]. However, the lack of human immunity in most of these
studies caused limited understanding regarding the immune mediated graft loss. Yet the
mechanism of BMSC-mediated protection to human islets in the presence of human
immunity has not been thoroughly understood. Although xenogeneic human islet
transplantation in immunocompetent rodents has been reported [142], the distinct
differences in the immune system between rodent and human hindered the translation
into a real clinical advance. The humanized mouse developed by Dr. Lenny Schultz is a
“state of the art” animal model for research related to human immunity [79]. First, it is a
perfect model to study the development of type 1 diabetes, which is an autoimmune
disease. Second, the interaction between transplanted islets and the adoptively transferred
human immunity provide useful information about immune rejection after human islet
transplantation. The human immunity was established in NSG mice by injection of
human PBMCs and validated by the presence of human IgG in the blood steam and
CD3+ T cells in the mouse spleen (Figure 6-1). The adoptively transferred human
immunity posed a challenge, which is similar to the clinical immune rejection, to the
transplanted human islets. Compared with previous studies using immunodeficient
animals [52, 54], the duration of insulin independence was significantly reduced in
humanized NSG mice, as evidenced by the rapid loss of islet and T cell infiltration
(Figures 6-6A, 6-7A). Co-transplantation with BMSCs significantly prolonged the
duration of insulin independence in the presence of human immunity (Figure 6-6A). The
intraperitoneal glucose tolerance test and the serum levels of human insulin and c-peptide
further validate the improved islet function in the islet/BMSC co-transplantation group
(Figures 6-6C-D). The interactions between BMSCs and T cells may of critical
importance to the protection to human islets. We previously demonstrated that BMSCs
“switched on” the production of immunosuppressive IL-10 by CD14+ monocytes to
prevent the proliferation and activation of T cells in co-culture (Figure 6-3). In vivo
results showed that BMSCs prevented the infiltration of CD3+ T cells into the
transplantation site, probably due to the reversal to T cell activation (Figure 6-7A).
Besides, we also found increased immunosuppressive Tregs in the blood stream of
humanized NSG mice receiving islet/BMSC co-transplantation, suggesting locally
injected BMSCs still had the potential to exert a considerable systemic effect (Figure
6-7B). Similar results were found in the MLR and supported by the results from Weng et
al. (Figure 6-7C) [150]. However, further explorations are still required to unveil the
underlying pathways to the proliferation of Treg.
Besides the immune modulatory effect, BMSCs improved insulin production of
human islets against inflammatory cytokines in an islet perifusion assay (Figure 6-5),
suggesting the role of BMSC as a trophic mediator to prevent the PNF of human islets.
BMSCs also produce multiple growth factors including HGF and VEGF to promote the
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revascularization, which has been explored in depth in immune deficient animal model
by us and other groups [52, 54].
Based on our results, we hereby propose three possible mechanisms for BMSCmediated islet tolerance (Figure 6-8): 1) BMSCs inhibit alloreactive T cells by the
immature antigen presenting and/or activating CD14+ monocytes to produce IL-10; 2)
BMSCs promote the proliferation of Tregs through soluble factors; 3) BMSCs prevent
the PNF of islets. The protection of human islets by BMSCs in the presence of human
immunity may be a result of the synergistic combination of all three mechanisms.
Despite the evidences that BMSCs significantly improved islet transplantation in
humanized NSG mice, the data should be interpreted with caution as several issues
needed to be resolved. First, we did not characterize the interactions of BMSCs with B
cells and natural killer cells. Such characterization may uncover the new aspects of
BMSCs mediated immune tolerance and is necessary in future. The second issue is the
GvHD caused by the infused mature immunocytes. Most humanized NSG mice or even
NRG-Akita mice, which simultaneously develop diabetes without STZ injection, will
develop GvHD in 5~7 weeks after the infusion of PBMCs [79], providing us a limited
window to evaluate the efficacy of BMSC cotransplantation. The amount of infused
PBMCs has great effect on the onset of GvHD. The dose of 5x106 PBMCs was reported
to be relatively safe to induce significant GvHD and adopted for this study [79]. Due to
the presence of BMSCs which hold strong immunomodulatory effects we did not detect
significant GvHD-like symptoms including weight loss, hunched posture, ruffled fur,
reduced mobility and tachypnea in the mice receiving islet/BMSC cotransplantation.
However, we did observe GvHD in the mice receiving islets alone from 5 weeks after the
infusion of PBMCs. Humanized mice generated from hematopoietic stem cells may
resolve the issue of GvHD [80]. The third issue is the route of the administration of
BMSCs. Many reports have shown that the systemic administration of BMSCs prevented
the onset of type 1 diabetes. However, the systemic injection of BMSCs may be
sequestered in the lung and other sites. In this study, we chose islet/BMSC cotransplantation to exert a local effect, which might have more impact on the future
clinical application because the immunity of the patients receiving islet transplantation
will not be compromised. Previous studies from us and other groups also ruled out the
possibility of BMSC migration and demonstrated that BMSC co-transplantation stayed in
the proximity of islet grafts and helped the engraftment and revascularization of islet
grafts [52, 54]. Last but not the least, despite our demonstration that BMSCs from the
third party is equally potent to protect human islets from adoptively transferred human
immunity (Figure 6-7A). The mismatch in HLA typing remains a concern for future
clinical application. To better fit the scope of personalized medicine, BMSCs and PBMCs
isolated from the same subject would be preferred. That requires further collaboration of
institutions with hospitals.
In summary, our studies demonstrated that co-transplantation with BMSCs can be
a promising strategy to improve the current status of human islet transplantation. The
BMSC served as a major role of immune modulator to protect islets from immune
destruction while also as a trophic mediator to prevent the PNF of islet transplantation.
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Figure 6-8. Schematic illustration of why BMSCs improved human islet
transplantation
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CHAPTER 7. A NOVEL COMPOUND DRUG FOR HUMAN ISLET
TRANSPLANTATION IN HUMANIZED MOUSE MODEL
Introduction
In the study described in Chapter 6, we used BMSCs to prevent the immune
rejection of human islet transplantation (Figures 6-6, 6-7). BMSCs also prevented the
PNF of islet transplantation caused by inflammatory cytokines (Figure 6-5). Compared
with gene therapy, stem cell therapy is a more biocompatible strategy for human islet
transplantation. However, the unlimited proliferative capacity and transdifferentiation
potential of stem cells especially genetically modified stem cells (Chapter 5) pose risks of
tumorigenicity and immunogenicity, though in a lesser extent to islet recipient.
BMSCs infused intravenously will be sequestered in the lung. Therefore BMSCs
were mostly co-transplanted with human islets and unsuitable for repeatedly injection,
making the transplantation outcome hard to predict and manage. The cost and time
needed for the isolation, expansion and even genetic modification of enough amounts of
BMSCs for clinical application is another of concern using BMSCs. Therefore, in this
study, we proposed a novel compound drug, in which an antiapoptotic drug is conjugated
with immunosuppressive compound, for human islet transplantation. We hypothesized
that the compound drug could prevent the inflammatory cytokine induced PNF and the
immune rejection at the same time. Most importantly, this compound is easy to
synthesize and can be injected repeatedly into a diabetic patient.
Zeng et al. synthesized a series of quinic acid (QA) derivatives and determined
their anti-inflammatory activity in human A549 cells [157]. They demonstrated that
among many QA derivatives, KZ41 had strongest inhibition of NK-kB activity against in
A549 cells the stimulation of TNFα and can be used for as an anti-inflammation drug
(Figure 7-1). We hypothesized that KZ41 was equally potent to suppress the
inflammatory pathway in human islets and could prevent the PNF caused by
inflammatory cytokines. MPA is an immunosuppressive drug frequently used in organ
transplantation. MPA is commonly marketed under the trade names CellCept (Roche) and
Myfortic (Novartis). MPA inhibits inosine monophosphate dehydrogenase, which
controls the purine synthesis in T cells and B cells.
Therefore, in this study, we synthesized JP-3-110 by conjugating quinic acid
amide and MPA via ester bond. We first compared the antiapoptotic effect of the
compound drug JP-3-110 with its antiapoptotic counterpart KZ41 on human islets against
inflammatory cytokines. We then compared the immunosuppressive effect of JP-3-110
with its immunosuppressive counterpart MPA against the activation and proliferation of T
cells. Lastly, we evaluated the effectiveness of this new compound drug to improve the
outcome of human islet transplantation in a diabetic humanized NSG mouse model. We
hypothesized that the compound drug JP-3-110 can prevent the immune rejection and the
PNF of human islet transplantation at the same time.
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Figure 7-1. KZ41 and NF-kB inhibition
A. The structure of KZ41. B. NF-kB activity was measured using A549 cells stably
transfected with a secreted alkaline phosphatase (SEAP) reporter at 18 hours after
addition of TNF-α (10 ng/mL) and either QA or QA derivatives (3–13; 1 μM). KZ41 was
lane 3. Dexamethasone (Dex; 1 μM) was used as a positive control. Data are presented as
percent (%) inhibition relative to control (ctl; TNF-α alone) and represent mean ± SD. n =
3. Blank: media only.
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Materials and Methods
Materials
Human islets were received from Integrated Islet Distribution Program (Duarte,
CA). CMRL-1066 medium for islet culture and DAPI were purchased from Sigma
Aldrich (St. Louis, MO). FBS was purchased from MediaTech Cellgro. (Herndon, VA).
PBS was purchased from GIBCO-BRL (Gaithersburg, MD). NF-kB SEAPorterTM Assay
Kit was purchased from IMGENEX (San Diego, CA). Human IL-2, IL-2sRa, IL-10
ELISA, TNFα and IFN-γ ELISA kits were purchased from R&D Systems (Minneapolis,
MN). The primary antibodies for CD3, CD4, insulin and the Dylight 488-conjugated
secondary antibody were purchased from Abcam (Cambridge, MA). The Alexa Fluor
568-conjugated secondary antibody and 0.25% trypsin were purchased from Invitrogen
(Carlsbad, CA). Ultrasensitive One Touch glucose test strips and One Touch Ultra
glucometer were purchased from LifeScan (Milpitas, CA). Tissue-Tek O.C.T. compounds
were purchased from Sakura Finetek (Torrance, CA).
Synthesis and characterization of antiapoptotic immunosuppressive drug
All reagents for the synthesis were purchased from commercial sources and were
used without further purification. Moisture-sensitive reactions were carried out under an
argon atmosphere. Routine TLC was performed on aluminum backed Uniplates
(Analtech, Newark, DE). NMR spectra were obtained on a Bruker ARX-400 MHz
(Billerica, MA) or a Varian Inova-500 MHz spectrometer (Varian NMR Inc., Palo Alto,
CA). Chemical shifts are reported as parts per million (ppm) relative to TMS (0 ppm) in
CDCl3. Temperature was regulated with a general accuracy of ±0.1°C. Mass spectral data
were collected on a Bruker ESQUIRE-LC/MS system equipped with an ESI source. The
synthesis of ester 4 used in the pancreatic islets protection studies was synthesized as
illustrated in Figure 7-2. The starting compound 5,7-dihydroxy-2,2-dimethyl-N-propylhexahydrobenzo[d][1,3]dioxole-5-carboxamide (amide 1), which has been described
before[158], was coupled with acetylated MPA 2 to obtain quinic acid ester 3 and further
deprotection of acetanoid group using 1N HCl in tetrahydrofuran (THF) to give
compound 4.
Synthesis of Compound 2. Acetic anhydride (0.2 mL, 1.9 mmol) was slowly
added to a pyridine (5 mL) solution of MPA (0.2 g, 0.62 mmol) and 4Dimethylaminopyridine (DMAP, 0.03 g, 0.25 mmol) at 0 °C. The reaction mixture was
stirred for 2 h and then poured onto crushed ice. The aqueous phase was acidified with 2
M aq. HCl (pH ~ 2) and extracted with EtOAc (3 x 400 mL). The combined organic
extracts were dried over Na2SO4, filtered, and the solvent was removed under reduced
pressure to afford acetylated MPA 2 (0.18 g, 83%) as a white powder mp 155-157 oC.
1H NMR (500MHz, CDCl3): δ 5.18-5.5 (m, 3H), 3.79 (s, 3H), 3.28 (d, J = 6.9 Hz,
2 H), 2.43-2.38 (m, 5H), 2.33-2.28 (m, 2H), 2.21 (s, 3H), 1.79 (s, 3H). Mass: 385.2

106

Figure 7-2. Synthesis and characterization of JP-3-110
A. The synthetic scheme of JP-3-110. i) DIC, DMAP, DCM, 73%; ii) IN HCl/THF, 12h,
21%. B. The 1H NMR spectrum of JP-3-110.
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(M+Na).
Synthesis of Compound 3. A solution of amide 1 (0.32 g, 0.88 mmol), acetylated
MPA 2 (0.24 g, 0.88 mmol), N,N-dimethyl amino pyridine (0.16 g, 1.32 mmol) and
diisopropyl carbodiimide (0.21 mL, 1.32 mmol) in CH2Cl2 (10 mL) was stirred at room
temperature under Ar atmosphere overnight. The reaction mixture was diluted with
CHCl3 (20 mL) and then washed with 1 N HCl (10 mL), water (10 mL), aqueous
saturated NaHCO3 solution (10 mL), and brine (10 mL). The organic layer was dried
(Na2SO4) and evaporated, and the residue was purified by column chromatography
(silica gel, 30% acetone in petroleum ether) to afford (E)-6-hydroxy-2,2-dimethyl-6(propylcarbamoyl)-hexahydrobenzo[d][1,3]dioxol-4-yl-6-(4-acetoxy-6-methoxy-7methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate (compound 3, 0.4 g,
73%) as a white solid mp 71-73oC.
1H NMR (400MHz, CDCl3): δ 7.08 (t, 1 H), 5.32-5.23 (m, 1H), 5.17 (s, 1H),
5.15-5.08 (m, 1H), 5.32-5.24 (m, 1H), 4.54-.48 (m, 1H), 4.14-4.08 ( m, 1H), 3.84 (s, 1H),
3.78 (s, 3H), 3.5 (d, J = 6.9 Hz, 2 H), 3.24-3.15 (m, 2H), 2.45- 2.36 (m, 5H), 2.33-2.28
(m, 2H), 2.23 (s, 3H), 2.03-1.90(m, 2H), 1.76 (s, 3H), 1.58 (s, 3H), 1.55-1.48 (m, 2H),
1.36 (s, 3H). 0.93 (t, 3H). Mass: 640.3 (M+Na).
Synthesis of Compound 4. Compound 3 (0.4 g, 0.64 mmol) was dissolved in THF
(3 mL), then aqueous 1N HCl (5 mL) was added at room temperature and the reaction
mixture was stirred for 12h and monitored by ESI-MS. After completion of reaction,
solution was saturated with solid NaCl and aqueous phase was extracted with ethyl
acetate (3x 100 mL). The organic layer was dried (Na2SO4) and evaporated, and the
residue was purified by column chromatography (silica gel, 90% ethyl acetate in
petroleum ether) to afford compound 4 (0.08 g, 21%) as a white solid mp 74-76 oC.
1H NMR (400MHz, CDCl3): δ 7.08 (t, 1 H), 5.22-5.16 (m, 3H), 5.11-5.05 (m,
1H), 4.84 (s, 1H), 4.29-4.24 (m, 1H), 3.80 (s, 3H), 3.68-3.61 (m, 1H), 3.38 (d, J = 6.9 Hz,
2 H), 3.32-3.30 (M, 1H), 3.25-3.16 (m, 3H), 2.45- 2.36 (m, 5H), 2.33-2.28 (m, 2H), 2.23
(s, 3H), 2.15-2.0 (m, 4H), 1.8 (s, 3H), 1.51-1.50 (m, 2H), 0.9 (t, 3H). Mass: 578.3
(M+H).
NF-kB activity
INS-1E cells which were stably transfected with the SEAP gene containing the
response-element for NF-kB were used to screen for anti-inflammatory activity. Briefly,
106 cells/well were seeded overnight followed by treatment with 10 ng/mL human
recombinant TNFα and either KZ41 or hybrid drug JP-3-110 (1μM). SEAP activity was
measured 18h later in supernatant samples (50 lL) using the NF-kB SEAPorterTM Assay
Kit (IMGENEX) and a microplate luminometer. SEAP activity was normalized to the
total protein content. Inhibitory potency (IC50) was determined from dose-response
curves (n = 3 separate experiments).
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Caspase assay
Caspase-Glo 3 assay kits were used to analyze caspase 3 as per the manufacturer’s
protocol (Promega). This assay kit provides a proilluminescent caspase substrate, DEVD,
that, when cleaved by caspases, will release luciferin to quantitatively determine caspase
concentration. Briefly, following sequential treatment by JP-3-110 for 48h and a cytokine
cocktail of recombinant TNFα (5 ng/ml) and IL-1β (5 ng/ml) for additional 48h, 100 μL
of Caspase-Glo reagent was added to 100 μL of culture supernatants in 96-well plates and
incubated at room temperature for 1 h. The contents were then transferred into culture
tubes, and luminescence was determined using a luminometer (Berthold, Germany).
Griess assay
Nitric oxide (NO) production and accumulation is a vital step in the apoptotic
pathway. Nitrite concentration was determined using the Griess assay (Promega,
Madison, MI). Fifty microliters of cell culture supernatant was added to a 96 well-plate
and mixed with 50 μL of 1% sulfanilamide in 5% phosphoric acid solution and incubated
for 5 min at room temperature in the dark. Then, 50 μL of 0.1% N-1naphthylethylenediamine dihydrochloride (NED) aqueous solution was added to each
well. The plate was incubated for an additional 10 min, and absorbance was measured at
560 nm using a microplate reader. To determine the nitrite concentration in each sample,
a standard curve was prepared using nitrite standard solution and blank culture.
Apoptosis studies
A cytokine cocktail was used to mimic the in vivo challenge to the INS-1E cells
and human islets by the inflammatory cytokines. Briefly, following JP-3-110 treatment
for 48h and cytokine cocktail treatment for additional 48h, INS-1E cells were
characterized by the DeadEnd™ Colorimetric TUNEL system (Promega, Madison, WI,
USA), in which fragmented DNA from apoptotic cells was labeled with biotinylated
nucleotide and detected using hydrogen peroxide and diaminobenzidine. Following
treatment with JP-3-110 and cytokines, human islets were digested with
0.25%trypsin/EDTA into a single-cell suspension, stained with the Annexin V-FITC
Apoptosis Detection Kit (Abcam) and analyzed with flow cytometry. Annexin V binds to
phosphatidylserine on the cell surface, which is a feature found in apoptotic cells.
Fluorescent intensity was analyzed using CellQuest software (BD Bioscience, Franklin
Lakes, NJ, USA). Three sets of independent transduction experiments were carried out
for each assay.
Islet perifusion study
The insulin secretion from human islets was quantified using a dynamic islet
perifusion assay. Briefly, 50 islets from each group were handpicked and loaded onto a
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Swinnex 13 chamber (Millipore, Burlington, MA, USA) and perifused with Krebs-Ringer
bicarbonate HEPES buffer of the following composition (in mM): 129 NaCl, 5 NaHCO3,
4.8 KCl, 1.2 KH2PO4, 1.2 MgSO4, 2.5 CaCl2, and 10 HEPES at pH 7.4. The flow rate
was maintained at 1 ml/min with a peristaltic pump (Themo Fisher, Waltham, MA) and
the temperature was maintained at 37°C with a solution heater (Warner Instruments,
Hamden, CT). Islets were first perifused with basal glucose (1.67mM) for 60 min and
stimulated with glucose (16.7mM) for 30 min and finally perifused with basal glucose
(1.67mM) until insulin release reversed to the basal level. Samples were collected once
per two minutes through an automatic fraction collector (Waters, Milford, MA) and
analyzed for insulin content by ELISA.
Mixed lymphocyte reaction (MLR)
PBMCs were isolated using Ficoll Paque as described in Chapter 6. T cells were
isolated from PBMCs using Dynabeads for. T cells were stimulated with PHA (1μg/ml)
for 24h and then cultured in the presence of KZ41 (5μM) or JP-3-110 (5μM) or additional
4 days. The total number of PBMCs was measured using T4 Automatic Cell Counter
(Nexcelom, Lawrence, MA). The extent of T cell activation was determined by
measuring the level of IL-2, IL-2sRa, TNFα and IFN-γ in the medium using ELISA at
indicated time.
Rebuild human immunity
Human PBMCs were isolated from buffy coats by gradient centrifugation using
Ficoll Paque. The T cells and B cells of PBMCs were stained with FITC conjugated CD3
antibody and APC conjugated CD19 antibody, respectively, and characterized using flow
cytometry. The PBMCs were infused into diabetic NSG mice at the concentration of
5x106/mouse to establish human immunity. The settlement of T cells in the spleen was
assessed by immunofluorescence staining. Briefly, spleen were isolated, washed with
PBS, fixed in 4% paraformaldehyde overnight, and embedded in optimal cutting
temperature compound. Frozen sections of 5 μm thickness were cut. The slides were
stained with rabbit anti-human CD3 primary antibody (1:200) at 4 °C overnight and
Alexa Fluor 568 conjugated goat anti-rabbit secondary antibody (1:500) at room
temperature for 1 h. The function of B cells was assessed by measuring human IgG
concentration in the mouse blood.
Statistical analysis
Statistical significance of the difference between the two groups was determined
by unpaired t-test and between several groups by one-way ANOVA.
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Results
Synthesis of JP-3-110
Quinic acid amide analog KZ41 was synthesized as described before [157]. JP-3110 was synthesized by conjugating KZ41with MPA and the structure of JP-3-110 was
confirmed by 1H NMR (Figure 7-2). The solubility of JP-3-110 was determined to be
0.48±0.16mg/ml (0.80±0.27mM) by HPLC, which is practically insoluble according to
USP solubility criteria (Figure 7-3).
Apoptotic effect of JP-3-110
Although the water solubility of JP-3-110 was extremely poor, we still tried to
determine whether JP-3-110 can suppress the NF-kB activity as its counterpart KZ41 in
insulin producing INS-1E cells. A cocktail of inflammatory cytokines (TNFα 10 ng/mL,
IL-1β 5ng/mL and IFN-γ 10 ng/mL) was used to mimic the inflammation in vivo. Results
indicated that JP-3-110 was equally potent as KZ-41 to suppress the NF-kB activity of
INS-1E cells under the stimulation of inflammatory cytokines (Figure 7-4). We then
determined the activities of caspase 3 which is a converging point of apoptotic pathway.
Results showed that INS-1E cells pre-treated with KZ-41 and JP-3-110 showed
significant decrease in caspase 3 activity (Figure 7-5A), suggesting the inhibition of
apoptotic pathway by KZ41 and JP-3-110. As a result, the inflammatory-cytokineinduced apoptotic cell death was significantly reduced in INS-1E cells in the presence of
KZ41 or JP-3-110 (Figure 7-5B).
We then determine the protective effect of KZ41 on human islets against
inflammatory cytokines. We demonstrated that the percentage of apoptotic cells in human
islets were significantly reduced in the presence of KZ41 at 2 days and 4 days after
stimulation with cytokine cocktail, suggesting a protective role of KZ41 (Figure 7-6).
Interestingly, we also demonstrated that the INS-1E cells and human islets conditioned
with KZ41 and JP-3-110 acquired similar resistance to the challenges of inflammatory
cytokines (data not shown), suggesting that KZ41 and JP-3-110 can be used as preventive
medicine.
Immunosuppressive effect of JP-3-110
Besides the PNF of islet grafts caused by inflammatory cytokines, immune
rejection is another key barrier for successful islet transplantation. We determined
whether JP-3-110 retained the immunosuppressive effect as MPA. Typically, T cell
activation is characterized by an early and transient expression of IL-2 and a long-lasting
expression of TNFα and IFNγ (Figure 7-7). JP-3-110 showed minimal effect on the
expression of IL-2 but it strongly inhibited the expressions of TNFα and IFNγ in long
term. Further study illustrated that JP-3-110 significantly suppressed T cell proliferation
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Figure 7-3. Use HPLC to determine the solubility of JP-3-110
A. Standard curve of JP-3-110. From top to bottom, 0.2, 2, 20, 200, 2000 mg/mL of JP-3110 in acetonitrile (ACN). B. Triplicates of JP-3-110 saturated water solution. C. HPLC
conditions. Column: Inertsil ODS-3, 250 x 4.6mm, 5μm.
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Figure 7-4. JP-3-110 and KZ41 suppressed NF-kB activity in INS-1E cells
A. Schematic illustration of the mechanism of SEAP reported gene assay to determine
NF-kB activity. Briefly, a plasmid construct containing NF-kB promoter and SEAP gene
was transferred into INS-1E cells by lipofectamine. SEAP was then expressed and
secreted into culture supernatant and allowed chemiluminescent detection using a
substrate PNPP under 405 nm. B. NF-kB activity was measured 24 hours after addition of
cytokine cocktail and either JP-3-110 (5μM) or KZ41 (5μM). CMV/SEAP construct
constitutively expressed SEAP and served as positive control.
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Figure 7-5. KZ41 and JP-3-110 pretreated INS-1E cells were resistant to cytokine
induced apoptotic cell death
A. Caspase 3 activities in INS-1E cells after treated with KZ41 (5μM) and JP-3-110
(5μM). Dexamethasone (Dex, 1μM) was used as a positive control. B. INS-1E cells were
stimulated with a cytokine cocktail alone or in the presence of KZ41 or JP-3-110 for 2
day. Then all cells were subjected to TUNEL assay using DeadEnd Colorimetric TUNEL
system. Apoptotic cells were stained in dark. *p<0.05 as determined by an unpaired
Student’s t-test, n=6.
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Figure 7-6. KZ41 inhibited the apoptotic cell death of human islets after
stimulation with cytokine cocktail
Briefly, after stimulated with cytokine cocktail in the presence or absence of KZ41 (5µM)
for indicated time, islet was collected and dispersed with 0.25% Trypsin/EDTA into
single cell suspension. Apoptotic cells were stained with FITC labeled annexin V and
counted by flow cytometry. P3 indicated the percentage of apoptotic cells. All
experiments were performed in triplicates. Results are presented as the mean ± SD.
*p<0.05 as determined by an unpaired Student’s t-test, n=6.
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Figure 7-7. JP-3-110 suppressed T cell proliferation but not T cell activation
A-D. The levels of IL-2, IL-2 receptor, TNFα and IFNγ of T cells following PHA
stimulation and the treatment JP-3-110 (5μM). The levels of IL-2 and IL-2 receptor were
not affected by the treatment of JP-3-110 but the levels of TNFα and IFNγ were
significantly reduced. E. The T cell proliferation after PHA stimulation is characterized
by a quick drop in the early stage (24h) and a following fast-proliferation stage. The
presence of JP-3-110 significantly reduced the T cell proliferation after PHA stimulation.
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following activation therefore the results of less expressions of TNFα and IFNγ might be
due to less number of total T cells (Figure 7-7) which is consistence with previous
reports [159, 160]. Taking together, the results indicated that JP-3-110 retained the
immunosuppressive function similar to MPA.
JP-3-110 inhibited the function of T cells and B cells in humanized NSG mice
NSG mice were adoptively transferred human PBMCs to build human immunity
as described in Chapter 6. The human IgG level in the serum and CD3+ T cell staining in
the spleen indicated that NSG mice can be readily humanized by injecting 5x106 human
PBMCs (Figure 7-8). No sign of GvHD was observed after humanization. To determine
whether JP-3-110 can suppress immune reactivity in humanized NSG mice, we
administered JP-3-110 intraperitoneally at 50mg/kg for consecutive 7 shots. Results
indicated that the amount of human T cells in the spleen of humanized NSG mice were
significantly reduced after JP-3-110 administration (Figure 7-8B). Serum human IgG
level of the mice receiving JP-3-110 was also significantly reduced compared with the
mice receiving equal amount of saline (Figure 7-8C), suggesting that JP-3-110
suppressed the function of T cells and B cells in humanized NSG mice.
Discussion
The idea of synthesizing a compound drug to prevent immune rejection and PNF
of human islet transplantation simultaneously emerged from the research in BMSC
mediated cell therapy. BMSC effective prevented the immune rejection and PNF as an
immune modulator and trophic mediator, respectively. However, BMSC was unsuitable
for intravenous injection therefore can only be co-transplanted with human islets.
All these drawbacks of BMSCs encouraged us to find an alternative for BMSC
based stem cell therapy. In our most recent work, we proposed to take advantage of
immunosuppressive drug and anti-apoptotic drug to test whether we can synthesize a
compound drug to prevent immune rejection and PNF of human islet transplantation
simultaneously.
Most immunosuppressive drugs have significant side effects. Therefore the dosing
of these compounds in the patients is closely monitored and controlled. Among these
immunosuppressive compounds, MPA is a commonly used for organ transplantation
especially human islet transplantation. MPA inhibits the purine synthesis and thereby the
proliferation of T cells and B cells [161]. However, MPA also impaired the viability and
function of human islets in the coculture condition [87]. Hereby we reported a new
compound JP-3-110, which combines the immunosuppressive drug MPA with a novel
anti-apoptotic compound KZ41. We hypothesized that on one hand, the compound drug
can used as a modified MPA so that the toxicity of MPA can be significantly reduced.
One the other hand, the conjugated part, KZ41 had antiapoptotic potential to prevent the
PNF of human islet transplantation.
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Figure 7-8. JP-3-110 inhibited the function of T cells and B cells in humanized
NSG mice
A. A representative spleen section of humanized NSG mice after receiving 7 consecutive
shots of JP-3-110 (50mg/kg, upper) and equal amount of saline (lower) each day. NSG
mice were humanized by intraperitoneal injection of 5x106 human PBMCs and allowed
to settle for two weeks. Sections were stained for CD3 positive T cells (red) and black
stained with DAPI (blue). B. The T cell intensity in the spleen section of humanized NSG
mice calculated from the immunofluorescence staining by ImageJ. C. The serum IgG
level of humanized NSG mice. P<0.05 under student t test. N=3.
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We demonstrated that the compound drug JP-3-110 had immunosuppressive effect
as its counterpart MPA in the MLR. Although JP-3-110 did not prevent the activation of
T cells by PHA, it did prevent the proliferation of T cells after activation (Figure 7-7). To
better fit the scope of clinical human islet transplantation, we employed a novel
humanized mouse model to evaluate the effectiveness of the JP-3-110 to prevent the
immune rejection caused by human immunity. The staining of CD3+ human cells in the
spleen section and the level of human IgG in the serum of NSG mice both suggested that
JP-3-110 suppressed the alloreactivity of T cells and B cells in vivo (Figure 7-8). This
study may provide useful insight into the modification of traditional immunosuppressive
drugs.
Previous studies indicated that KZ41 is a potent suppressor of NF-kB activity of
human alveolar A579 cells and thus a potent anti-inflammatory compound [157]. We
demonstrated that the anti-inflammatory effect of KZ41 can be transferred into insulinproducing INS-1E cells and human islets against the stimulation of a cytokine cocktail
(Figures 7-5, 7-6). We also demonstrated that the conjugation of KZ41 with MPA did
not affect the pharmacological activities of MPA as a single drug.
Unfortunately, this work is not close to complete at this stage as we faced lots of
challenges in the research of this small molecular compound. The major challenge is
about the rationale of the project, how we are going to evaluate the compound drug JP-3110. As shown in Table 7-1, KZ41 inhibits the production of inflammatory cytokines
through NF-kB inhibition while MPA inhibits the proliferation of T cells and B cells,
suggesting a potential synergistic effect to prevent the immune rejection of human islets.
However, KZ41 and MPA demonstrate opposite effects on the apoptosis of human islets.
Without compelling evidences that the anti-apoptotic effect of KZ41 is significantly
higher than the pro-apoptotic effect of MPA, the compound drug may not show a benefit
to prevent the apoptosis of human islets. Further studies are needed to compare the antiapoptotic effect of KZ41 alone, KZ41 in the presence of MPA and JP-3-110. If KZ41 is
not capable to mask the pro-apoptotic effect of MPA, JP-3-110 is just a less toxic
immunosuppressant instead of a compound drug with two therapeutic potentials.
Moreover, there are other challenges regarding this project. The first issue is the
solubility of JP-3-110. KZ41 is still fairly water-soluble (~0.8 g/mL), but JP-3-110 is not
even close to that range with water solubility of only 0.5 mg/mL. The difficulties of
working with a compound of such solubility are 1) the poor solubility of JP-3-110 is
unsuitable for injection into animals because a huge amount of water is needed to fully
dissolve the compound and 2) a micellar or liposomal delivery system cannot be used to
formulate JP-3-110 because the solubility of JP-3-110 is not that poor and JP-3-110 may
leak out from the delivery system. To solve issue, we need to modify the molecular
structure of JP-3-110 to drastically change the solubility toward either direction while
keeping the pharmacological activities of JP-3-110.
The second issue is the stability of the compound. The ester bond of JP-3-110 is
susceptible to hydrolytic degradation, releasing KZ41 and MPA as two single drugs.
More than 40% of JP-3-110 in the aqueous solution will be degraded when stored in 4oC
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Table 7-1.

The pharmacological activities of KZ41 and MPA

Pharmacological activity

KZ41

MPA

Apoptosis impact

Prevents apoptosis of
human islets at 5μm

Toxic to human islets at
10μm

Immune impact

Inhibits the production of
inflammatory cytokines

Prevents the proliferation
of T cells and B cells
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for 1 week (Figure 7-9). Although this degradation has not caused us any problem in
efficacy, it may pose potential problem in the formulation of this drug.
The third issue is the difficulty in the synthesis process therefore limited amount
of JP-3-110 had been synthesized for each batch. We have synthesized a total amount of
80 mg of JP-3-110, which was just enough for the in vitro characterization but far from
enough for human islet transplantation, which last for months.
In summary, we demonstrated a proof of concept that a compound drug
composing of a immunosuppressive part and an antiapoptotic part can be an effective
strategy to prevent the immune rejection and PNF of human islet simultaneously.
However, further effect is still needed to improve the solubility and stability of this
compound and formulate it for in vivo test.
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Figure 7-9. The hydrolysis of JP-3-110 in aqueous solution
A. The characterization of JP-3-110 aqueous solution (0.4mg/mL) stored in 4oC for 1
week. The peak at 2 minutes was denoted as MPA degraded from JP-3-110. KZ41 does
not have a benzene ring therefore cannot be detected under UV detector. B. The HPLC of
MPA under a same setting as a reference. C. The HPLC setting.
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CHAPTER 8.

CONCLUSION

What We Achieved in the Past 5 Years
The limited supply of human islet, the inadequate means to prevent graft rejection
and the PNF remains three important obstacles for successful human islet transplantation.
In the past five years, we have developed several strategies for the PNF and immune
rejection. For example, we identified XIAP as a potent anti-apoptotic gene to prevent the
PNF caused by inflammatory cytokines. We generated RGD modified adenovirus to
achieve efficient gene transfer while reducing the viral titer. We also identified BMSC as
a novel gene carrier to express therapeutic genes while avoiding the viral transduction on
human islets. The establishment of humanized NSG mice has been a significant
milestone in five years’ research. This novel animal model provided us a clinical relevant
platform to evaluate the immune rejection of human islets. Using humanized NSG mice,
we successful evaluated the efficacies of BMSCs and a novel compound JP-3-110 to
prevent the immune rejection of humanized mice.
In the past five years, our knowledge and skills about human islet transplantation
has also been reshaped. For the strategies, we moved from gene therapy to stem cell
therapy and stem cell based gene therapy. For the materials, we stopped using INS-1E
cells but focused on the human islets. For the target genes, we are now targeting at least
two genes simultaneously instead of one gene at a time. For the molecular cloning, we
moved from buying commercially available vectors to constructing vectors and even
surface-modified vectors. For in vitro islet studies, we designed and developed a new set
of perifusion equipment for dynamic measurement of islet function. For the animal
model, we started to use a more clinically-relevant humanized model to substitute the
immunodeficient models we used before. For the transplantation techniques, we are
generating a more reliable diabetic animal model and successful render a majority of
diabetic mice insulin-independent after surgery.
New Challenges and Future Directions
Humanized animal model will be among the most popular animal models for the
research in solid organ transplantation and immunology in the next decade. There are so
many studies requiring the involvement of human immune system. Humanized model
could be a perfect model for the proof of concept for these studies without the
involvement of human subjects. However, the occurrence of GvHD remains a big
challenge for our humanized mouse model.
The GvHD is characterized by the recognition and destruction of the major organ
of mouse by the infused mature human lymphocytes. Dr. Leonard Shultz, the pioneer of
humanized mouse, has reviewed his previous work and concluded that the humanized
mice generated from mature human lymphocytes will develop GvHD typically in 5-7
weeks [79, 162]. The GvHD causes short life-span and a limited window to evaluate the
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immune rejection. The only way to avoid GvHD seems is to introduce the progenitor
cells of human immunocytes, which are hematopoietic stem cells into NSG mice at early
age [163]. As long as the maturation of human lymphocytes happens inside the thymus or
bone marrow immunodeficient mice, those mature human lymphocytes seem to be less
likely to attack the mouse organs.
Gene therapy, even in its best scenario, cannot prevent the immune rejection from
the islet recipient. Stem cell therapy through immunomodulatory BMSCs will be a better
strategy to prevent the immune rejection. However, three weakness of stem cell therapy
cannot be overlooked. First, BMSCs are unsuitable for intravenous injection, making
repeated dosing impossible. Secondly, BMSC produces minimal levels of HGF and
VEGF, which are not enough to support a fast and functional revascularization of human
islets. Thirdly, if BMSCs from a third party were used in large quantities, they may cause
immunogenicity and tumorigenicity.
To address these concerns, we raise three questions here: 1) can we expand Treg
in vitro as a substitute for BMSC therapy, 2) can we modify stem cells in such a way that
the therapeutic potential of stem cells can be increased and these cells can be selective
cleared from body at a indicated time point and 3) can we substitute stem cells with a
non-proliferation system which holds similar therapeutic potential. We believe that
finding proper answers for these questions will expand our research in width and depth to
further improve human islet transplantation.
The size of BMSC is quite large, making them susceptible to be sequestered in the
lung after intravenous injection. Tregs are relatively smaller cells which travel freely
through the bloodstream. Our data suggested that BMSCs promoted the proliferation of
Tregs which in turn may contribute to the immune tolerance in human islet
transplantation (Figure 6-7). Therefore, if we isolate and expand Tregs in vitro and
infused back into the diabetic patient, we can increase the immune tolerance of human
islets to a similar extent. Two groups in University of Chicago and University of
Maryland have independently reported their preliminary data in rodent model to support
this hypothesis [164, 165].
We demonstrated that BMSCs supported the revascularization of human islets in
immune deficient NOD-SCID mice (Figure 5-9). However, our results suggested that
BMSCs produce marginal level of HGF and VEGF which are incapable to support a fast
and functional revascularization. Therefore, one possible outcome might be that the islets
which are not destructed by the immune rejection will be PNF due to poor
revascularization. In fact, we are thinking about using genetically modified BMSCs to
prevent the immune rejection and PNF in humanized mouse model. To proceed with this
idea, we must prove that genetic modifications, either with adenoviruses or plasmids, do
not change the stem-cell-like properties and the immunomodulatory effect of BMSCs.
Since telomerase reverse transcriptase (TERT)-modified BMSCs have been reported to
induce tumor in animal models [55], the tumorigenicity of genetically modified BMSCs
should be evaluated as well.
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For the last question whether a non-proliferative system with similar therapeutic
effect can be used to substitute BMSC, we believe that the exosome secreted from BMSC
can be good candidate. Exosomes are 40 to 100 nm vesicles secreted by a wide range
of mammalian cell types, including BMSC. Exosomes also have a way to avoid the
reticulo-endothelial system (RES) system [166]. These features make exosome good
candidate for intravenous delivery. Exosomes typically contain proteins and RNA and
therefore can be used for a wide range of purpose. For example, exosomes be used as a
bridge connecting BMSC mediated stem cell therapy and adenovirus mediated gene
therapy as shown in Figure 8-1.
In this ideal application of exosomes for human islet transplantation, step 2 can be
further improved if we can insert genes of interest and target-ligand expression cassette
into one single adenoviral vector. Step 5 needs to be optimized experimentally as the
necessary dose for an optimal transplantation outcome should be determined. Since our
preliminary data suggested that the BMSCs suppressed the proliferation and activation of
PBMCs through soluble factors (Figure 6-3). We expect that the exosomes secreted by
BMSC had similar immunomodulatory effect. Moreover, since we can introduce any
gene of interest which may increase the resistance of islets to PNF, we expected that the
exosome therapy would provide additional benefit compared with BMSCs therapy alone.
Exosomes mainly delivery secreted proteins and RNA. In our preliminary study
we demonstrated that the adenoviral transduction significantly increased the total
expression of HGF by BMSCs. Among the total HGF production, a majority stayed in
the exosomes instead of being directly released into the media. These results suggested
two important facts that 1) the expression of HGF by BMSCs is mainly through
exosomes and 2) exosomes from genetically modified BMSCs hold therapeutic
advantage above exosomes from primary BMSCs.
Future studies regarding exosomes generated from BMSCs can be approached
from two directions. First, we will identify the immunosuppressive factor(s) produced by
BMSCs and generate the exosomes to deliver the factor(s). If we failed to identify any of
the immunosuppressive factors, we can hijack the cellular machinery of BMSCs with
adenoviral vectors to produce exosomes containing well-known immunosuppressive
factors such as IL-10 or TGFβ. The second direction is to modify the exosomes with
targeting ligands for targeted delivery to the transplantation site. The glucagon-like
peptide 1 receptor (GLP1R) is one well-known receptor of pancreatic β cells. Itoh et al.
recently reported high expression of a type of G protein–coupled receptor GPR40 on the
surface of pancreatic β cells [167]. These receptors can be potential candidate for the
targeted delivery of exosomes to human islets in vivo.
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Figure 8-1. An ideal application of targeting exosomes for islet transplantation in
humanized NSG mice
Step 1: Isolation and expansion of primary BMSCs. Step 2: Gene transfer into BMSCs.
Adenoviral vectors encoding genes of interest and a plasmid encoding targeting ligand
were transferred together into BMSCs. Step 3: Expression of targeting ligand and
“cargo”. Targeting ligands (red) are typically expression on the membrane and released
with exosomes. “Cargo” (blue) can be secreted proteins if an expression adenoviral
vector is used or shRNA if a silencing adenoviral vector is used. Step 4: Harvest of the
targeting exosomes. Step 5: Intravenous injection of exosomes into humanized NSG mice
receiving islet transplantation.
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